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1 Introduction
The immune system is one of the most complex and controlled systems of an organism. It
is necessary for the defense against many di erent threats like bacteria, viruses or fungi.
Additionally, it plays an important role during the identification and abatement of cancer.
In general the immune system can be divided into two di erent parts [1].
The innate immune system The first part is called the innate immune system, also
known as the nonspecific immune system. It consists of various mechanisms passively
protecting against invaders. Additionally, it recognizes structures, which are only present
on pathogens.
The passive mechanisms of the innate immune system include all epithelial surfaces building
a mechanical barrier for pathogens as well as the mucus in the respiratory tract, which
can capture invaders and transport them out of the organism. The second, more active
group of mechanisms depends on the recognition of highly conserved pathogen associated
molecular patterns (PAMPs), such as lipopolysaccharides (LPS). These structures can
be detected by pattern recognition receptors (PRR). One example for PRRs are toll like
receptors (TLRs), which are expressed on di erent cell types, like neutrophils or dendritic
cells (DCs). After ligand-detection they are able to activate multiple signaling pathways
resulting in the modification of cellular functions and thereby in the activation of di erent
immune mechanisms of these cells.
The combination of these protection structures of the innate immune system enables
a very fast recognition of invaders and represents the first line of defense against an
infection [2, 3].
The adaptive immune system The second part of the immune system is the adaptive
immune response building upon the innate system [4]. This second line of defense is only
present in vertebrates and provides a more specific and longer lasting protection. After
a short activation period, it o ers a diversified repertoire of mechanisms to delete the
pathogen and eliminate the threat to an organism. In addition to its high specificity, this
part of the immune system also contains a memory of previously encountered pathogens,
which enables a very fast reaction in the case of reinfections [5, 6].
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The adaptive immune system is again divided into two parts, the humoral and the cellular
immune response. The humoral response is mediated by antibodies, which are highly
specific to a particular pathogen. They are produced by B-cells with the assistance of
CD4+ T-helper lymphocytes (T-helper cells) and designed to protect against extracellular
pathogens [1, 7].
The other part of the adaptive immune system is called the cellular immune response,
which is specialized to remove intracellular pathogens like viruses. To enable this cellular
response nearly all cells of an organism present their intracellular peptides at their surface.
After activation, CD8+ cytotoxic T-lymphocytes (CTLs) recognize presented peptides of
pathogens (like parts of viruses) or other unknown proteins (for example from cancer cells)
and eliminate the infected or mutated tissue [8, 9, 10].
1.1 Dendritic cells in the immune system
Dendritic cells (DCs) belong, besides macrophages (M„), B-cells and some other cell types,
to the group of professional antigen presenting cells (APCs) [1]. These APCs have the
ability to take up various antigens, process them and present their peptides at their cell
surface to activate other parts of the adaptive immune system. While B-cells internalize
antigens with a high specificity by B-cell receptors [11], DCs and M„ have di erent pos-
sibilities to pick up antigens. They can nonspecifically internalize soluble antigens from
their surrounding by pinocytosis, particles by phagocytosis or alternatively use various
receptors to take up defined substances, including pathogens, by receptor-mediated endocy-
tosis [12, 13, 14]. Macrophages mainly fulfill regional functions in the peripheral tissue,
like the local elimination of pathogens or uptake of dead cells (for example cells killed
by CTLs). In contrast to this, DCs build a bridge between the innate and adaptive
immune system and play a very important role during the activation of adaptive immune
responses [14, 15, 16, 17].
The DCs of an organism are a widespread system of cell-subtypes with di erent
functions [18]. Roughly they can be divided into lymphoid-resident DCs, migratory
DCs and inflammatory DCs [1, 19]. Lymphoid-resident DCs di erentiate from bone
marrow-derived myeloid precursor cells and are resident in lymphoid tissues, like the
lymph nodes or the spleen, where they represent the main part of the DC population
[20, 21]. They again can be split into di erent subsets specified by CD4 and CD8 ex-
pression. These DC subsets di er in their ability to process antigens as well as in their
presentation mechanisms. CD8+ DCs are described to be able to e ciently present extra-
cellular antigens on their cell surface to CTLs, while the CD4+ DCs and double negative
DCs prefer the activation of CTLs by the presentation of intercellular antigens [22]. In
contrast to lymphoid resident DCs, inflammatory DCs, also called monocyte-derived DCs,
di erentiate from monocytes. This subset is activated in presence of stimulatory signals
and is recruited to the site of inflammation. There, they support the local immune response
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of macrophages and migratory DCs [23, 24]. Migratory DCs, again di erentiating from
bone marrow-derived precursor cells, are present in many peripheral organs in an inactive
state [25, 26]. Also here subgroups di ering in their possibility to present antigens are de-
scribed. For these, CD103 is used to distinguish the subpopulations [27, 28], because CD4
and CD8, which are available for the characterization of lymphoid-resident DCs, are poorly
expressed on migratory DCs. The presence of CD103 is thereby associated with the ac-
tivation of CTLs by the presentation of extracellular antigen. Recently an additional marker
of DCs, which mediate the presentation of extracellular antigens to CTLs, was
discovered (XCR1) [29]. Present on migratory DCs as well as lymphoid-resident DCs, this
marker reveals a connection of these two subgroups and enables a further characterization
of the DC-subsets in the organism [30].
In the peripheral tissue, migratory DCs are able to take up big amounts of molecules and
particles from their surrounding to screen for pathogens. After uptake of an antigen and
activation by innate PRR like TLRs, these DCs start to mature [4, 16] and up-regulate
di erent sets of chemokine receptors, which induce and control their migration towards
the lymphoid tissue [31, 32]. During maturation and movement, co-stimulatory molecules
like CD40 and CD80/86 are up-regulated [16, 33] and proinflammatory cytokines secreted.
Additionally, the antigen processing is enhanced. This increases the number of presented
antigens on the surface of the migrating DC. In contrast to this, the antigen uptake is
severely reduced [4, 16]. After arriving in the lymphoid tissue, the antigens are displayed
to T-lymphocytes. The specific recognition of the presented antigen in combination with
co-stimulatory molecules as well as inflammatory cytokines finally leads to an e cient
activation of the e ector function of T-lymphocytes. Depending on the mode of antigen
presentation by the DCs, di erent subsets of T-lymphocytes are activated [8].
1.2 Di erent pathways of antigen processing and
presentation
DCs as well as other professional APCs have two major possibilities to present protein-
derived antigens to activate di erent types of T-lymphocytes. On the one hand, they can
present intracellular antigens on major histocompatibility (MHC)-I molecules. This enables
the activation of CTLs, which have a specific receptor directed against the MHC-I peptide
complex on the DCs. After stimulation, these T-cells can scan cells in the periphery for the
presentation of the same MHC-I peptide complex. Because all nucleolus-containing cells
express MHC-I molecules and present intracellular peptides to their surrounding, CTLs
can screen the whole body for potential intracellular infections and destroy contaminated
cells [8, 34, 35]. On the other hand, professional APCs can display peptides on MHC-II
molecules. These MHC-II complexes are loaded with antigens, which have been taken up
from the surrounding of the APC. Afterwards, this complex can be recognized by T-helper
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cells, which are stimulated, when the T-cell receptor matches to the presented MHC-II
peptide combination. Subsequently, activated T-helper cells can for example support the
antibody production of B-cells against the pathogen, which has been detected by the
T-helper cell before [8].
1.2.1 MHC-I presentation
The presentation on MHC-I molecules is a constant mechanism in all nucleated cells
and used to detect changes in the protein expression of a cell, for example caused by
viruses or bacteria. Therefore, intracellular proteins are labeled for degradation (mostly by
polyubiquitination) and segmented into small peptides by cytosolic proteasomes. These
fragments can afterwards be loaded on MHC-I molecules for presentation [34, 36].
Generally, proteasomes are used by cells to degrade old or misfolded proteins. They
consist of four subunit complexes in combination with a regulatory structure on each
side. The two subunits in the middle mediate the proteolytic activity by N-terminal
threonine residues [37, 38, 39]. In professional APCs a second set of subunits for the
Figure 1.1: The MHC-I presentation pathway
After proteasomal degradation, peptides
are transported into the ER and loaded
onto MHC-I molecules, which subse-
quently can be presented to CTLs on
the cell surface.
active region of the proteasome is
available, namely lmp2 (low molecu-
lar mass protein 2), lmp7 and MECL-1
(multi-catalytic endopeptidase complex
like I). These are produced and inte-
grated into proteasomes in parallel to
the normal proteasomal subunits and
their expression is increased after ac-
tivation of the DC by pathogens or
occurrence of proinflammatory cyto-
kines [40, 41]. The replacement of
the normal subunits by the immune-
induced components leads to a changed
structure inside of the active center,
which influences the speed of protein
degradation as well as the preferred
cutting sides [42, 43]. The proteasomes
containing these subunits are called im-
munoproteasomes and described to be
important for the generation of “im-
munogenic” peptides, which can be
presented more e ciently on MHC-I
molecules at the surface of APCs [44].
After proteasomal degradation of the
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protein, the resulting 6 to 30 amino acids long peptides are transported into the endo-
plasmatic reticulum (ER) via a transporter named TAP (transporter associated with
antigen processing). The TAP complex consists of two di erent subunits (TAP1 and
TAP2) [45, 46] and interacts at its luminal side via tapasin with unloaded MHC-I molecules,
which contain a heavy and a light chain (b2-micro-globulin). Furthermore, this complex is
stabilized by di erent chaperones like calreticulin, calnexin as well as Erp57. After the
peptides are imported into the ER, they can be loaded on MHC-I molecules to form the
presentation complex [47, 48]. Finally, to completely fit the peptide into the binding site
of the MHC-I molecule the aminopeptidase ERAP (ER-associated peptidase) is required
to split overhanging amino acids during the loading procedure [49].
1.2.2 MHC-II presentation
In contrast to intracellular antigens, extracellular antigens are presented on MHC-II
molecules, which are mainly expressed by APCs [1, 50]. Therefore, pathogens are taken up
by various mechanisms like pinocytosis, phagocytosis or receptor-mediated endocytosis and
are transported into late endosomal and lysosomal compartments. In these, the proteins,
Figure 1.2: The MHC-II presentation pathway
The extracellular antigen is taken up
and digested in lysosomal compartments.
The resulting peptides are loaded on
MHC-II molecules, transported to the
surface and presented to T-helper cells.
for example from bacteria, are cleaved
by several proteases (e.g. di erent
cathepsins) as well as other digestive
enzymes (e.g. phosphatases or nucle-
ases) [51, 52]. This process provides
the peptides for the loading of MHC-II
molecules.
The MHC-II complex itself consists of
two transmembrane chains, is produced
in the ER and stabilized by the bind-
ing to an invariant chain (Ii). Addi-
tionally, the Ii blocks the peptide bind-
ing site to avoid the loading with ER
peptides [53]. After synthesis, this com-
plex is transported through the golgi-
apparatus to late endosomal compart-
ments, where the digested peptides are
present.
The compartment that is thereby gen-
erated is described as a class II vesicle
(CIIV). Inside of this compartment the
Ii is digested by proteases and only a
small fragment (CLIP, Class II associ-
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ated invariant chain peptides) remains in the peptide binding site of the MHC-II molecule.
For antigen presentation, the CLIP can now be exchanged with antigen peptides by the
MHC-like molecule HLA-DM [54]. Sequentially, the loaded MHC-II peptide complex is
transported to the cell surface and presented to T-helper cells.
1.3 Cross-presentation as additional presentation
pathway
A third possibility for DCs to present antigens to T-cells is cross-presentation [55, 56].
This allows the immune system to display extracellular proteins on MHC-I molecules and
is important for the immune response against pathogens that impair direct presentation
of antigens or do not infect APCs [57, 58], for example papilloma viruses which are
mainly infecting epithelial cells [59]. In addition, tumor cell-fragments can be taken up
by APCs and subsequently be cross-presented to enable an immune response against the
tumor [60, 61]. Although cross-presentation is reported for several phagocytic cells, DCs
are considered to be the primary cross-presenting cells. However, despite of intensive
investigations, the molecular mechanisms behind the cross-presentation pathway are still
not fully clarified. Nonetheless, the various mechanisms described during the last years
point out that not only one single possibility for cross-presentation exists. So far, at least
four di erent pathways are known and discussed.
1.3.1 The “endosome to cytosol” pathway
The most prominent pathway for cross-presentation is the “endosome to cytosol”
pathway (Fig. 1.3) [62, 63, 64], which is also called “phagosome to cytosol” pathway for
particulate antigens [65, 64]. During this presentation pathway, the antigen is taken up by
the DC and transported into a specialized compartment, where the cross-presentation is
mediated. From this the antigen is translocated into the cytosol to enable proteasomal
degradation. The peptides generated thereby are afterwards reimported into these spe-
cialized compartments [66, 64, 67, 63] or transported into the ER [65, 68, 63]. There, the
peptides are loaded on MHC-I molecules, which can be presented on the cell surface to
CTLs.
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Protection of the antigens from lysosomal degradation To enable a constant supply
of antigens and thereby a cross-presentation over a long period of time, the maturation
of the antigen-containing compartment needs to be slowed down to avoid lysosomal
degradation, which would lead to a rapid destruction of antigenic epitopes [62, 69, 70, 71].
Besides low expression of lysosomal proteases in DCs in general [72], the pH in these
compartments is stable at a neutral level to keep pH-dependent lysosomal proteases inactive.
These conditions are mediated by the recruitment of the NADPH oxidase NOX2 [73, 74],
which produces reactive oxygen species to neutralize protons within the compartment.
Additionally, lipid bodies controlled by the interferon-inducible ER-resident GTPase (Igtp),
are involved in lowering down the maturation of the antigen-containing endosomes [75].
However, the exact mechanisms of this influence by lipid bodies is not clarified so far.
Since not all endosomes are slowed down in their acidification and some mature towards
degradative lysosomal compartments, it is important for cross-presentation that the
antigen is localized in a stable endosomal compartment after its uptake. At least for
soluble antigens the decision, whether an antigen is transported into a slow-maturing
endosome or is directed towards lysosomal degradation, which can mediate MHC-II
presentation, is already influenced by the used uptake mechanism and the involved
receptors. While receptors like the mannose receptor [69] or monovalent dectin1 [76] direct
their ligands into a cross-presenting compartments, pinocytosed antigens or ligands taken
up by other receptors, like scavenger receptors [69] and cross-linked dectin1 [77], prefer
the transport towards lysosomal compartments and MHC-II presentation. The dectin1
receptor additionally shows that not only the receptor itself, but also the structure of the
ligand (for dectin1 it is —-glucan) has an influence on the antigen localization and its fate.
While monovalent —-glucan is mainly transported into stable endosomal compartments and
therefore is cross-presented, multivalent —-glucan rather ends up in degradative lysosomal
compartments and is available for presentation on MHC-II molecules.
Antigen processing and loading on MHC-I molecules After antigen uptake and trans-
port into a stable endosomal compartment, a decisive, but still not fully clarified step of
the endosome to cytosol pathway is the translocation of the antigen out of the endosomal
compartment into the cytosol for further processing.
The needed energy to overcome the membrane barrier between the endosome and the
cytosol might be delivered by the ATPase p97, which could act as a driving force for
the antigen [78, 66]. It has thereby been shown that the receptor involved in antigen
uptake might also support the antigen translocation by recruiting the ATPase p97 via
ubiquitination to the site of the antigen-containing endosome [66]. Additionally, it has
been reported that some proteins need to be unfolded for their export into the cytosol
and that the disulfide bonds of the protein have to be split by the “-interferon induced
lysosomal thiol reductase (GILT) [79]. Arriving in the cytosol, the exported antigen is
delivered to proteasomes, where it is e ciently cleaved into immunogenic peptides [44, 80].
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After degradation, these peptides are reimported by TAP into the ER [63, 65, 68] or
into the antigen-containing compartment itself, which has recruited the MHC-I loading
machinery before [63, 64, 66, 67]. In these compartments the processed peptides are
loaded on MHC-I molecules and trimmed by di erent aminopeptidases, like ERAP in the
ER or the endosomal IRAP, which is more e cient at the neutral pH, in the endosomal
cross-presenting compartments [63, 65, 81]. Although the ER as well as the endosomal
compartments are described as locations for MHC-I loading, recent data suggest that
antigen loading for cross-presentation might mainly occur within the antigen-containing
compartment rather than in the ER [62, 67].
Figure 1.3: The “endosome to cytosol” pathway of cross-presentation Extracellular
antigens are taken up by DCs and transported into a specialized compartment for
antigen cross-presentation. The antigens are exported into the cytosol, degraded
by proteasomes and the peptides are reimported into the same compartment or
alternatively into the ER. There they are loaded on MHC-I molecules for presentation
to CTLs.
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Recruitment mechanisms of components for cross-presentation towards antigen-
containing endosomes Although the presence of many components of the cross-presen-
tation machinery has been shown on these specialized endosomal compartments, it is
not fully understood how the recruitment of the needed ER-components for the loading
machinery works. However, some parts of potential pathways have been uncovered during
the last years. Besides the possibility of direct ER-involvement in endocytosis by providing
membrane for antigen engulfment [82], especially the role of di erent rab (ras-related
in brain) and SNARE proteins (soluble N-ethylmaleimide-sensitive-factor attachment
receptor) has been described in several publications. These two protein families are im-
portant for vesicular fusion events and are therefore able to mediate and control di erent
recruitment processes [83]. In context of NOX2, which is important for pH regulation
in the cross-presenting endosomes, it has been shown that its recruitment depends on
rab27, a GTPase described to be involved in exocytosis of secretory vesicles [73, 84]. Also
the rac2 GTPase as well as VAMP-8, interacting with the partly phagosomal SNARE
proteins syntaxin4 and SNAP23, were reported to be important for NOX2 translocation
to antigen-containing compartments [63, 85]. During the recruitment of the endosomal
peptidase IRAP a co-localization with rab14 as well as with the SNARE protein syntaxin6
was observed, indicating that these two factors might also contribute to the recruitment
machinery [63, 86]. Additionally, the SNARE protein sec22b seems to play a central role
for the translocation of parts of cross-presentation machinery (like TAP and Tapasin) from
the ER to the endosomal cross-presenting compartments [64].
Besides the molecular mechanism of the recruitment pathways also the origin of the single
components of the cross-presentation machinery in endosomal compartments is under
intense investigation. In a recent publication it was described that the MHC-I molecules
for cross-presentation are recruited rather from the plasma membrane than from the ER.
Therefore the MHC-I molecules are transported from the plasma membrane to a sort
of “storage” compartment, which afterwards provides MHC-I molecules exclusively for
cross-presentation and is essential for e cient presentation of extracellular antigens on
MHC-I molecules [67]. Interestingly, the supply with MHC-I molecules is completely
independent from the sec22b-mediated protein transport [67], indicating that several, more
or less independent, pathways are needed for the full function of the cross-presenting
endosomal compartment.
1.3.2 The vacuolar pathway
The second mechanism of cross-presentation is the vacuolar pathway (Fig. 1.4A). The
antigen is thereby taken up and directly digested in endosomal or lysosomal compartments
by proteases like cathepsin S [87, 88]. Afterwards, generated fragments are loaded on
MHC-I molecules inside of these compartments and can be presented on the cell surface
later on.
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The fact that MHC-I molecules can tra c to di erent compartments for peptide loading has
already been postulated before [89], but the origin of the MHC-I molecules for endosomal
antigen loading is so far not fully clarified. Newly synthesized MHC-I molecules might
be tra cked from the ER to antigen-containing compartments. Alternatively, MHC-I
molecules from the cell surface could be reused and the old peptides replaced by new ones.
This exchange might be supported by the acidic environment inside of the endo-lysosomal
compartments [90]. Important for the supply with MHC-I molecules is thereby a conserved
tyrosine residue in the cytoplasmatic tail included in the heavy chain of the MHC-I
molecule. The lack of this amino acid impairs the ability to present extracellular antigens to
CTLs [91]. As this cross-presentation mechanism takes place within a single compartment,
it is also independent of any proteasome or TAP activity.
In the context of MHC-I loading in endo-lysosomal compartments, also the possibility to
“cross-present” peptides engaged by autophagy is described. Especially in DCs, cytosolic
aggregates of mainly ubiquitinated proteins (DC aggresome-like structures, DALIS) are
enclosed by autophagy and degraded in endo-lysosomal compartments. Subsequently, the
resulting peptides can be presented on MHC-I molecules [92].
1.3.3 Gap-junctions
Apart from of the endosome to cytosol and the vacuolar pathway for presentation of
extracellular antigens on MHC-I molecules, two additional pathways for cross-presentation
are described in the literature, which may play a role under certain conditions.
The first one is utilizing gap-junctions to transfer antigens between two cells and to couple
their peptide presentation (Fig. 1.4B). Gap-junctions consist of connexins and build a
channel between two interacting cells to connect their cytosol. Through this construct
the already processed peptide is transported from one cell to another (for example from
a viral infected cell to a DC) [93]. Afterwards, the peptide directly enters the ER via
the TAP channel and is loaded on MHC-I molecules by the same way as an endogenous
peptide [94]. This cross-presentation pathway might be used to detect viruses, which are
hiding in cells and suppress their direct presentation. The transfer of virus-peptides to DCs
by gap-junctions might thereby enable an immune response. The theory that this system
plays a role during viral infection is enforced by the fact that for example herpesviruses
can suppress the expression of connexins [93]. Additionally, gap-junctions can be involved
in the immune defense in the surroundings of tumor cells. Investigations have shown that
Salmonella-infected tumor cells increase the formation of gap-junctions. Subsequently, the
antigen transfer through these channels to DCs can induce an immune response against
the tumor cells. Therefore, this might also be usable for potential tumor therapies in the
future [93, 95].
10
1 Introduction
1.3.4 Cross-dressing
The second alternative method for APCs to cross-present an antigen is to take over the
MHC-I peptide complexes from other cells, which are infected and have already loaded
antigenic peptides on the MHC-I molecules at their cell surface (Fig. 1.4C). This process
is independent of any antigen uptake or processing and enables the DC, which receives
the MHC-I peptide complex, to activate CTLs for an e cient immune response [96, 97].
Studies have revealed that a short fusion event of the plasma membranes is essential for
the translocation of the MHC-I peptide complex. The involvement of small vesicles like
exosomes is still discussed controversially [96, 98].
Figure 1.4: The vacuolar pathway as well as cross-dressing and gap-junctions in
cross-presentation A The proteasome independent vacuolar pathway. Peptides
are generated by intra-endosomal proteases and directly loaded on MHC-I molecules
for presentation. B The peptides for cross-presentation are transferred to DCs
by gap-junctions. C Loaded MHC-I molecules are transferred to DCs (also called
cross-dressing).
1.4 TLRs and their influence on cross-presentation
Signaling and tra cking of TLRs To activate the immune system, DCs have to be
stimulated by PRRs like TLRs [16, 33]. Contacts between PRRs and their ligands
thereby influence not only the expression of activation markers, but also intracellular
mechanisms like protein interactions [99]. In context of antigen presentation especially
TLRs play a central role. Due to their tra cking and recruitment to endosomes or
phagosomes, they allow a compartment-specific control for potential ligands as well as a
spacial response to their stimuli [100]. An example is the TLR4. It is natively localized
at the plasma membrane of the cell and is activated by LPS (lipopolysaccharide). In
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the presence of its ligand, it recruits the TIRAP (toll-interleukine 1 receptor (TIR)
domain-containing adaptor protein) as well as MyD88 (myeloid di erentiation primary-
response protein). This recruitment leads to a first response originating from the cell
surface. Subsequently, the receptor and its ligand are transported into an endosomal
compartment, from which an additional signaling by TRIF (TIR domain-containing adaptor
inducing IFN-—) in combination with TRAM (TRIF-related adaptor molecule) occurs.
Importantly, this second signaling step strictly depends on the endosomal localization of the
TLR4 [101]. Besides endocytosis from the plasma membrane, TLR4 can also be recruited
from endosomal recycling compartments (ERC) to antigen-containing structures. This
occurs for particular antigens, which contain LPS, in a rab11a and adaptor protein 3 (AP3)
dependent manner [102, 103].
In contrast to TLR4, another group of TLRs, like TLR9, is mainly localized in the ER. There
it associates with UNC93B, which mediates the tra cking of this TLR. After a stimulation
of the cell, TLR9 is selectively recruited to compartments, where its ligand (pathogenic
DNA) is present. Importantly, the induction of the recruitment of TLR9 requires no DNA-
ligand sensing itself, but a Fc receptor “-mediated uptake of immunoglobulin (Ig)-DNA
complexes [104, 105].
TLRs and cross-presentation How TLRs and their signaling directly influence the
molecular mechanisms of cross-presentation is still under intensive investigations. As
mentioned above the proteasome subunits are exchanged after the stimulation of the DC
took place [40, 41]. In addition to this, especially the recruitment of cross-presenting
components from the ER to the endosomal compartments is strictly controlled and
depends on the detection of defined signals [106]. It was shown that IRAP, which
is needed for peptide trimming in endosomal compartments, only co-localized with the
MHC-I loading machinery, when a stimulus with yeast cells occurred [63]. Additionally, the
translocation of TAP to antigen-containing compartments depends on TRL4 signaling after
a LPS stimulus was detected. For this recruitment only a MyD88 signal is important, while
a missing TRIF signal did not influence the TAP co-localization with the antigen. Also for
the MHC-I molecule a TLR-dependent translocation to antigen-containing compartments
has been described. Therefore, a TLR4-MyD88 signal induces the phosphorylation of the
SNARE protein SNAP23, which is localized at the antigen-containing compartment and
enables a fusion with MHC-I-containing vesicles. In addition, TRIF signaling seems to
participate in cross-presentation in general, but the mechanisms behind this pathway are
not clarified so far [62].
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1.5 The ERAD machinery
One important, but still sparsely described step in cross-presentation is the antigen export
out of the cross-presenting endosomal compartment into the cytosol. However, a very
similar process is known from the ER, used to recycle misfolded proteins.
1.5.1 From protein misfolding to degradation at the ER
Nearly one third of the proteins synthesized in a cell are transported or co-translated into
the ER, where they are folded and modified in di erent ways. While some proteins find
their functional state within seconds, others need several hours. The whole folding process
is very sensitive to stress, faulty protein sequences and many other factors. Therefore,
it often results in a misfolded protein. To protect the cell from the aggregation of these
faulty proteins within the ER, they need to be exported into the cytosol for proteaso-
mal degradation. This recycling process is mediated by the ER-associated degradation
machinery (ERAD; Fig. 1.5) [107, 108].
Recognition of misfolded proteins Multiple factors, which are only partly identified,
are involved in the detection of ERAD substrates. For ER quality control and recog-
nition of misfolded proteins, especially ER chaperones and chaperone-like proteins (for
example Hsp70s or lectins) play an essential role [109]. An example is the chaper-
one BiP, which is able to recognize hydrophobic parts of misfolded proteins, to keep
them in solution and to recruit these proteins via interaction with other factors, like
Herp, towards degradation. This detection system is very important for unglycosylated
proteins [110, 111, 112, 113]. Besides recognition of hydrophobic domains, the glyco-
sylation structure, which is added to many proteins after their import into the ER,
plays a central role in the ERAD substrate detection. Mostly an N-linked glycan struc-
ture, consisting of two N-acetylglucosamines, nine mannoses and three terminal glucose
residues, is co-translationally added to the proteins. During the folding process of the
protein, de- and re-glycosylations are done to coordinate the interactions with the lektin-
like chaperones calnexin and calreticulin [114]. When a protein is not folded within
several cycles, mannose residues are trimmed by the ER-mannosidase and EDEM1 (ER-
degradation enhancing –-mannosidase-like protein 1). This results in a free –-1,6 mannose
residue, which is recognized by a receptor of the ERAD machinery (namely OS-9). Subse-
quently, this receptor directs the misfolded protein towards the proteasomal degradation
complex [115, 116].
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Figure 1.5: The function of the ERAD system Misfolded proteins are recognized
by di erent chaperones as well as by their modulated glyco-structure. After
detection, the targeted protein is transported towards the ERAD complex,
where it is translocated into the cytosol. There, it is ubiquitinated and the
ATPase p97 is recruited as energy delivering subunit. Finally, the misfolded
protein is degraded by proteasomes.
Export and degradation After the detection of the potential ERAD substrate, it is
recruited towards the ERAD complex, which consists of substrate detection receptors,
several linker-proteins (like SEL1) [117], ER-associated E3 ubiquitin ligases and potential
channel proteins for substrate delivery into the cytosol. Also other additional components,
like the protein disulfide isomerase (PDI) for splitting disulfide bonds to completely un-
fold the ERAD substrate and enable the protein translocation, are integrated into this
complex [118, 119].
In yeast three di erent pathways for the ERAD machinery are well characterized. In
the center of this process are two ER-associated E3 ubiquitin ligases expressed in yeast.
For transmembrane proteins defective on the cytosolic site of the ER (ERAD-C), the
E3 ubiquitin ligase Doa10 is described to be important for ubiquitination and further
processing. For soluble proteins (ERAD-L) and proteins with defects in their ER-luminal
part (ERAD-M) the E3 ubiquitin ligase Hrd1 plays an essential role [120, 121, 122]. Both
E3 ubiquitin ligases are multiple transmembrane (TM) proteins with their catalytic do-
main in the cytosol. At least for Hrd1 it is additionally known that the TM-regions can
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recognize misfolded TM-domains of di erent ERAD substrates itself [123]. In mammals
both E3 ligases have orthologs, but additional 14 other ER-associated E3 ligases are
identified, emphasizing the complexity of the ERAD machinery [124].
Once the misfolded protein reaches the cytosolic site of the ER-membrane, it is ubiq-
uitinated by the E3 ubiquitin ligase, which marks the protein for proteasomal degra-
dation [125, 126]. At the same time, the ATPase p97, which is described in many cellular
mechanisms as the energy delivering component, is recruited directly to the backbone of
the exported protein [127]. This interaction is enforced by the polyubiquitin chain, which is
linked to the translocated protein [128]. p97 is now proposed to pull the misfolded protein
into the cytosol [129, 130, 131]. Additionally, p97 has chaperone-like properties, which
keeps the exported protein soluble and thereby mediates the transport to the proteasome,
where the final degradation takes place [132, 133]. Interestingly, independent of the selected
ERAD pathway, p97 is involved in the final steps of protein degradation for the great
majority of ERAD substrates.
1.5.2 Di erent candidates for the export channel of the ERAD
system
One still not fully clarified and intensively discussed step during the ERAD processing
is, how the misfolded protein can overcome the membrane barrier for the translocation
into the cytosol, where it interacts with p97 and is degraded by proteasomes. For this
transport various channel proteins have been described.
1.5.2.1 Hrd1
During the last few years it has been reported that the E3 ubiquitin ligase Hrd1 can
directly take over the export of the misfolded protein by building a transmembrane
channel by itself or at least contribute to the core of a channel in combination with
co-factors [134, 135]. For the translocation of the ERAD substrate the TM-domains of
the Hrd1 protein contain several conserved polar and hydrophilic residues. By muta-
tion of these to hydrophobic amino acids the translocation of several substrates is dis-
rupted, while the general interaction of Hrd1 with the misfolded proteins is
una ected [123, 134, 136]. Additionally, it was shown in an in-vitro model system that
Hrd1 as only membrane component was su cient to mediate the transport of the ERAD
substrate through a membrane structure [135].
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1.5.2.2 Derlin1
The mammalian derlin protein family includes at least three di erent homologs and
is member of the rhomboid-like clan of polytopic membrane proteins containing four
transmembrane domains [137, 138, 139]. While derlin1 has only a similarity of about 30%
to the sequence of derlin2, derlin2 and derlin3 are closer related to each other (about 70%
of the sequence is identical). The derlin proteins are present inside of ERAD complexes
and interact with other components connected to the protein degradation machinery,
like ERAD substrate recognition structures and the ubiquitination machinery (including
Hrd1). Additionally, derlin1 interacts with p97 and proteasomes via the adaptor protein
VIMP [137, 138, 140]. In yeast, derlin is described to be involved in the degradation of
luminal ER proteins, but not in the recycling of TM-proteins [141], whereas in mammalian
cells all three derlins participate in the translocation of soluble and membrane proteins.
The di erent derlin homologs are thereby responsible for the processing of distinct ERAD
substrates. Derlin1 is for example mediating the MHC-I degradation in the presence of
the cytomegalovirus (CMV) protein US11 [137, 138]. Under these conditions it was shown
that derlin1 interacts with the ERAD substrate on both ER sites, before and after protein
export [138]. Additionally, derlin1 was described to be involved in the transport of the
pre-pro –-factor [142]. On the other hand, derlin2 and derlin3 are important in the context
of an –1-antitrypsin mutation and its ERAD-dependent degradation [143].
1.5.2.3 Sec61
The third channel protein, described in context of the ERAD machinery, is the sec61
protein complex [144, 145]. Sec61, which has first been described and is mainly known
from protein synthesis [146, 147, 148], is build of three subunits. The – subunit generates
the pore in the membrane, which consists of two transmembrane complexes, each divided
in 5 domains. The “ subunit is in close contact to the – subunit and connects their
substructures [148]. The importance of sec61 for an organism is emphasized by its high
conservation. Compared to S. cerevisiae the pore building – subunit of mammalian cells
is 55% identical on protein level [146]. Even more astonishing is the 100% conservation
of the sec61– protein between vertebrates. In addition to this, a second gene encoding a
paralogue sec61– protein (sec61–2) was found in several species [146], which is about 80%
identical to it sec61–1 and again 100% conserved between vertebrates. Like sec61–, also
the sec61“ subunit shows a high conservation between eukaryotes, while the — subunit,
which is required for the lateral release of TM-regions of newly synthesized proteins, is
more variable [149].
In context of the ERAD machinery, sec61 interacts with several described ERAD
substrates [113, 150, 151, 152, 153]. One example is the cholera-toxin, which is pro-
cessed in the ER and afterwards misuses the retrograde transport machinery of the ERAD
system to get into the cytosol. During the export of the toxin out of the ER into the
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Figure 1.6: Models for protein translocation into the cytosol A The ubiquitin-
ligase Hrd1 is mediating the protein export and might create the pore by
oligomerization. B Derlin1 in combination with Hrd1 builds the channel
protein. C Sec61 is involved in ERAD and takes over the transport of misfolded
proteins.
cytosol it can be co-purified with sec61. Also an interaction of sec61 with SEL1, an
important linker protein for the Hrd1 ubiquitin ligase [153] was observed and a contact
site between sec61 and the proteasome itself was found [154]. Additionally, two di erent
mutation-constructs of the yeast sec61 protein emphasize its role as channel for the ERAD
mechanism. These mutants showed an accumulation of unprocessed ERAD substrates
in the ER, while the presence of the cytosolic precursor of the misfolded protein was
not increased. This indicates that the protein translocation by sec61 into the ER was
una ected, while the ERAD transport function was impaired [113, 155].
1.5.3 The ERAD machinery in cross-presentation
For some components of the ERAD machinery an important role in cross-presentation
is proposed, which might use a similar transport system to deliver antigens from the
endosomal compartment into the cytosol for proteasomal degradation. It was shown
that p97 is recruited to antigen-containing endosomes and its function is essential for
delivering the antigen into the cytosol [78, 66]. However the channel protein for cross-
presentation is still not fully identified. Some studies indicate that beside of components of
the MHC-I loading machinery, the sec61 channel protein is present in antigen-containing
phagosomes [78]. Also the inhibitor exotoxinA, described to interact with sec61 [156], led
to a significant reduction of cross-presentation and antigen translocation into the cytosol,
indicating that sec61 is involved in this export process [78]. However, direct evidences are
still missing and the question, which export channel is responsible for cross-presentation is
controversially discussed.
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2 Aim of this study
Cross-presentation is the possibility for DCs to present extracellular antigens on MHC-I
molecules. One of the major pathways for this presentation is the “endosome to cytosol”
pathway. During this, the antigens are internalized and have to be translocated into the
cytosol for proteasomal degradation.
One of the main unanswered questions of this cross-presentation pathway is, how the
antigens can overcome the membrane barrier between the endosomal compartment and
the cytosol. Therefore, the machinery regulating such an non-canonical protein transport
across endosomal membranes is intensively and controversially discussed.
The aim of this study was to clarify, whether the ERAD machinery is involved in cross-
presentation and which channel protein enables the extracellular antigen to pass the
membrane barrier into the cytosol for proteasomal degradation and further processing
for MHC-I presentation. Especially the role of sec61 in context of cross-presentation
was supposed to be analyzed in greater detail. This channel protein has already been
reported to be involved in the ERAD system, transporting proteins in the same di-
rection as needed for antigen export [151, 152]. Furthermore, it was in the center of
interest, whether sec61 or other components of the ERAD machinery can be recruited
to the antigen-containing compartments. For these analyzes we used a novel method of
endosomal flow cytometry [157] in combination with ER-retaining antibodies (intrabodies).
As it is known that recruitment of other ER-components to the site of cross-presentation is
strictly controlled and TLRs have an influence on cross-presentation in general [106, 158],
we additionally planed to investigate the role of TLR-signaling during the antigen translo-
cation into the cytosol.
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3 Material and Methods
3.1 Material
Here, the used material and equipment is listed. Additionally, the procedures during the
di erent experiments are described below.
3.1.1 Technical equipment
Device Specification and company
Flow cytometry LSRII, BD Bioscience
Cell-homogenisator Wheaton Dure-Grind steal-dounce
NanoDrop2000 spectrophotometer Thermo Scientific
ELISA plate reader Molecular Devices
Electroporator BioRad GenPulser X-cell, Biorad
Microscope ApoTome, Carl Zeiss
ChemiDoc MP imaging system BioRad
Centrifuge 5417R Eppendorf
Ultracentrifuge Beckman
3.1.2 Consumables
All not listed consumables were purchased from Sarstedt and Eppendorf.
Consumable Company
6-well plates TPP
24-well plates TPP
Non-treated 24-well plates Costar
96-well plates TPP
ELISA plates, Microlon 96-well flat bottom Greiner
1 l BottleTop vacuum filter (0.45µm pore) Corning
Sterile syringe filter, 0.20µm and 0.45µm, CA Whatman
Falcon cell strainer, 0.40µm BD Bioscience
Filter pipette tips Axygen
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Consumable Company
Cyrotubes Nunc
Electroporation cuvettes BioRad
PD10 desalting columns GE Healthcare
Zebra desalt spin columns ThermoFisher
Nitrocellulose membrane Whatman
Filter paper Whatman
Ultracentrifugation tubes Beckman
3.1.3 Chemicals, reagents and experimental kits
All chemicals and reagents, as far as not otherwise marked, were purchased from Sigma-
Aldrich in analytic quality.
General reagents
Chemicals Company
Sulfo-NHS-LC-biotin ThermoFisher
Complete EDTA-free protease inhibitor Roche
Neutravidin-horseradish peroxidase ThermoFisher
IL-2, recombinant ELISA-standard eBioscience
IGEPAL Sigma-Aldrich
Low-fat dry milk powder Applichem
Tween-20 Sigma-Aldrich
Coomassie staining Roth
Bovine serum albumin (BSA) Roth
Bromphenol blue Roth
AnnexinV bu er BD Bioscience
Fluromount Sigma-Aldrich
Molecular biology
Reagents Company
Protein A/G PLUS-agarose Santa Cruz
DynBeads ProteinG Invitrogen
SYBR Safe DNA gel stain Invitrogen
AccuPrime DNA-polymerase Invitrogen
Phusion High Fidelity DNA-polymerase New England Biolabs GmbH
Superscript II (reverse transcriptase) Invitrogen
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Reagents Company
RNeasy Mini Kit Qiagen
ProteoExtract®SubcellularProteome Extraction kit Calbiochem
mMESSAGE mMACHINE T3 kit Ambion, Applied Biosystems
mMESSAGE mMACHINE T7 ultra kit Ambion, Applied Biosystems
Poly-A tailing kit Ambion, Applied Biosystems
DNA-ladder 1 kb New England Biolabs GmbH
Phosphate bu ered saline (PBS) Biochrom
Ampicillin Carl Roth
Kanamycin Carl Roth
Restriction enzymes New England Biolabs GmbH
NucleoBond Xtra Midi kit Macherey-Nagel
NucleoSpin Xtract kit Macherey-Nagel
Protein ladder New England Biolabs GmbH
Cell biology
Reagents Company
Lipofectamine2000 Invitrogen
MHC-I OVA peptide (257-264) Tebu-Bio
MHC-II OVA peptide (323-339) Tebu-Bio
IC fixation bu er eBioscience
Permeabilization bu er 10x eBioscience
Fixation/Permeabilization concentrate (4x) eBioscience
DAPI for nucleic acid staining Sigma-Aldrich
Hoechst 33258 Invitrogen
Ovalbumin (OVA) Serva
Endotoxin-free (endograde) OVA Hyglos
OVA-alexa 488, 568 and 647 Invitrogen
MG132 (z-Leu-Leu-Leu-Al) Sigma-Aldrich
Transferrin-alexa 647 Invitrogen
—-lactamase (Enterococcus cloacae) Sigma-Aldrich
CCF4 FRET substrate Life technologies
Cytochrome c (horse) Sigma-Aldrich
Polybrene (Hexadimethrine bromide) Sigma-Aldrich
Eeyarestatin I Santa Cruz
ExotoxinA Sigma-Aldrich
BrefeldinA Sigma-Aldrich
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Cell culture
Reagents Company
OptiMEM Invitrogen
DMEM, high glucose (4,5 g/l), with L-glutamine PAA
IMDM, with L-glutamine PAA
RPMI-1640, w/o L-glutamine, with HEPES PAA
Sodium pyruvate, 100mM PAN
L-glutamine, 200mM PAN
NEAA (100 x) PAN
—-mercaptoethanol Sigma-Aldrich
Trypsin 0,05% / EDTA 0,02% PAN
FCS Clone PAA
Penicillin/Streptomycin PAA
EDTA 2mM Sigma-Aldrich
3.1.4 Antibodies
Primary Antibodies
Antigen Clone / Lot Company Usage Dilutions
IL-2 purified JES6-1A12 eBioscience ELISA 1:1000
IL-2 biotinylated JES6-5H4 eBioscience ELISA 1:1000
Rab5 D-11 Santa Cruz IF, FlowCyt
IF 1:200,
FlowCyt 1:100
Sec61– 07-204 Upstate WB 1:1000
Sec61— ab78276 Abcam IF 1:200
Sec61“ 11147-2-AP Proteintech WB 1:500
Derlin1 derlin1-1 Sigma-Aldrich
WB,
FlowCyt
WB 1:1000,
FlowCyt 1:200
EEA1 H-300 Santa Cruz IF 1:200
Lamp 1D4B eBioscience IF
IF 1:500,
FlowCyt 1:1000
GM130 — Sigma-Aldrich IF 1:250
AnnexinV — BD Bioscience FlowCyt 5µl/stain
Actin AA20-33 Sigma-Aldrich WB 1:5000
Calnexin ab22595 Abcam WB 1:1000
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Antigen Clone / Lot Company Usage Dilutions
IgG isotype P3.6.2.8.1 eBioscience FlowCyt
depending on
primary antibody
concentration
HIS-tag MAC1396 Serotec WB 1:1000
Myc-tag 9E10 Biolegend WB 1:1000
H-2Kb-
SIINFEKL
25.D1.16 eBioscience FlowCyt 1:60
Secondary antibodies
Antibody Company
–-mouse-IgG-alexa 568 Invitrogen
–-rabbit-IgG-alexa 488 Invitrogen
–-rabbit-IgG-alexa 568 Invitrogen
–-rabbit-IgG-alexa 647 Invitrogen
–-mouse-IgG-HRP Santa Cruz
–-rabbit-IgG-HRP Santa Cruz
–-human-IgG-HRP Santa Cruz
All alexa-coupled antibodies were used in a 1:1000 dilution, all Santa Cruz antibodies were
diluted 1:5000.
3.1.5 Primers and cloning vectors
Primers
All primers were purchased from Life technologies.
cDNA production
Name Sequence
oligo-dt-T7 TTTTTTTTTTTTTTTTT
mRNA production
Name Sequence
EGFP forw. TAGTGAACCGTCAGATCCG
EGFP rev. TAATACGACTCACTATAGGG
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RT-PCR
Name Sequence
GAPDH forw. CAGCAATGCATCCTGCAC
GAPDH rev. GGATGACCTTGCCCACAG
Sec61–1 forw. CCGAGTGGACCTTCCAATC
Sec61–1 rev. CACTGAGCCGAACGATTCC
Sec61–2 forw. TCGTGTTGACTTGCCCATT
Sec61–2 rev. AAATATGGCTCCCATAGACTCAG
Cloning strategies
Name Sequence
Cloning into the target vector pEGFP-C3
Sec61— forw. GATCAAGTTCATGCCGGGTCCAACGCCCAGTG
Sec61— rev. GATCGTCGACCATGATCGCGTGTACTTGCCCC
Cloning into the target vector pCMV-tag2B
IB forw.ú
GCGCCGCGGGAGCTCGCCACCATGGGATGGAGCTGTATCATCCTCTTC
TTGGTAGCAACAGCTACAGGCGCGCACTCCCAGGTGCAGCTG
IB bicist rev. GCGCGAATTCGTCGACTCAGGAGAGCACACACTTGCAGCTC
IB mono with
KDEL rev.
GCGCGAATTCGTCGACTTATAGTTCGTCCTTATGATGATGG
IB mono w/o
KDEL rev.
GCGCGAATTCGTCGACTTAATGATGATGGTGATGATGGGATAG
CD3” -SIINFEKL
forw.
GCCGGCGCGGCCGCAAGCTTGCCACCATGGAACAC
AGCGGGATTCTGGCTAGTC
CD3”-SIINFEKL
rev.
GAGGGAACTGGCCCCGGAACAAGAAATCTGCCCTTGAGCAGCTTGAGAG
TATAATCAACTTTGAAAAACTGACTGAATGGACCAGTTAACTCGAGGGCCG
TCR–
-SIINFEKL forw.
GCCGGCGCGGCCGCAAGCTTGCCACCATGGACAA
GATCCTGACAGCATCGTTTTTAC
TCR–-
SIINFEKL
rev.
GAGGCTCCAGCAAAGCCCTGCTGTGGGCGCCCTTGAGCAGCTTGAGAGTA
TAATCAACTTTGAAAAACTGACTGAATGGACCAGTTAACTCGAGGGCCGG
Cloning into the target vector pCMV-LV
Sec61—-GFP sec61—-GFP was cloned from pEGFP-C3 into pCMV-LV by AgeI and SalI
IB bicist forw. GCGCCCGCGGGGCGCGCCGCCACCATGGGATGGAGCTGTATCATCCTC
IB bicist rev. GCGCGAATTCCTCGAGTCAGGAGAGCACACACTTGCAGCTC
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Name Sequence
Cloning into the target vector pEGFP-C3
IB mono forw. GCGCCGCGCGCGCCGCGGGCCACCATGGGATGGAGCTGTATCATCCTC
IB mono rev. úú GCGCGAATTCCTCGAGGGCAACTAGAAGGCACAGTCGAGGC
IB mono rev. úúú GCGCGAATTCCTCGAGGGTACCGGGCCCCCCCTCGAGGT
* This primer was used for all intrabody (IB) constructs (AMA56 as well as all SH814-A2
variants). Alternatively to the cloning of mono-IB constructs into the lentiviral vector
also an elimination of the GFP sequence in the pCMV-LV-bicist-IB by NheI digest was
performed.
** Used for cloning with pKD-bicist-SH814-A2 or pKNC-mono-SH814-A2 vector as tem-
plate.
*** Used for cloning with IB-constructs within a pCMV-tag2B vector as template.
Sequencing primers
For DNA-sequencing the standard primers of GATC were used.
Vectors
Name Resistance Origin
pEGFP-C3 Kanamycin Clontech
pCMV-tag 2B Kanamycin Clontech
pCMV-LV Ampicillin Addgene
pCMV-gag Ampicillin Addgene
pCMV-VSVG Ampicillin Addgene
pCMV-GFP Kanamycin AG Burgdorf
pCMV-OVA-flag Kanamycin AG Burgdorf
pKD-mono-AMA56 (control vector)ú Ampicillin University of Braunschweig
pKD-bicist-AMA56 (control vector)ú Ampicillin University of Braunschweig
pKD-bicist-SH814-A2 (with KDEL)ú Ampicillin University of Braunschweig
pKD-mono-SH814-A2 (with KDEL)ú Ampicillin University of Braunschweig
pKNC-bicist-SH814-A2 (wo KDEL)ú Ampicillin University of Braunschweig
pKNC-mono-SH814-A2 (wo KDEL)ú Ampicillin University of Braunschweig
* The ”bicist” vectors contain an IRIS-GFP sequence, which is missing in “mono” vectors.
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3.1.6 Bu ers and solutions
If not otherwise noted, the pH of the solution was adjusted by HCl or NaOH and the
solutions were stored at RT.
Substrates for bacteria culture
TFB I
NaAc, pH=6, 30mM
MnCl2¶4 H2O, 50mM
NaCl 100mM
CaCl2 10mM
glycerol 15% (v/v) pH=6, sterile filtered
TFB II
MOPS, pH=7, 10mM
NaCl 10mM
CaCl2 75mM
glycerol 15% (v/v) pH=7, sterile filtered
YB-media 2x
YT-Media 98%
KCl (Stock 1M) 10mM
MgSO4 (Stock 2M) 20mM
20min at 121 °C autoclaved
stored at 4 °C
YT-media (2x)
NaCl 0,5%
Bacto Yeast Extract 1%
Tryptone 1.6%
pH=7.5; 20min at 121 °C autoclaved
stored at 4 °C
LB-media
Tryptone 10 g/l
Yeast extract 5 g/l
NaCl 5 g/l
20min at 121 °C autoclaved
stored at 4 °C
Ampicilin was used with a final concentration of 100µM/ml, kanamycin with 50µM/ml.
DNA-preparation and analysis
Mini-prep. solution 1
Tris/HCl, pH=8, 50mM
EDTA 10mM
RNaseA 100µg/ml
stored at 4 °C
6xDNA-loading bu er
Bromphenol blue 0,25%
Xylencyanol blue 0,25%
Glycerol 30%
EDTA 50mM
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Mini-prep. solution 2
NaOH 200mM
SDS 1%
Mini-prep. solution 3
KAc 3M (pH=5.5)
TAE-bu er (50x)
Tris 2M
acetic acid 1M
EDTA 0,05M
pH=8,3
DNA-transfection
2x BBS bu er
BES 50mM
NaCl 280mM
Na2HPO4 1.5mM
pH=7
stored at -20 °C
CaCl2
CaCl2 2.5M (highest purity)
stored at 4 °C
Transfections in 6-well or 24-well plates were done by Lipofectamine2000 according to the
standard lipofectamine transfection protocol.
Protein analysis
Phosphate-lysis-bu er (pH=8)
NaPO4 20mM
NaCl 140mM
MgCl2 3mM
NP-40 0.5%
Complete protease inhibitor freshly added
stored at 4 °C
TEA-lysis-bu er
NaCl 150mM
MgCl2 1mM
CaCl2 1mM
TEA 10mM
TritonX 1%
Complete protease inhibitor freshly added
4x Laemmli bu er
Tris-HCl (pH=6,8) 250mM
SDS 8%
Glycerol 40%
Bromphenol blue 0.08%
(10% —-mercaptoethanol)
stored at -20 °C
SDS-PA-stacking gel
dH2O 1.2ml
Rotiphorese-Mix 330µl
Tris-HCl (Stock 1M, pH=6.8) 250µl
SDS (10%) 20µl
APS (10%) 20µl
TEMED 2µl
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SDS-PA-resolving gel 10%
dH2O 1.9ml
Rotiphorese-Mix 1.7ml
Tris-HCl (Stock 1.5M, pH=8.8) 1,3ml
SDS (10%) 50µl
APS (10%) 50µl
TEMED 2µl
Towbin-bu er (10x)
Glycine 1.92M
Tris 250mM
pH=8.53
(if needed 20% methanol was added)
SDS-running bu er (10x)
Glycine 1.92M
Tris 250mM
SDS 1%
Coomassie staining solution
MeOH 40%
C2H4O2 10%
Coomassie 0,1%
TBS bu er
Tris-HCl (Stock 1M, pH=7.5) 50mM
NaCl 150mM
Wash bu er (TBS-Tween)
Tris-HCl (Stock 1M, pH=7.5) 50mM
NaCl 150mM
Tween20 0.05%
ELISA-bu er
ELISA coating bu er
NaHCO3 0,1M, pH=8.2
ELISA blocking bu er
BSA 1% in PBS
ELISA washing bu er
Tween20 0.05% in PBS
ABTS bu er
Citric acid 0.1M, pH=4.35
ABTS development solution
ABTS bu er including 1mg/ml ABTS and
15µl H2O2 (30%) per 10ml
Endosome preparation and —-lactamase bu ers
Cell homogenization/endosomal flow cytometry bu er
MES 25mM
NaCl 150mM
pH=6.5
Complete protease inhibitor was freshly added, sterile filtered
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—≠Lactamase EM-bu er
KCl 7mM
NaCl 120mM
CaCl2 1.8mM
MgCl2 0.8mM
Glucose 5mM
HEPES 25mM, pH=7.3
1mM protease inhibitor Probenicid was freshly added
—≠Lactamase CCF4 loading bu er
Sol.A 12µl (contains 1 µM CCF4) stored at -20 °C
Sol.B 60µl
mixed well
Sol.C 928µl
mixed well
Sol.D 50µl
—-Lactamase EM-bu er with Probenicid 4950µl
3.1.7 Bacteria strains, cell lines and mice strains
Bacteria Strain Genotype
Escherichia
coli
DH5– F-, Ï80dlacZDM15, D(lacZYA-argF)U169, deoR, recA1, endA1,
hsdR17(rk-, mk+), phoA, supE44, l-, thi-1, gyrA96, relA1
Escherichia
coli
XL-1
blue
endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F’[ ::Tn10 proAB+
lacIq D(lacZ)M15] hsdR17(rK- mK+)
Cell line Description Culture conditions
HEK293T Human embryonic
kidney cells infected with
adenovirus E1A/B
DMEM (4.5 g/l glucose), 10% FCS, 100 units/ml
penicillin, 0.1mg/ml streptomycin and 1mM sodium
pyruvate. Cells were harvested by Trypsin/EDTA in
PBS.
DC2.4 Murine, immortalized
and immature dendritic
cells [159]
RPMI 1640, 10% FCS, 50µM —-mercaptoethanol,
100 units/ml penicillin, 0.1mg/ml streptomycin, 1mM
sodium pyruvate and 1% non essential amino acids.
Cell harvesting was done by 2mM EDTA in PBS.
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Cell line Description Culture conditions
J558L-
GMCF
Transgenic BALB/c
myeloma cell line
producing and secreting
GM-CSF into the
supernatant.
RPMI 1640, 10% FCS, 100 units/ml penicillin,
0.1mg/ml streptomycin. These cells contain a G418
resistance for selection and are subcultured by
dilution into fresh media.
Primary
cells
Description Culture conditions
BMDCs Bone marrow-derived
dendritic cells,
di erentiated from the
bone marrow of the
relevant mouse strain
IMDM, 10% FCS, 2.5% GM-CSF-containing
supernatant of J558L cells, 50µM —-mercaptoethanol,
100 units/ml penicillin and 0.1mg/ml streptomycin.
The culture was done as described below.
T-cells OT-I or OT-II T-cells
gained out of the spleen
of the correspondent
mice
RPMI 1640, 10% FCS, 50µM —-mercaptoethanol,
100 units/ml penicillin, 0.1mg/ml streptomycin, 1mM
sodium pyruvate.
Mouse strain Description
C57BL/6 Wild-type strain
TRIF -/- Contains a point-mutation in the gene encoding for TRIF-/-, which leeds
to a frame shift and a non-functional, truncated TLR-TRIF signaling
molecule. The TRIF-/- mice have a C57BL/6 genetic background.
MyD88 -/- Is missing the TLR-MyD88 signaling molecule. The mice have a C57BL/6
genetic background.
OT-I RAG1 -/- Only produces CD8+ T-cells, recognizing the OVA-peptide (257-264) on
H-2Kb MHC-I molecules.
OT-II Produces CD4+ T-cell recognizing the OVA-peptide (323-339) on I-Ab
MHC-II molecules.
For all experiments 8 to 16 weeks old mice were used. These were bred under specific
pathogen-free conditions. The treatment of the animals was in accordance with local
animal experimentation guidelines.
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3.1.8 Software
Software Company
Papers 2 Mekentosj
FlowJo V8.7 TreeStarInc
FACS-DIVA BD Biosciences
ImageJ National Institute of Health
Axiovision Zeiss Software
Photoshop CS6 Adobe Systems
Illustrator CS6 Adobe Systems
Microsoft O ce Mac 2011 Microsoft
Image Lab Software Bio Rad
Prism6 GraphPad Software
Lyx open source
Serial Cloner 2-5 SerialBasics
3.2 Methods
3.2.1 Molecular-biological methods
3.2.1.1 Generation of transformation competent bacteria
For the production of chemical competent bacteria the method of Hanahan et al. was
used [160]. Therefore, 3ml of bacterial pre-culture were grown overnight at 37 °C in LB
medium. Subsequently, this culture was extended to 100ml in YB medium and stopped
dividing during their exponential growth period (optical density of 0.45 - 0.55 OD600) by
cooling on ice for 10min. The bacteria were centrifuged for 10min with 3220 rcf and the
pellet was resuspended in 20ml TFB-I. After 10min of incubation on ice, the bacteria were
spun down again (3220 rcf, 10min) and finally taken up in 4ml TFB-II bu er. Aliquots of
100µl were shock frozen with liquid nitrogen and stored at -80 °C.
3.2.1.2 RNA-extraction and cDNA synthesis
The RNA isolation out of the relevant cells was done as described in the Qiagen RNeasy
Mini-Kit protocol. Subsequently, the reverse transcription of mRNA was prepared and
incubated at 42 °C for 90min. The storage of synthesized cDNA was done at -20 °C.
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Reaction mixture Stock-solution
RNA 5µl
RNase free H2O 5.5µl
RNAsin 0.5µl
5x reaction bu er 4µl
0.1 DTT 2µl 5mM
10mM dNTPs 1µl each 0.5mM
Oligo dT primer 1µl 25µg/ml
Superscript II 1µl 10 units/ml
3.2.1.3 DNA amplification (PCR) and analysis
Polymerase chain reaction The amplification of DNA was done by polymerase chain
reaction. Therefore, prove-reading polymerases were used to avoid mutations inside of the
amplificates. The reaction conditions were chosen as indicated by the instructions of the
used polymerase. The annealing temperature was specifically adapted to the used primer
constructs. The PCRs for cloning strategies contained 30 cycles of amplification, while
PCRs, which were done to determine relative expression levels of specific gens, run only
for 25 cycles.
Reaction mixture
H2O 36.5µl —
5xReaction bu er 10µl —
Primer 1µl each 0.5µM
Template 1µl 0.5-1µg cDNA
50-100 ng
DNA-Plasmid
dNTP 1µl each 0.2mM
Phusion polymerase 0.5µl 0.02 units/µl
DNA analysis and purification by agarose gel electrophoresis Gel electrophoresis was
done as described by Sambrook et al.. Therefore, the negative charge of DNA was used
to separate DNA fragments by size. The agarose gels contained 0.8% to 2% agarose in
1xTAE bu er, depending on the expected DNA length. Additionally, SyBR-Safe DNA gel
stain for the detection of the DNA bands by UV light was used. The size of DNA fragments
was determined by 100 bp or 1 kb markers. For further processing of the DNA, the gel,
containing the DNA of interest, was sliced out and purified regarding the instructions of
the NucleoSpin Extract KitII. The elution was done with pure H2O.
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3.2.1.4 Cloning protocols and plasmid generation
Restriction digest For the generation of plasmid constructs, the DNA insert and the
targeted plasmid were cut by the same or by matching restriction enzymes. For the DNA
inserts, the restriction sides were added by PCR with primers containing the required
cleavage sides. Additionally, the DNA was purified by Nucleo Spin Extract KitII before
the sample was used for further processing. The reaction-mixture was incubated for 1 hr
at 37 °C, if not otherwise indicated in the restriction enzyme descriptions. If the usage of
both enzymes at once was not possible, the incubations were done sequential. As soon as
the cutting of the DNA was completed, it was again purified by agarose gel electrophoresis
and Nucleo Spin Extract KitII.
Reaction mixture for restriction digest
PCR product or 1µg plasmid in H2O 28µl
Appropriate 10x reaction bu er 4µl
10xBSA 4µl
Enzyme 1 2µl
Enzyme 2 2µl
Ligation For the ligation a 5’ phosphate on the one side and a 3’ OH on the other side
were required to connect the two DNA fragments. The fusion of this two groups was
done with the T4 DNA-ligase by ATP hydrolysis. Therefore, the reaction mixture was
incubated for at least 2 hrs at room temperature or overnight at 16 °C.
Reaction mixture for ligation
PCR fragment 5.5µl
Vector 3µl
T4 DNA-ligase bu er 1µl
T4 DNA-ligase 0.5µl
Transformation of chemical competent bacteria For transformation, 50µl of compe-
tent bacteria, which were thawed on ice before, were added to the whole ligation of newly
cloned constructs or 10 ng of already purified plasmid. After 30min of incubation on ice,
the bacteria were heated to 42 °C for 90 sec and cooled for one additional minute on ice.
Sequentially, 1ml antibiotic-free LB-medium was added and the incubation was done for
1 hr at 37 °C on a shaker. After short spinning, the pellet was resuspended in a small
amount of LB media and the bacteria were plated on LB agar plates, containing the
correspondent antibiotic. For the growth of colonies the incubation was done overnight
at 37 °C.
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Analytical DNA preparation This preparation was used to identify positive colonies on
LB agar plates. Selected colonies were picked from the LB agar plate and transferred into a
15ml falcon, containing 3ml LB media with the corresponding antibiotic. After incubation
overnight at 37 °C, the bacteria suspension was transferred and pelleted in an Eppendorf
reaction tube (21000 rcf, 5min). Subsequently, the pellet was resuspended in 100µl
Mini-preparation bu er I (resuspension bu er) and mixed with 200µl Mini-preparation
bu er II (an alkalic lysis bu er) by inverting the tube three times. After 5min of incubation,
the Mini-preparation bu er III was added for neutralization of the alkaline lysis bu er
and the sample was again mixed by inverting the tube. Thereafter, the lysate was spun
down for 5min at 21000 rcf to separate the plasmid DNA from bacteria fragments and
genomic DNA. The supernatant was transferred into a new tube and mixed well with
1ml ice cold 100% pure ethanol as well as 50µl Mini-preparation bu er II by vortexing.
The precipitated DNA was pelleted for 30min with 21000 rcf at 4 °C. After washing one
time with 70% ethanol, the DNA was centrifuged again (21000 rcf, 5min) and the pellet
was dried at 37 °C. Resuspension was done in 25µl pure H2O. The gained plasmid DNA
was tested for successful cloning by digesting with di erent restriction enzymes and gel
electrophoreses. The enzyme combination was selected to achieve a definitive identification
of a successful insert integration.
Preparative DNA purification The bacteria with successful cloned plasmids were ex-
pended overnight in 300-500ml LB medium and pelleted in 50ml falcons by centrifugation.
The preparation was done as described in the instructions of the NucleoBond Xtra Midi
Kit. Afterwards, the plasmid-pellet was resuspended with pure H2O and the concentration
was measured with the Nanodrop2000 at 260 nm. The DNA purity was determined by the
ratio of the absorption at 260 nm and 280 nm, aiming a ratio of 1.7 to 1.9. The sequences
of the cloned constructs were analyzed by GATC Biotech AG.
3.2.1.5 In-vitro mRNA production out of DNA templates
For mRNA production a PCR was done on the gene encoding plasmid (for GFP) or the
plasmid was spliced by restriction enzyme digest (BamHI digest on the OVA encoding
plasmid). Important for the template DNA was that a T3 or a T7 binding side was
present on it, where the transcription enzyme can bind. After purification by Nucleo Spin
Extract KitII, mRNA synthesis was done as described in the instructions of the T3 or
T7 mMESSAGE mMACHINE kit. Additionally, a polyA tail was added after successful
mRNA synthesis by a poly-A tailing kit according to the kit protocol. For final purification
of the mRNA, the RNeasy MiniKit of Qiagen was used. The synthesized mRNA was
directly electroporated into cells for experimental analysis or stored in aliquots at -80 °C.
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3.2.2 Biochemical methods
3.2.2.1 Cell lysis and western blot
Cell lysis For western blot analyses, the cells containing the proteins of interest were
harvested, pelleted with 300 rcf for 5min and washed with PBS. After repeated pelletizing
and removement of the supernatant, the cells were lysed in cell-lysis bu er by detergents.
The amount of cells as well as of the lysis bu er variated between the experiments. For
quantitative protein expression analysis, 1.25¶106 cells per 100µl lysis bu er were dissolved
with PLP bu er. For immunoprecipitation 2.5¶106 cells per 100µl TEA-lysis bu er
were used. The lysate was incubated for 20min on ice and afterwards spun down with
21000 rcf at 4 °C for 5min to remove the remaining cell fragments. After transferring the
supernatant into a new tube, 4x Laemmli bu er was added. If needed, —-mercaptoethanol
was intermixed to reduce disulfide bonds within the protein of interest. The mixed samples
were heated for 5min at 95 °C. Subsequently, the samples were directly used or stored
at -20 °C.
SDS gel electrophoresis For analysis of the lysate the method of SDS-page was used
as described by Laemmli et al. [161]. Therefore, the protein structure was denatured and
charges of the proteins were covered by SDS. This enabled a partition only regarding
the size of the proteins. The separation was done in a polyacrylamide gel surrounded by
SDS-containing running bu er. After concentration and collection of the samples within
the stacking gel on the top of the separation gel by a low amperage of 15mA per gel,
protein separation was done by 30mA per gel.
Western blot After gel separation, the proteins were transferred to a nitrocellulose
membrane by western blotting. Therefore, the gel in combination with a nitrocellulose
membrane was placed into a wet blotting chamber containing cooled Towbin blot bu er.
For transfer constant 300mA were used for 1 hr. Subsequently, the membrane was blocked
with 5% milk powder in TBST bu er for 1 hr to avoid unspecific binding of other proteins
or antibodies. After a short washing with TBST the antibody-staining was done. For
this, TBST, containing the antibody in corresponding concentrations, in combination with
0.05% milk powder was used. The incubation took place for at least 1 hr at RT or at 4 °C
overnight. For neutravidin-Hrp staining no milk powder was added during the staining
procedure. Thereafter, the membrane was washed three times and secondary antibody
staining was done for 1 hr at RT. Finally, after threefold washing for 15min with TBST,
the membrane was incubated for 1-2min with ECL substrate. This was processed by Hrp,
which is coupled to the secondary antibody. The detection was done by x-ray film or by a
ChemiDoc detection system.
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Coomassie staining For the detection of all proteins inside of the lysate, Coomassie
staining was used. Therefore, the SDS gel was incubated for at least 4 hrs in Coomassie
reaction solution, which non-specifically marks all proteins by interaction with the basic
side chains of the amino acids. The incubation was done at RT. After staining, the
polyacrylamid gel was washed several times with H2O to remove unbound Coomassie
molecules. This washing was continued until clear bands were visible.
3.2.2.2 Immunoprecipitation
For immunoprecipitation of sec61– with the sec61–-binding intrabody construct, BMDCs
were lysed with TAE lysis bu er. Additionally, they were homogenized during lysis by
pulling the cells five times through a 27G needle. In parallel to this, anti-human IgG
Dynabeads were loaded with 40µg sec61–-binding intrabody construct, which was fused
to a human IgG-Fc part. The loading took place at RT for 20min. After cell lysis and
removement of the remaining cell fragments with centrifugation (21000 rcf, 5min), the
lysate was distributed equally to the construct-loaded and washed beads or to control
beads. This suspension was incubated at 4 °C under rotation overnight. Subsequently,
the beads were separated from the lysate by magnetic force and the supernatant was
carefully removed. After three times of washing, beads were transferred into a new tube
and washed one more time. Next, 60µl TAE lysis bu er mixed with —-mercaptoethanol
and Laemmli bu er, were added to the beads. After 10min elution by 70 °C, the beads
were removed and the samples heated at 95 °C. The analysis were done by Coomassie
staining and western blotting.
3.2.3 Cell-culture conditions
All cells were cultured at 37 °C with 5% CO2 by a humidity of 90%. If not otherwise
indicated, all incubation steps of cell culture experiments were done under this condi-
tions. HEK293T cells as well as DC2.4 cells were cultured up to 60-70% confluence
before splitting was done for further culturing. HEK293T cells were harvested with a
0.05% Trypsin / 0.02% EDTA combination, while DC2.4 cells were spit with
2mM EDTA only. Both cell lines were plated on cell culture dishes. BMDCs were
cultured as described below and T-lymphocytes were directly used for experiments after
isolation. All cells were spun with 300 rcf for 5min. The complete work inside of the
cell culture was done under sterile conditions. Additionally, the cell culture was tested
mycoplasma-free within frequent time periods by the kit “Micotrace” (GE Healthcare).
36
3 Material and Methods
3.2.3.1 Production of GM-CSF supernatant
The GM-CSF-containing medium for BMDC di erentiation was produced by the transgenic
J588L cell line, which secrets GM-CSF into its supernatant. These cells were freshly thawed
and expanded for each production. Thereafter, 1¶106 cells were plated per 15 cm dish in
30ml of their recommended medium and incubated for 8 to 10 days. After this incubation,
the cells were spun down and the supernatant was filtered by a BottleTop-filter. The
resulting sterile solution was aliquoted and stored at -20 °C.
3.2.3.2 Generation of BMDCs
For the generation of BMDCs, the bone marrow of a mouse was isolated by flushing it out
of the hind limbs with PBS by using a 26G needle. The extracted cells were resuspended
and filtered through a 40µm cell strainer. After centrifugation, the cells were taken up in
BMDC culture medium and plated on three 10 cm petri dishes per mouse. For each plate
15ml culture medium were used. After three days of incubation, the cells were harvested.
Therefore, the supernatant was collected and adherent cells were incubated for 5min with
2mM EDTA at 37 °C and detached by pipetting. Following pelleting and uptake in fresh
culture medium, the cells were plated on six 10 cm petri dishes per mouse. BMDCs
between culture-day 7 or 8 were used for all experiments, if not otherwise indicated.
3.2.4 Cell-biological methods
3.2.4.1 Production of lentivirus and transduction of DCs
Transfection of HEK293T cells For the generation of lentiviruses a three plasmid sys-
tem was used. Therefore, 3¶106 HEK293T cells were plated on a 10 cm cell culture dish
one evening before transfection was done and incubated overnight to get a 70% covered
dish. At the next morning, the supernatant was replaced by 5ml fresh culture medium
and the cells were incubated for additional 2 hrs. For transfection, a mixture of three
plasmids was generated. Therefore, 10µg of the transfer plasmid were used. This con-
tained the gene construct, which was supposed to be included inside of the virus between
the long terminal repeats (LTRs). Additionally, 10µg packaging plasmid (pCMV-gag)
encoding the viral genes gag (capsid protein), pol (reverse transcriptase as well as integrase)
and RRE (rev-response element) were added. For the viral envelop 2µg plasmid encod-
ing the G-glycoprotein of the vascular stomatitis virus (pCMV-VSVG) were intermixed.
These plasmids were subsequently transfected into HEK293T cells by a calcium-phosphate
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precipitation. Therefore, the DNA was filled up to 450µl with sterile H2O and mixed
well with 50µl CaCl2. The precipitation was done by adding the CaCl2-DNA solution to
500µl 2x BBS bu er and mixing it well by vortexing. After 1 - 10min crystals formed and
became visible under the microscope. These crystals were distributed drop-wise over the
whole area of the cell culture dish.
Harvest and concentration of the lentivirus After incubation and crystal uptake
overnight, the supernatant was carefully replaced by 12ml fresh media. The virus pro-
ducing cells were incubated for 24 hrs and the supernatant containing viral particles was
harvested afterwards. This procedure was repeated once to gain the maximal amount of
virus from one plate. The collected supernatant was spun down with 500 rcf and filtered
through a 0.45µl syringe filter to get rid of the cellular fragments. If needed, the volume
of the viral solution was reduced and the virus concentrated by ultra-centrifugation. Here
we used a SW-32Ti rotor with 21000 rpm (13000 rcf) for 2 1/2 hours. After centrifugation,
the supernatant was discarded and the pellet resuspended in the culture medium of the
cells, which were planned to be infected in the further experiment. The virus suspension
can be stored for several days at 4 °C.
Transduction of DCs by lentivirus For transduction of BMDCs as well as DC2.4 cells
the concentrated virus was used. Additionally to the needed additives of the culture
medium, 10µg/ml polybrene were added before the infection took place. For this, the
cells were harvested and the needed number of cells (depending on the experiment) was
pelleted with 300 rcf. The cells were resuspended in the virus-containing medium and
cultured at 37 °C for 1 day. After this incubation time, the virus was removed and fresh
culture medium was added.
For BMDCs, which are very resistant to viral infections, virus harvested from 3-6 HEK293T
cell dishes was used per 1¶106 BMDCs. The infection was done during the splitting
procedure at day three of their culture. Following to the infection, BMDCs were cultured
for four additionally days and used at day 7 for all experiments. The DC2.4 cell-infection
was done with the virus of one plate HEK293T cells per 1¶106 cells. After incubation
overnight, the supernatant was replaced by fresh medium and the infected cells were
cultured for at least three additional days before the experiments were performed.
3.2.4.2 OVA uptake assay
To control the antigen uptake of di erently treated cells, they were incubated with
250 ng/ml fluorophore-labeled OVA for 15min at 37 °C. After incubation, the cells were
harvested with 2mM EDTA and a cell scraper, washed once with PBS and analyzed by
flow cytometry.
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3.2.4.3 Enzyme linked immunosorbent assay (ELISA)
Cell culture for IL-2 production To analyze the e ciency of antigen presentation, dif-
ferently treated DCs were plated in a 96-well plate with 50000 cells/well and incubated, if
not otherwise notified, with the model antigen OVA for 2 hrs. After antigen uptake and
processing, the supernatant was discarded and the cells were washed once with T-cell
medium to remove the remaining antigens. In experiments, where the incubation time
of the treated DCs needed to be limited to 2 hrs, the cells were fixed before the T-cells
were added. For fixation, the DCs were washed three times with PBS and incubated for
60 sec with 0.08% glutaraldehyde - PBS solution. After fixation, the cells were washed
again three times with PBS and once with T-cell culture medium.
To detect the antigen presentation on DCs, OT-I or OT-II T-cells were added recogniz-
ing the MHC-I OVA-peptide complexes (by OT-I) or the MHC-II peptide presentation
arrangements (by OT-II). These cells were gained out of the spleen of the corresponding
mice. Therefore, the spleen was triturated by a steel cell-strainer and the fragments were
well resuspended in PBS by pipetting. Subsequently, the cells were transferred into a
50ml falcon through a 40µm cell-strainer and the cell number was determined. After
centrifugation of the T-cells, they were resuspended in the appropriate volume of T-cell
medium. For incubation with the DCs, 0.1¶106 OT-I cells in 100µl medium or 0.125¶106
OT-II cells in 100µl medium were added to each well. By detection of the peptide com-
plexes via the T-cell receptor, the T-cells are activated and the IL-2 secretion is induced.
After incubation overnight, the supernatant was harvested for the measurement of the IL-2
concentration. The IL-2 amount in the supernatant thereby allows conclusions about the
T-cell activation, which again represents the antigen presentation e ciency of the DCs.
ELISA The determination of the IL-2 amount was done by a sandwich ELISA. All
incubation steps took place at 37 °C for 1 hr or alternatively at 4 °C overnight, if not
otherwise mentioned. Between all steps, the plate was washed three times with 150µl
washing bu er. For IL-2 detection the bottom of a special ELISA 96-well plate was
covered with the coating bu er containing an IL-2 antibody. Per well 50µl solution with
0.5µg/ml antibody were used. Afterwards, the plate was washed and sequentially
150µl blocking solution per well were incubated for 30min at RT. The blocked plate
was washed again and the collected T-cell supernatant was added into the coated wells
(50µl per well). To determine the exact concentrations of IL-2 within the samples, an
IL-2 standard was placed on the plate. After incubation, the plate was washed and a
second IL-2 antibody was added. Importantly, this antibody had a di erent binding-side
against IL-2 as the first one. Additionally, it was coupled to a biotin molecule. The
secondary antibody was used in the same concentration as the first one and the binding
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occurred during standard incubation conditions. For detection, the plate was washed,
50µl of a neutravidin-coupled Hrp (1mg/ml stock solution) per well were incubated for
30min at RT and afterwards washed away again. The analyses were done by adding
ABTS-reagent soluted in ABTS-bu er. This substance was processed by the peroxidase
and was detectable at 405 nm. The read-out by the plate reader was done between 1min
and 15min after adding ABTS, depending on the intensity of the signal.
3.2.4.4 DC electroporation
siRNA electroporation To knock down single proteins in DCs a siRNA (small interfering
RNA) approach was used. For this, di erent siRNA molecules were generated matching
only to the mRNA sequence of the targeted protein. After siRNA-binding, the mRNA
was degraded and consequently the protein production inhibited.
To permeabilize BMDCs for siRNA-transfection, electroporation was used. Therefore, a
determined electrical pulse was set on the solution, containing the DCs as well as siRNA.
For transfection, the DCs were harvested between culture day 4 and 7 depending on the
incubation time used for siRNA-mediated protein down-regulation. The electroporation
time point was selected in a way that the experiments itself could be done at culture
day 7 or 8. The harvested DCs were washed once with OptiMEM and the cell number
was determined. For electroporation 4¶106 cells in 100µl OptiMEM were used. Before
cells were added, 10µg in H2O soluted siRNA were propounded in a 4mm electroporation
cuvette. The siRNA-cell mixture was incubated for 3min and pulsed two times by 1000V
for 0.5 sec. Between the pulses was a time space of 5 sec. After electroporation, the cells
were immediately transferred into pre-warmed culture medium and incubated until culture
day 7 or 8 at 37 °C with 5% CO2 for upcoming analysis.
mRNA electroporation The synthesized mRNA of OVA or GFP was electroporated
into the cells by a protocol similar to siRNA electroporation. The cells were harvested
and washed with OptiMEM. For electroporation, the mRNA was added into a 4mm
electroporation cuvette and adjusted to a H2O solution of 20µl. The amount of the
used mRNA depended on the experiment and is pointed out in the correspondent figure
legends. The propound mRNA was mixed with 180µl cell suspension in OptiMEM. For the
endogenous presentation assay 0.2¶106 cells per electroporation were used. After mixture
of the cells with mRNA, the electroporation was done immediately with 300V for 6msec.
The mRNA-transfected DCs were afterwards directly used for di erent experiments.
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3.2.4.5 Usage of di erent inhibitors
For inhibitor assays, the cells were pre-incubated with the respective inhibitor for at least
15min before an experiment was started. During the experiment, the inhibitors were
present during all incubation steps. For ELISA analysis, the cells were incubated with
OVA in presence of the inhibitor, washed three times with PBS and fixed afterwards,
to avoid the cell death of the DCs and an inhibitor contact to the T-cells. These were
added for presentation analyses. ExotoxinA was used in a concentration of 10µg/ml
and Eeyarestatin I in a concentration of 3µM. In the context of sec61-recruitment assays
BrefeldinA was used with 10µg/ml.
3.2.4.6 Analysis of ERAD function by the HEK-Venus cell line
The analysis of the function of the ERAD machinery was done by a cell line kindly
provided by Prof. Cresswell [162]. This cell line was expressing a split version of the
fluorescence protein Venus with one half localized in the ER and the other one in the
cytosol. Importantly, the protein can only reunion and emit fluorescence light, when the
ER-part has successfully been exported via the ERAD machinery. For analysis, di er-
ently treated HEK cells were incubated in presence of the proteasome inhibitor MG132
with a final concentration of 5µM for 6 hrs to block proteasomal degradation and get
functional Venus proteins in the cytosol. After incubation, the cells were harvested with
2mM EDTA in PBS and washed once with pure PBS. Subsequently, analysis was done by
flow cytometry.
For positive control, the HEK cells were treated with the inhibitor ExoA for 1 hr and
subsequently incubated 6 hrs with MG132 in presence of the inhibitor, before flow cy-
tometric analysis was done. Alternatively, the HEK cells were transfected with siRNA
following the instructions of the lipofectamine2000 protocol. One day after transfection,
the supernatant was exchanged and the cells were incubated for another day. Thereafter,
MG132 was added for 6 hrs and the analysis was done as described above.
3.2.5 Antigen export assays
3.2.5.1 Isolation of cytosolic fractions to analyze the export of OVA
Biotinylation of OVA To analyze the antigen export of the model antigen OVA, it
was biotinylated to enrich the exported cytosolic OVA and detect it by western blotting.
Therefore, OVA was dissolved in PBS with a concentration of 100mg/ml and spun down
with 3220 rcf to remove unsolved OVA. Afterwards, OVA was purified by gel filtration
(PD10 columns) to get rid of small OVA-fragments. Subsequently, the filtered OVA-solution
was diluted to a concentration of 8mg/ml. Of this solution 620µl were mixed with 180µl
biotin reagent. For this biotin solution, 10µg freshly opened Sulfo-NHS-LC-biotin were
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solved in 180µl H2O. The mixture with OVA was incubated for 2 hrs at RT. Finally, the
unbound biotin was removed by Zeba spin column filtration as described in the product
instructions.
Isolation of exported OVA For OVA export 0.5mg/ml biotinylated OVA were incubated
for 45min with di erently treated DCs in presence of 5µM MG132 to inhibit proteasomal
degradation. After this incubation, the cells were harvested and collected in a 15ml
falcon. While 1/10 of the cells was removed for the total OVA-uptake control and lysed
for western blot, 9/10 of the cells were pelleted and the cytosolic fraction was isolated by
the subcellular proteome extraction kit of Calbiochem. Therefore, the cells were washed
twice with washing bu er and afterwards lysed in 500µl lysis bu er of the kit, containing
2.5µl protease inhibitor. The lysate was incubated on ice for 1min and spun down for
5min with 500 rcf at 4 °C. The supernatant, containing the cytosolic fraction, was carefully
transferred into a new tube and OVA-biotin in the cytosolic fraction was enriched by a nity
chromatography using 50µl PBS-washed neutravidin-agarose beads. The incubation
was done for 1 hr at 4 °C under rotation. Afterwards, the agarose beads were pelleted by
centrifugation with 8000 rcf, the supernatant discarded and the beads washed once with
PBS. The OVA-biotin was eluted by adding 30µl lysis bu er and 10µl 4x Laemmli bu er
in combination with heating for 10min at 50 °C. Subsequently, the beads were spun down
with 21000 rcf for 5min and the supernatant was analyzed by western blot to determine
the quantity of exported OVA. Additionally, the cell lysate was used to analyze the total
amount of OVA taken up by the DCs.
3.2.5.2 Cytochrome c export assay
Sample preparation The second export assay was based on the translocation of
cytochrome c into the cytosol and subsequently on the induced apoptose of the
cell [163]. This apoptose was detected by the staining of phosphatidylserine, which
is presented on the cell surface of apoptotic cells. For this labeling, AnnexinV was used. To
analyze the cytochrome c export, di erently treated DCs were harvested and 0.5¶106 cells
were plated per well in a non-treated 24-well plate in 250µl medium. The non-treated dishes
were used to avoid any stress e ects on the cells during the final harvest procedure, which
would lead to a high background level of phosphatidylserine at the cell surface. After 30min
of incubation, the supernatant was replaced by a reaction solution containing cytochrome c.
This solution was based on PBS and included 9mg/ml cytochrome c, 200 ng/ml OVA,
5mM glucose and 10mM NH4Cl. After 8 hrs, the cells were washed one time with PBS and
once with AnnexinV bu er on the plate. Sequentially, the cells were harvested in 500µl
AnnexinV bu er by careful cell scraping and the well was rinsed once more with additional
500µl AnnexinV bu er. The cells were collected in a FACS tube for the staining procedure.
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Staining protocol For staining, the cell number was determined and the samples were
adjusted to the same cell density. After spinning down the cells with 300 rcf for 3min,
the supernatant was discarded, the cells were taken up in 50µl AnnexinV bu er and
transferred into a new tube. Afterwards, 50µl AnnexinV bu er, containing 5µl AnnexinV,
was intermixed carefully. Following 15min of light protected incubation at RT, 400µl
additional AnnexinV bu er were added and the staining was detected by flow cytometry.
Directly before measurement, 5µl of Hoechst (stock concentration 100mM) were intermixed
to identify corrupted or dead cells and exclude these during the analysis of the apoptosis
induced by the cytochrome c export.
3.2.5.3 —-lactamase export assay
CCF4-loading in DCs As a third method to analyze the export of the antigens into
the cytosol, the —-lactamase assay was used as described before by Cerbrian et al. [64].
Therefore, DCs were loaded with CCF4, a FRET (Fröster resonance energy transfer)
substrate containing a cephalosporin-core connected to a fluorescein by a coumarin-link.
This structure is sensitive to —-lactamase cleavage. For loading, di erently treated DCs
were harvested and plated in a 24-well plate with 0.5¶106 cells per well. After 60min of
incubation for cell adhesion, the cells were washed two times with EM-bu er within the
well plate and the loading solution (2 µM CCF4 substrate as well as the anion transport
inhibitor solutionD in EM-bu er) was added. The incubation was done light protected for
1 hr at RT. During this incubation time the FRET substrate was enriched in the cytosol
of the cells.
—-lactamase export assay For analysis of the antigen translocation into the cytosol,
1mg/ml —-lactamase and anion transport inhibitor solutionD in EM bu er were added
to the CCF4-loaded DCs, after washing them twice with EM-bu er. Additionally, the
proteasome inhibitor MG132 (5µM) was intermixed. The ability of —-lactamase to splice
the lactam ring inside of the chephalosporine was used to split the FRET substrate and
get a fluorescence shift from 535 nm to 450 nm. This cleavage can only occur, when the
—-lactamase is translocated into the cytosol, where CCF4 was concentrated. Therefore,
the cells were incubated light protected for 2 hrs at 37 °C and harvested afterwards with
pre-cooled EM-bu er at 4 °C by cell scraping. Subsequently, the cells were transferred into
FACS tubes, washed once with PBS and analyzed by flow cytometry. The e ciency of
conversion of CCF4 was determined by calculating the ratio between 450 nm and 535 nm.
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3.2.6 Endosomal flow cytometry
Endosome preparation for endosomal flow cytometry For endosomal flow cytometry
at least 5¶106 cells were plated on a 10 cm culture dish and incubated for 1 hr to enable cell
adhesion and recovery. After regeneration, the DCs were fed with 500 ng/ml fluorescence-
labeled OVA for 20min. Subsequently, the supernatant was exchanged and the cells were
chased for additionally 20min, if not otherwise notified. The antigen loaded DCs were
harvested by a cell scraper with 2mM EDTA in PBS, spun down and washed once with
ice cold PBS. After repeated centrifugation, the pellet was resuspended in pre-cooled
homogenization bu er and the cells were carefully homogenized two times in a steel
homogenizer on ice. Afterwards, the homogenate was spun down with 200 rcf for 5min to
remove big cell fragments. Finally, the supernatant was transferred into a new tube and
was ready for analysis by flow cytometry or for further processing and staining.
Analysis of sec61 recruitment To analyze the sec61 recruitment by endosomal flow
cytometry, BMDCs were transduced with GFP-sec61— expressing lentivirus at culture
day 3 and incubated for four additional days. At culture day 7 the BMDCs were loaded
with the fluorophore-labeled antigen and endosomal preparation was done as described
above. For analysis of the inhibition of the sec61 recruitment by intrabodies, the DC2.4
cell line was transduced with GFP-sec61— expressing lentivirus first and expanded for one
week at 37 °C. Afterwards, the cells were distributed to the single probes and additionally
transduced with the di erent intrabody constructs. After three days of incubation for
infection and construct expression, analysis were done by endosomal preparation and flow
cytometry.
Immunofluorescence staining for endosomal flow cytometry For the endosomal stain-
ing the homogenate was distributed to the single staining reactions and the volume was
adjusted to 200µl per sample. To this suspension, the primary antibodies were added
in 50µl homogenization bu er with a final concentration as listed in the material part
above. After 20min of incubation at 4 °C, the secondary antibody staining was done using
additional 100µl antibody solution in homogenization bu er with a final dilution of 1:1000.
After 20min of incubation at 4 °C, 100µl of the 4x permeabilization/fixation solution were
added and the reaction was mixed well by short vortexing. The endosomes were fixed for
20min at RT and spun down with 8000 rcf for 5min afterwards. Finally, the pellet was
resuspended in at least 200µl homogenization bu er for analysis by flow cytometry.
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Analysis of the endosomal compartments The endosomal preparations were analyzed
by flow cytometry at a LSRII (BD life science). Therefore, the threshold was reduced to a
minimum and FCS/SSC voltages were adjusted to localize the endosomal population in
the lower left of the dot blot in a biexponential scale. The samples were measured by a
low flow ratio with about 2000 events per second to circumvent the risk of two or more
particle within one drop during the measurement. This avoided the analysis of two or
more compartments at once, which might lead to false positive samples.
3.2.7 Immunofluorescence microscopy
For immunofluorescence microscopy di erently teated DCs were plated on a coverslip
within a 24-well plate and incubated for 1 hr. For each well 0.1¶106 cells were used. After
adhesion of the cells, the antigen or other substances were fed, if needed and indicated.
Subsequently, the cells were carefully washed twice with PBS and fixed by IC fixation
substrate for 15min at RT. Thereafter, the cells were washed and permeabilized by perm
solution (purchased from BD life science) for additional 15min. Before antibody staining
was done, the cells were blocked with 5% serum for 1 hr. The origin of the serum was, if
possible, mouse. If this was not usable because of cross-reaction with required antibodies,
a serum of an appropriate species was used. The antibodies were added in perm solution
with concentrations as indicated in the material part above. After 1 hr of incubation at RT,
the cells were washed again with PBS and stained with the matching fluorescence-labeled
secondary antibodies. This step was done light protected at RT for an additional hour.
Finally, the samples were washed three times with PBS (5min for each washing step) and
incubated with 1µg/ml 4,6-diamidino-2-phenylindole (DAPI) during one washing step.
After a last rinsing with pure H2O to remove salt crystals, the cells were mounted with
Fluromount and stored at 4 °C till microscopic analysis was done.
3.2.8 Statistical analysis
The analyses of the flow cytometry results were done with FlowJo. For evaluation of the
fluorescence microscopy results ImageJ and Photoshop were used. The MOC and POI
correlation coe cients were calculated with ImageJ. General statistical analyses were done
by using ImageJ, Excel or Prism.
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4.1 The role of the ERAD machinery in the “endosome
to cytosol” pathway of cross-presentation
The fact that the protein transport by the ERAD machinery has the same transport
direction as the antigen translocation during cross-presentation (lumen of the ER or the
endosomal compartment into the cytosol), highlights the ERAD system as an interest-
ing target for the investigation of cross-presentation. Additionally, some components of
the ERAD machinery have already been described to be involved in this presentation
pathway [64, 66, 78]. Therefore, we started our analyzes by investigating the influence
of two di erent inhibitors of the ERAD system, namely ExotoxinA (ExoA) and Eeyare-
statin I (EeyI), on cross-presentation. While ExoA is described as an inhibitor of sec61 and
impairs the export function of the ERAD system [78, 156], EeyI is supposed to interact
with the ATPase p97 and thereby inhibits the protein transport from the ER into the
cytosol [164, 165].
First we examined, whether the addition of these inhibitors has an e ect on antigen
presentation. Therefore, we fed the model antigen ovalbumin (OVA) to DCs and
determined the e ciency of antigen presentation by the activation of OVA-specific
CD8+ CTLs (OT-I) or CD4+ T-helper cells (OT-II). The IL-2 production measured
by ELISA was used as read out. In accordance to previous observations [78] we detected
a reduced activation of OVA-specific OT-I T-cells by cross-presentation in presence of
ExoA (Fig. 4.1A), while the OT-II T-cell activity was una ected (Fig. 4.1B). In order to
exclude other unspecific e ects, like for example di erent activation states of the DCs or
di erent availability of fitting MHC-I molecules in presence or absence of the inhibitor,
we loaded a fully processed MHC-I OVA peptide (SIINFEKL) on MHC-I molecules. Be-
cause this peptide can displace already loaded peptides on fitting MHC-I complexes, its
presentation is independent of any processing.
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Figure 4.1: Inhibition of the ERAD machinery specifically impairs cross-presentation
A,D) BMDCs (bone marrow-derived DCs) were incubated with the indicated amounts
of OVA for 2 hrs in the presence or absence of 10µg/ml ExoA or 3µM EeyI. After OVA
incubation the cells were washed, fixed and co-cultured with OT-I T-cells overnight. T-cell
activation was measured by IL-2 ELISA. B,E) identical to A and D using OT-II cells.
C,F) same as A and D using 10 nM SIINFEKL instead of OVA. All graphs depict
representative results of at least 3 independent experiments. Data are represented as
mean ± SEM.
Here we observed no di erence between T-cell activation with or without
inhibitor (Fig. 4.1C), confirming that the amount of MHC-I molecules or the expression
of co-stimulatory molecules was not a ected by the inhibitor. In parallel to these results,
also the inhibitor EeyI reduced cross-presentation in DCs (Fig. 4.1D), while the MHC-II
presentation as well as the T-cell activation by the presentation of the processed SIINFEKL
peptide were not influenced (Fig. 4.1 E and F). Additionally, we analyzed the e ect of the
inhibitors ExoA and EeyI on the endogenous presentation of OVA on MHC-I molecules.
After electroporation of OVA-encoding mRNA, intracellularly expressed OVA was pro-
cessed and loaded on MHC-I molecules by the classical endogenous MHC-I presentation
pathway. This mechanism of antigen presentation, like the MHC-II presentation, remained
una ected in the presence of both inhibitors, ExoA or EeyI (Fig. 4.2A and B), indicating
that cross-presentation might be specifically impaired by these inhibitors, while other
antigen presentation pathways were not influenced.
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Figure 4.2: Inhibitors do not a ect endogenous MHC-I presentation BMDCs were electropo-
rated with OVA- or GFP-encoding mRNA and incubated with the inhibitors. A) 10µg/ml
ExoA. B) 3µM EeyI. After 2 hrs incubation, the cells were fixed and co-cultured with OT-I
T-cells overnight for IL-2 production. Data are represented as mean ± SEM. All graphs
depict representative results of at least 3 independent experiments.
The e ect on cross-presentation was also not due to a di erent amount of antigen
available for processing, because antigen uptake was not influenced by presence of the
inhibitors (Fig. 4.3). To emphasize that indeed the loading of antigen-derived peptides on
MHC I molecules is impaired by the inhibition of the ERAD system, we stained OVA-
treated cells with the MHC-I OVA-peptide detecting antibody 25.D1-16 and analyzed
the cells by flow cytometry. A reduction of the MHC-I OVA-peptide complexes on the
cell surface was visible in presence of the inhibitor ExoA or EeyI (Fig. 4.4A and B),
while the total surface expression of MHC-I molecules suitable for OVA-presentation
remained una ected. This was controlled by loading of the DCs with SIINFEKL peptide
before the staining with the 25.D1-16 antibody was done (Fig. 4.4). Importantly, the
MHC-I OVA-peptide staining on DCs expressing endogenous OVA was not a ected by the
presence of the inhibitor ExoA (Fig. 4.4C), emphasizing that the MHC-I OVA-peptide
presentation was only impaired in context of cross-presentation but una ected in context
of the endogenous MHC-I presentation of OVA. These data point out that the ERAD in-
hibitors might indeed specifically influence the molecular mechanism of cross-presentation.
Figure 4.3: Antigen uptake is unaltered in the presence of ERAD inhibitors
BMDCs were incubated with 250 ng/ml fluorophore-labeled OVA in the presence
or absence of 10µg/ml ExoA or 3µM EeyI. OVA uptake was measured by flow cytometry.
Data representative of at least 3 independent experiments are shown and are pictured as
mean ± SEM. ExoA: ExotoxinA; EeyI: EeyarestatinI.
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Figure 4.4: MHC-I presentation of OVA is reduced by ERAD inhibitors
A) BMDCs were incubated with 5mg/ml OVA or 10 nM SIINFEKL in combina-
tion with 10µg/ml ExoA for 6 hrs. Afterwards the cells were stained with the 25.D1-16
antibody. Analysis was done by flow cytometry. B) Same as A) with 3µM EeyI instead
of ExoA. C) BMDCs were electroporated with mRNA encoding for GFP or OVA and
incubated for 6 hrs in presence or absence of 10µg/ml ExoA. Finally the cells were stained
with the 25.D1-16 antibody and analyzed by flow cytometry. All graphs depict representative
results of at least 3 independent experiments. Data are represented as mean ± SEM.
ExoA: ExotoxinA; EeyI: Eeyarestatin I.
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To clarify, whether the inhibition of cross-presentation is due to an impaired ability of
the DC to export the antigen from the endosomal compartment into the cytosol, we fed
biotinylated antigen (OVA) to DCs treated with inhibitor or to DCs without inhibitor.
From these cells we isolated the cytosolic fraction (scheme see Fig. 4.5A), concentrated the
translocated OVA by a nity chromatography using neutravidin beads and analyzed the
amount of the cytosolic antigen by western blot. We thereby registered a strong reduction
of OVA in the cytosol in presence of either ExoA or EeyI, while the total amount of OVA
taken up by the DCs was not influenced by the inhibitor treatment (Fig. 4.5B and C).
This confirms a putative role of the ERAD machinery during the antigen translocation
from the endosomal compartments into the cytosol in context of cross-presentation.
Figure 4.5: The antigen export is impaired by the inhibition of the ERAD machinery
BMDCs were incubated with biotin-labeled OVA in presence of the proteasome inhibitor
MG132 for 45min and the cytosolic fraction was isolated. Afterwards, the samples were
analyzed by western blot. A) Scheme of the experimental setup for the isolation of the
cytosolic fraction of DCs B) Isolation of the cytosolic fraction from cells treated with
10µg/ml ExoA C) Analysis of the cytosolic fraction from cells treated with 3µM EeyI.
Western blots show representative results of at least 3 independent experiments.
4.2 Sec61, but not derlin1 influences cross-presentation
and antigen export into the cytosol
4.2.1 No e ect of derlin1 down-regulation on antigen
cross-presentation
Due to the results of the inhibitor assays, connecting the ERAD system with antigen
translocation into the cytosol, we decided to analyze, which pore-building proteins of the
ERAD system is involved during the intracellular antigen translocation.
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Figure 4.6: Down-regulation of the derlin1
protein BMDCs were electroporated
with derlin1-specific siRNA or control
siRNA. Expression was analyzed by
western blot.
To investigate potential channel proteins,
we used a siRNA knock-down approach.
Therefore, we first down-regulated derlin1,
which plays a role in the export of mis-
folded proteins in the context of the ERAD
machinery [137, 138]. Three days after
siRNA electroporation derlin1 expression
was strongly reduced in the DCs (81.5% in
siRNAA samples and 69.8% in siRNAB
samples; Fig. 4.6). To uncover the con-
sequences of the knock-down of derlin1
for cross-presentation e ciency, IL-2 deter-
mination after T-cell activation was used.
Although derlin1 expression was severely reduced, no e ect on cross-presentation was
observed (Fig. 4.7). Considering these results, the derlin1 channel protein seems not to
play a major role during the antigen translocation of OVA from endosomal compartments
into the cytosol.
Figure 4.7: Down-regulation of derlin1 has no influence on cross-presentation BMDCs
were electroporated with siRNA specific against derlin1 (two di erent siRNA -A and
B) or control siRNA. After incubation with di erent OVA-concentrations for 2 hrs,
antigen presentation was analyzed by IL-2 ELISA after T-cell co-culture overnight.
A) Co-culture with OT-I T-cells. B) Co-culture with OT-II T-cells. C) Instead of OVA
10nM MHC-I peptide SIINFEKL were loaded on BMDCs. Afterwards, these were co-
cultured with OT-I T-cells overnight. Data are represented as mean ± SEM. All graphs
depict representative results of at least 3 independent experiments.
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4.2.2 A crucial role of sec61– in antigen cross-presentation as well
as in antigen translocation into the cytosol
Next, we investigated the role of the trimeric channel protein sec61, which is, besides of its
role in protein synthesis [146, 147, 148], also described as a channel protein in the context
of the ERAD system [113, 150, 151, 152].
To analyze the influence of sec61 in cross-presentation, we aimed to knock-down the sec61–
subunit, which builds the core of this channel protein. Because two paralogs of sec61–
are available, which are nearly identical on protein level, but very di erent in their DNA
sequence [146], we first used RT-PCR to clarify, which sec61– protein is expressed in
BMDCs. The results thereby revealed that mainly the sec61–1 protein was present in our
DCs (Fig. 4.8A). As shown by the western blot in figure 4.8B, the siRNA knock-down
of sec61–1 reduced the total sec61– expression severely within two days, whereas only
a very mild e ect on the sec61– protein level was observed after sec61–2 knock-down.
Importantly, due to the nearly identical protein sequence, the western blot signal always
represents the expression of both sec61– paralogs.
Analyzing the cross-presentation ability of OVA-treated DCs two days after sec61– knock-
down, we observed a reduction in the cross-presentation e ciency (Fig. 4.8C). However,
at the same point in time after siRNA treatment also the MHC-II presentation was
a ected (Fig. 4.8D). Additionally, the presentation of external loaded MHC-I OVA-
peptides (SIINFEKL) was reduced by the sec61– knock-down (Fig. 4.8 E). These results in-
dicate that the observed e ect on cross-presentation might not be specific, but the missing of
sec61– impairs the whole antigen presentation ability of DCs. This might be due to cellular
stress, because of impaired protein synthesis as well as ER stress caused by a reduced ERAD
function and aggregation of misfolded proteins in the ER. To circumvent these potentially
stressful e ects of sec61– silencing, we reduced the incubation time after siRNA electropora-
tion to one day. At this earlier time point a significant sec61– knock-down could already be
detected (Fig. 4.8B and 4.9A) and the cellular functions might not be severely a ected.
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Figure 4.8: Strong siRNA knock-down a ects antigen presentation of DCs in general
A) Expression analysis of sec61–1 and –2 by RT-PCR on mRNA of BMDCs. B) Down-
regulation of sec61– in BMDCs by siRNA. C) BMDCs were treated with siRNA against
sec61– or control siRNA and cultured for 48 hrs. After sec61– knock-down, the cells were
incubated with di erent concentrations of OVA for 2 hrs and OT-I T-cells were added.
Following 18 hrs co-culture, an IL-2 ELISA was done for read out. D) same as C) with
OT-II cells. E) same as C), but the cells were loaded with 10 nM SIINFEKL instead of
OVA. Data are represented as mean ± SEM.
Importantly, to avoid potential stress e ects during the further experiment, we imme-
diately fixed the cells after incubation with OVA and before addition of the T-cells.
Under these conditions we observed neither an e ect of sec61– knock-down on MHC-II
presentation (Fig. 4.9D) nor on T-cell activation after external loading of the SIIN-
FEKL peptide (Fig. 4.9C). In contrast to this, the cross-presentation of the antigen
OVA was still reduced one day after sec61– knock down (Fig. 4.9B). To exclude that
the MHC-I presentation pathway in general might be more stress-sensitive than the
MHC-II peptide display, we analyzed the presentation of endogenously expressed OVA
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on MHC-I molecules. This experiment showed that the presentation of the classical endoge-
nous MHC-I pathway was not influenced by the sec61– knock-down after 24 hrs of incu-
bation (Fig. 4.9E). Additionally, the reduced cross-presentation was also not due to
di erences in antigen uptake after sec61– knock-down (Fig. 4.10A).
In accordance with the low expression of sec61–2 in DCs (Fig. 4.8A) and western blot
analysis of total sec61– expression after siRNA treatment (Fig. 4.8B and 4.9A), cross-
presentation was not a ected by sec61–2 knock-down (Fig. 4.9).
Figure 4.9: Reduced Sec61–1 expression leeds to specifically impaired cross-presentation
A) Sec61– knock-down 24 hrs after electroporation of siRNA.B) BMDCs electroporated with
sec61– specific siRNA or control siRNA were cultured for 24 hrs and sequentially incubated
with di erent OVA-concentrations. After additional 2 hrs, the cells were fixed and co-cultured
with OT-I T-cells overnight. After 18 hrs, the IL-2 concentration was determined by ELISA.
C) same as B) with 10 nM SIINFEKL instead of OVA. D) same as B), but OT-I T-cells
were replaced by OT-II T-cells. E) 24 hrs after sec61– knock-down the BMDCs were
electroporated with mRNA encoding for GFP or OVA. The mRNA electroporated cells were
chased for 2 hrs and fixed before OT-I T-cell co-culture and IL-2 determination by ELISA
was done. All graphs show representative results of at least 3 independent experiments.
Data are represented as mean ± SEM.
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To confirm the data gained by ELISA, we additionally stained against OVA peptide-loaded
MHC-I molecules by the 25.D1-16 antibody. Subsequent flow cytometric analysis thereby
revealed less cross-presentation after electroporation with sec61–1 specific-siRNA compared
to DCs electroporated with a control siRNA or with siRNA directed against
sec61–2 (Fig. 4.10B) after 24 hrs of down-regulation. As shown by external loading
Figure 4.10: MHC-I OVA-peptide staining shows a reduced cross-presentation after sec61–1
knock-down A) The BMDCs were electroporated with siRNA against sec61– or control
siRNA and chased for 24 hrs. Afterwards, the cells were incubated with 250 ng/ml OVA
for 15min and analyzed by flow cytometry. B) 18 hrs after sec61– knock-down BMDCs
were incubated for 6 hrs in presence of 5mg/ml OVA and stained for MHC-I OVA-peptide
complexes by 25.D1-16 antibody. The analysis was done by flow cytometry. All graphs
depict representative results of at least 3 independent experiments. Data are represented
as mean ± SEM. MFI: mean fluorescence intensity.
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of the SIINFEKL peptide on DCs, the amount of MHC-I molecules suitable for OVA-
peptide presentation on the cell surface was not a ected by siRNA treatment. These data
are concordant with the specifically reduced IL-2 secretion of activated T-cells in context
of cross-presentation after sec61–1 knock-down and clearly demonstrate that the sec61
channel protein has a specific influence on this antigen cross-presentation pathway.
To investigate, whether the observed impairment of cross-presentation was due to a reduced
antigen translocation into the cytosol, we separated the cytosolic fraction of OVA-treated
DCs from the rest of the cell, including all antigen-containing compartments, 24 hrs
after siRNA knock-down. The analysis of the cytosolic fraction of these OVA-treated
DCs showed less exported antigen, when the sec61–1 expression was reduced by siRNA
knock-down (Fig. 4.11A). To confirm these data and exclude potential artifacts during
the isolation of the cytosolic fraction, like the rupture of antigen-containing endosomal
compartments, we decided to use two additional assays to investigate the possibility for
DCs to export antigens into the cytosol. First, we added cytochrome c to the di erently
treated DCs. After uptake and export from the endosomal compartment into the cytosol,
cytochrome c can be localized in the cytosol and induce apoptosis (scheme shown in Fig.
4.11B) [163]. The used experimental setup revealed that the apoptosis ratio observed in
DCs was lower with a reduced sec61– expression compared to DCs treated with control
siRNA. This indicated that the export of cytochrome c into the cytosol is impaired by the
sec61– knock down (Fig. 4.11C), emphasizing the importance of sec61– for intracellular
antigen translocation. The second assay we conducted used the FRET (Förster resonance
energy transfer) substrate CCF4, which can be split by the bacterial enzyme —-lactamase.
After loading of the cells with this FRET substrate, it is concentrated in the cytoplasm
of the DC and can be cleaved by —-lactamase, when the enzyme is taken up by the
DC and translocated from the endosomal compartment into the cytosol. Afterwards,
the resulting fluorescence shift from 450 nm to 535 nm was measured by flow cytometry.
For analyzes, the ratio between cleaved and unprocessed substrate was used (scheme
shown in Fig. 4.11D) [64]. In the context of Sec61– knock-down this ratio was reduced
24 hrs after siRNA electroporation, indicating an impaired export of —-lactamase into the
cytosol in absence of sec61– (Fig. 4.11E, the presented FRET experiment was done by
Dagmar Fehrenschild, bachelor student). These data confirmed the results of the first two
experimental setups and again point out the necessity of sec61– for antigen translocation
into the cytosol.
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Figure 4.11: The antigen export into the cytosol is impaired by sec61– knock down
A) BMDCs were electroporated with sec61– specific siRNA or control siRNA and in-
cubated for 24 hrs. Subsequently, the cells were loaded with 0.5mg/ml biotinylated OVA
for 45min in presence of the proteasome inhibitor MG132. Afterwards, the cytosolic fraction
was isolated and the exported amount of OVA was determined by western blot. B) Scheme
of the cytochrome c export assay. C) BMDCs treated with siRNA were cultured for 18 hrs
and co-incubated with 9mg/ml cytochrome c and 200 ng/ml OVA for additionally 8 hrs.
Afterwards cells were harvested, stained by AnnexinV and analyzed by flow cytometry.
D) Scheme of the —-lactamase export assay. E) siRNA treated BMDCs were incubated
for 18 hrs and afterwards loaded with CCF4 for 1 hr and treated with —-lactamase for
additional 2 hrs. Thereafter, the cells were harvested and analyzed by flow cytometry.
Scoring was done by the ratio of cleaved FRET substrate (emission at 535 nm) to the
remaining loaded FRET-substrate (emission at 450 nm). The presented —-lactamase data
were generated by Dagmar Fehrenschild, bachelor student. All graphs depict representative
results of at least 3 independent experiments. Data are represented as mean ± SEM. MFI:
mean fluorescence intensity.
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4.2.3 Sec61“ is needed for e cient antigen export
To further verify the specific role of sec61 in antigen translocation, we also investigated the
influence of sec61“ on cross-presentation. Sec61“ is another subunit of the sec61 protein
complex and is important for the function of the channel protein [148, 149]. Like for sec61–,
we used a knock-down approach to analyze the role of sec61“ in the cross-presentation
machinery (Fig. 4.12A).
The down-regulation of sec61“ expression thereby impaired the ability of DCs to cross-
present OVA and subsequently reduced the activation of T-cells and IL-2 secretion, which
Figure 4.12: The knock down of the sec61“ subunit a ects the antigen cross-presentation
A) Western blot of the siRNA knock down of sec61“ in BMDCs. B) The siRNA treated
BMDCs were incubated with 250 ng/ml fluorophore-labeled OVA for 15min and analyzed
by flow cytometry. C) After sec61“ knock down, the BMDCs were incubated with OVA
for 2 hrs, fixed and co-cultured with OT-I T-cells overnight. The T-cell activation was
determined by the IL-2 amount in the supernatant. D) same as C) with OT-II T-cells.
E) same as C) with 10 nM SIINFEKL instead of OVA. F) The siRNA pretreated BMDCs
were electroporated with mRNA encoding for GFP or OVA and incubated for 2 hrs.
These cells were fixed and co-cultured with OT-I T-cells overnight and secreted IL-2 was
determined by ELISA. All shown graphs are representative results of at least 3 independent
experiments. Data are presented as mean ± SEM. MFI: mean fluorescence intensity.
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was measured by ELISA (Fig. 4.12C). On the other hand, the antigen presentation on
MHC-II molecules to CD4+ T-helper cells was una ected (Fig. 4.12D). The observed e ect
on cross-presentation was also not due to other unspecific e ects like di erent activation
of the DCs or di erent availability of suitable MHC-I molecules on the cell surface, shown
by the SIINFEKL peptide loading control (Fig. 4.12E). Additionally, the presentation of
endogenously expressed OVA on MHC-I molecules was not impaired (Fig. 4.12F). This
specific e ect on cross-presentation was neither caused by di erences in antigen uptake,
which stayed on the same level in sec61“ siRNA treated cells compared to control siRNA
treated cells (Fig 4.12B).
Importantly, analyzing the intracellular antigen export revealed a reduced amount of translo-
cated antigen in the cytosolic fraction of DCs pretreated with sec61“
siRNA (Fig. 4.13A). Similar to sec61–, the knock-down of sec61“ also resulted in a
lower apoptosis ratio in DCs after the addition of cytochrome c.
Figure 4.13: Sec61“ knock down reduces the antigen export A) The siRNA treated BMDCs
were incubated with 0.5mg/ml biotinylated OVA in presence of the proteasome inhibitor
MG132 (5µM). After 45min incubation, the cytosolic fraction was isolated and analyzed
by western blot. B) Sec61“ knock-down BMDCs and control BMDCs were incubated with
9mg/ml cytochrome c and 200 ng/ml OVA for 8 hrs, harvested and stained by AnnexinV to
determine apoptosis. C) The siRNA treated BMDCs were loaded with CCF4 for 1 hr and
co-incubated with —-lactamase for additional 2 hrs. Cells were harvested and analyzed by
flow cytometry. The —-lactamase activity was determined by the ratio between the cleaved
and the uncleaved FRET substrate. All graphs depict representative results of at least 3
independent experiments. Data are represented as mean ± SEM. MFI: mean fluorescence
intensity.
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Parallel results occurred after feeding —-lactamase to DCs containing the FRET sub-
strate CCF4. The sec61“ down-regulation reduced the conversion of the FRET substrate
in the cytosol indicating a lower translocation of the —-lactamase from endosomal
compartments into the cytosol of the investigated DCs (Fig. 4.13C). These results
confirmed an impaired antigen translocation into the cytosol, when sec61“ is
missing (Fig. 4.13B).
In conclusion, these observations proved that the specifically reduced cross-presentation
after sec61– or sec61“ down-regulation was due to an impaired antigen export into
the cytosol and emphasizes that the sec61 channel protein is involved in the antigen
translocation out of endosomal compartments into the cytosol.
4.3 Sec61 is recruited to endosomal cross-presenting
compartments
Considering the influence of sec61 during cross-presentation and antigen export, we
wondered, whether this e ect is an indirect one originating from the ER or if the
sec61 channel protein is recruited to the side of antigen processing at the endosomal
compartments [69].
To investigate this inaquantitative fashionweused theflowcytometryofendosomes.
Therefore,wefeedfluorophore-labeledOVAtothecellsweaimedtoanalyze.Afterantigen
uptake,we openedup the cellsmechanically, isolated a crude endosomal fraction and
analyzedthis fractionbyflowcytometry. Inapreviousstudy,wedemonstratedthatthe
resultingantigen-positive compartments (Fig.4.14A)are individual, intact endosomes
with a size of about 500nN [157],which is the expected size of these endosomal com-
partments [166]. To furtherverify the specificityof thisanalyticalmethod,we stained
thecrudeendosomal fractionofantigen-loadedmacrophagesagainsttheearlyendosomal
markerrab5(ras-relatedprotein5)orthe lysosomalmarker lamp1(lysosomal-associated
membrane protein 1) after di erent incubation periods. The staining thereby clearly
showedthatantigen-positiveendosomalcompartments(Fig. 4.14A)matureduringthe
incubation,resulting inadecreasingnumberofrab5positiveandan increasingnumberof
lamp1positivecompartments(Fig. 4.14BandC).Thispointsoutthepossibilityofthis
methodtoanalyze functionalanddynamicprocessesonendosomalcompartments.
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Figure 4.14: Antibody staining in flow cytometry of endosomes Bone marrow-derived
macrophages were feed with 500 ng/ml fluorophore-labeled OVA for 10min and chased for
di erent periods of time. Afterwards, the cells were homogenized and the resulting compart-
ments were stained with a rab5 or lamp1 antibody. A) An example for gating on antigen
positive compartments. The gating for further analysis was always done on these OVA-
positive endosomal compartments. B) Lamp1 staining on OVA-positive compartments.
C) Rab5 staining on OVA-positive endosomal compartments. Data represent results of 2
independent experiments.
To subsequently investigate the potential recruitment of sec61 by flow cytometry of
endosomes, we transduced DCs with a GFP-sec61— construct and treated them afterwards
with fluorophore-labeled OVA. The analysis of the isolated endosomal fraction of these
cells by flow cytometry revealed that the antigen-positive endosomal compartments clearly
showed the presence of GFP-sec61— proteins (Fig. 4.15), pointing out that sec61 is indeed
transported to these compartments and thereby is directly available to mediate the antigen
translocation into the cytosol.
For further characterization of the sec61-positive antigen-containing compartments, we
additionally stained the crude endosomal fraction of DCs expressing GFP-sec61— for the
early endosomal marker rab5, because it was reported before that antigen-containing
compartments have early endosomal characteristics [69]. A co-localization of the rab5
labeling and the GFP-sec61— signal was thereby observed (Fig. 4.16A), emphasizing that
the investigated compartments are indeed the endosomal cross-presenting compartments,
which have described in previous investigations [62, 66, 69].
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Figure 4.15: The sec61 channel protein is recruited to antigen-containing compartments
BMDCs were transduced by a lentivirus encoding for GFP or a GFP-sec61— fusion
protein. After 3 days, these cells were treated with 250 ng/ml fluorophore-labeled OVA for
20min and chased for additional 20min. The endosomal compartments were isolated by
homogenization and OVA-positive endosomes (left panel) were analyzed for the presence of
GFP by flow cytometry (right panel). The histograms on the right depict, as indicated,
OVA-positive endosomal compartments. All shown graphs are representative results of
at least 3 independent experiments. Data are presented as mean ± SEM. MFI: mean
fluorescence intensity.
Interestingly, adding BrefeldinA (BrefA), which inhibits the vesicular tra cking in a cell
by impairing the activation of a group of ARF (ADP-ribosylation factor) proteins [167],
during antigen uptake, diminished the correlation between OVA and sec61— (Fig. 4.16B).
This additionally illustrates that the observed recruitment is no artificial membrane fusion
event during the endosomal preparation. Even more it indicates that sec61 localization
in endosomal compartments is not a steady state system, but needs functional vesicular
tra cking during the antigen presence and is therefore an active recruitment process.
Furthermore, when we looked at derlin1 localization by flow cytometry of endosomes,
we observed only derlin1 signals in OVA-negative compartments, but not in antigen-
containing endosomes (Fig. 4.16C). This is in agreement with the results of the knock-
down experiments, which show no detectable influence of derlin1 on this pathway of
cross-presentation (Fig. 4.7).
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Figure 4.16: Sec61 is actively translocated to compartments containing the early endosomal
marker rab5 A) BMDCs were transduced with lentivirus encoding GFP or GFP-sec61—
fusion protein. After 3 days of incubation, the cells were fed with fluorophore-labeled
OVA (250 ng/ml for 20min) and chased for additional 20min. Compartments of BMDC were
isolated by homogenization, stained with a rab5-specific antibody and analyzed by flow cy-
tometry of endosomes. As indicated OVA-positive compartments are shown on the right side.
B) GFP-Sec61— expressing BMDCs were incubated with 250 ng/ml fluorophore-labeled
OVA with or without 10µg/ml BrefA. After homogenization, endosomal compartments
were analyzed by flow cytometry. Histograms on the right side show OVA-positive compart-
ments. C) BMDCs were loaded with fluorophore-labeled antigen (250 ng/ml OVA) and
incubated for 20min. After homogenization, the compartments were stained by derlin1-
specific antibodies and analyzed by flow cytometry. All graphs depict representative results
of at least 3 independent experiments. Data are represented as mean ± SEM. MFI: mean
fluorescence intensity.
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4.4 Specific inhibition of the sec61 recruitment by
intrabodies
To analyze the recruitment of sec61 to antigen-containing compartments more closely as
well as to definitely prove the involvement of sec61 in cross-presentation, we aimed to
specifically inhibit its transport to endosomal compartments. To avoid the use of unspecific
inhibitors and to target only sec61 without a ecting its general function, we decided to use
an intracellular antibody (also termed intrabody (IB)) to keep sec61 in the ER. IBs are
intracellular expressed constructs containing the variable parts of an antibody connected
by a linker sequence (Fig. 4.17A).
Figure 4.17: Generation of a sec61– specific IB A) The general structure of an IB construct
compared with a classical antibody. The used IB contained an ER-localization sequence
and the ER-retention signal KDEL. Additionally, a HIS-tag for the detection of the IB in
western blot or fluorescence microscopy was integrated. B) Scheme of the sec61 channel
protein complex with its three subunits –, — and “. The targeted area of the sec61–-specific
IB is highlighted in red.
This intracellular construct can be targeted against various proteins and is able to be
expressed at di erent locations in the cell by the variation of its localization sequences.
Aiming the ER-retention of sec61– we directed an sec61–-binding IB towards the ER and
additionally added a KDEL-retention sequence to retain it inside of the ER (Fig. 4.17).
The e ciency of this ER-retention has already been shown for other proteins before [168].
4.4.1 Generation and characterization of the sec61–-binding
intrabody
To generate an IB against sec61–, a phage display targeted against a peptide originating
from the first ER-internal luminal loop of the sec61– protein (Fig. 4.17B) was done by
Andrea Marschall in the laboratory of Prof. Dübel at the University of Braunschweig.
In this screen an IB was isolated, which binds specifically and with a high a nity to
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this peptide. To confirm this interaction also for intracellular expressed sec61– we did
an immunoprecipitation with the IB construct. Therefore, we used a purified protein
construct of the sec61–-specific IB. This construct was loaded on magnetic beads, added
to a lysate of DCs and incubated overnight at 4°C. Afterwards, the IB-loaded beads were
pulled down together with potentially interacting proteins by a magnet. Subsequently the
pull down was analyzed on a coomassie gel.
Figure 4.18: Characterization of the sec61–-specific intrabody A) Immunoprecipitation of
BMDC lysates. The purified IB was added to the lysate and pulled down by a mag-
netic bead system. The samples were loaded on a SDS gel and analysis was done by
coomassie staining. B) The immuno-precipitated samples of A) were used for western
blot analysis employing a sec61–-specific antibody for staining. Gels shown here depict
representative results of at least 3 independent experiments.
This gel showed, besides the IB itself and a faint band at 80 kDa, a clear band at about
40 kDa, which is the expected size of the sec61– subunit (Fig. 4.18A). The western blot
staining of the same samples with a sec61–-specific antibody proved that this band repre-
sents the sec61– protein (Fig. 4.18B) and confirmed that the IB can also bind to the full
sec61– protein, which is expressed inside of DCs, with a high specificity. To verify whether
the intrabody was indeed targeted towards the ER, we performed immunofluorescence
microscopy of DCs transduced with this IB. A co-localization with calnexin, an often
used ER-marker protein, as well as with sec61—, another subunit of the sec61-channel
complex, was detected (Fig. 4.19A and B). These pictures clearly demonstrate that the
IB is localized inside of the ER. Additionally, a non-specific control IB, which also contains
a KDEL sequence, was transduced into DCs. Also this IB co-localized well with calnexin,
emphasizing that the ER-retention is caused by the KDEL sequence and not by the binding
to the sec61– protein (Fig. 4.19C).
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Figure 4.19: The sec61–-specific IB is localized in the ER A) Immunofluorescence microscopy
pictures of sec61–-binding IB expression in BMDCs. The cells were stained us-
ing antibodies against the His-tag of the IB and against calnexin. B) Same as A)
with an antibody against sec61— instead of calnexin. C) Immunofluorescence mi-
croscopy as in A), but the BMDCs were transduced with a control IB, which is
not binding to sec61–. Nucleoli were stained with DAPI (blue). Co-localization
analysis was done by Pearson correlation coe cient (PCC) and Mander’s overlap
coe cient (MOC).
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4.4.2 The sec61–-binding intrabody does not a ect the general
function of sec61
Importantly, to exclude potential side e ects of the interaction between the sec61 channel
protein and the sec61–-binding IB, we analyzed, whether the expression of this IB alters
the function of sec61 in the ER. First, we controlled the total cellular expression level of
sec61– in presence of the sec61–-binding IB or the control IB by western blot analysis.
The IB interaction with the sec61 channel thereby neither reduced the expression of sec61–
in HEK293T cells nor in BMDCs (Fig. 4.20).
Figure 4.20: Sec61–-specific intrabody-binding does not impair the sec61– expression in the
cell HEK293T cells or BMDCs were transduced by lentivirus expressing the sec61–-binding
IB or the control IB and incubated for 3 days. Analysis of sec61– expression was done by
western blot. Shown western blots are representative of at least 3 independent experiments.
Next we investigated, whether the general function of sec61 is a ected by the IB expression.
To this end, a HEK cell line expressing a cleaved fluorescent protein (Venus) was used to
analyze the functionality of sec61 in the ER [162]. In this cell line one half of the Venus
protein (ZV2) is expressed in the cytosol, while the other half (ddV1Z) is localized in the
ER. Importantly, the fluorescence only occurs after reunion, if the ddV1Z part is e ciently
expressed as well as glycosylated in the ER and subsequently deglycosylated before the ex-
port through the ERAD system is done. Thus, the missing of important components of the
ERAD system, including sec61, impairs the translocation of the ER-part of the Venus pro-
tein and thereby reduces the fluorescence intensity [162]. Using this cell line we expressed
the sec61–-binding IB or a control IB for 3 days. Subsequent analysis by flow cytometry
showed no di erence in fluorescence intensity, reflecting an unaltered function of the ERAD
system, between cells containing the sec61–-binding IB and cells containing a control
IB (Fig. 4.21A). Contrary to this, the sec61-associated inhibitor ExoA as well as sec61
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down-regulation resulted in an impaired Venus-protein fluorescence, confirming that a full
functionality of sec61 is required for the fluorescence signaling of these cells (Fig. 4.21B
and C). This emphasizes that the expression of the IB does not a ect the sec61 activity in
the ER.
Figure 4.21: Sec61–-specific intrabody expression does not a ect the general function of
the sec61 protein A) HEK293T-Venus cells were transduced with the control IB or
the sec61–-binding IB and incubated for 3 days. The proteasome inhibitor MG132
(5µM) was added for additional 6 hrs and the fluorescence of the cells was finally mea-
sured by flow cytometry. B) HEK293T-Venus cells were co-cultured with 10µg/ml
ExoA and 5µM MG132 for 6 hrs and subsequently fluorescence was analyzed by flow
cytometry. C) Sec61–-specific siRNA treated HEK293T-Venus cells were incubated for
2 days and afterwards 6 hrs in presence of MG132. Determination of the amount of reunited
Venus protein was done by flow cytometry. All shown graphs are representative results
of at least 3 independent experiments. Data are presented as mean ± SEM. MFI: mean
fluorescence intensity. ExoA: ExotoxinA.
To fully exclude any influence of the sec61–-binding IB on the function of ERAD system in
the ER, we constructed fusion proteins between an extended SIINFEKL epitope and two
well-known ERAD substrates, TCRa or CD3d [169, 170]. These proteins are translated
into the ER and their final degradation depends on the ERAD-mediated translocation
from the ER into the cytosol. Afterwards, the proteins are split by proteasomes and
the SIINFEKL peptide becomes available for MHC-I presentation. The expression of
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theses fusion proteins in DCs, transfected with the sec61–-binding IB or with a control
IB, and subsequent analysis of the MHC-I SIINFEKL peptide presentation by IL2 ELISA
revealed no di erence in MHC-I presentation of both cell groups and therefore no di erence
in their ERAD function (Fig. 4.22A and B). This again points out that the presence of
the sec61–-binding IB does not influence the function of the ERAD system in the ER.
Figure 4.22: Expression of the sec61–-specific intrabody has no influence on the processing
of di erent ERAD-substrates A) BMDCs were transduced with sec61–-binding IB or
a control IB and incubated for additional 3 days. Afterwards the cells were harvested and
electroporated with di erent amounts of CD3” mRNA containing or missing a SIINFEKL
coding sequence. Electroporated cells were directly plated in a 96well plate and OT-I
T-cells were co-cultured overnight. After 18 hrs, the IL-2 concentration in the supernatant
was determined by ELISA. B) Same as in A) but with TCR– mRNA instead of CD3”
mRNA. All shown graphs are representative results of 2 independent experiments. Data
are presented as mean ± SEM.
4.4.3 The sec61–-binding intrabody retains sec61 specifically inside
of the ER
To analyze a potential role of sec61 in cross-presentation with the help of the sec61–-
binding IB, we first controlled, if the expression of this IB has an influence on the antigen
uptake of these DCs. Feeding fluorophore-labeled OVA to DCs expressing sec61–-binding
or control IB showed no di erence in the internalized amount of antigen (Fig. 4.23A).
Additionally the localization of the antigen, which has been taken up by DCs expressing
the sec61–-binding IB, was controlled by immunofluorescence microscopy. This revealed
that the fluorophore-labeled antigen OVA co-localized with the early endosomal marker
EEA1 as well as with transferrin, whereas no co-localization with the lysosomal protein
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Figure 4.23: The sec61–-binding intrabody does not influence antigen uptake or intracel-
lular localization A) BMDCs transduced with a sec61–-binding IB or a control IB
were fed with 250 ng/ml fluorophore-labeled OVA and analyzed by flow cytometry.
B) For immunofluorescence microscopy the cells were transduced with the IB construct
and incubated for 3 days. Afterwards, the cells were fed with 250 ng/ml fluorophore-labeled
OVA alone or in combination with 1µg/ml fluorophore-labeled transferrin, incubated for
15min and additionally chased for 10min in fresh medium. Subsequently, the cells were
fixed and the OVA-treated cells afterwards stained with antibodies against EEA1 or Lamp1.
Nuclei (blue) were marked with DAPI. Co-localization was analyzed by Pearson correlation
coe cient (PCC) and Mander’s overlap coe cient (MOC). All shown graphs and pictures
are representative results of at least 3 independent experiments. The data are presented as
mean ± SEM. MFI: mean fluorescence intensity.
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Lamp1 was observed. This is in agreement with the characteristics of endosomal cross-
presenting compartments described before [69]. Importantly, no di erence between DCs
transduced with the sec61–-binding IB or with a control IB was observable (Fig. 4.23B),
emphasizing that the antigen routing also stayed untouched by the IB binding to sec61–.
Next we wondered, whether the sec61–-binding IB is indeed able to retain sec61 specifically
in the ER. For analysis, we transduced this IB or a control IB into GFP-Sec61— expressing
DCs and loaded them again with fluorophore-labeled OVA. After preparation of a crude
endosomal fraction of control IB-containing cells, a clear recruitment of GFP-Sec61— to
endosomal antigen-containing compartments was detected by flow cytometric analysis.
Contrary to this, the expression of the sec61–-specific IB containing the KDEL sequence
strongly inhibited the transport of sec61 to these compartments (Fig. 4.24).
This demonstrated that the IB is indeed able to retain sec61– e ciently inside of the ER.
Figure 4.24: Sec61 recruitment to endosomal compartments is inhibited by the sec61–-
specific intrabody DC2.4 cells were transduced with lentiviral constructs expressing
GFP or GFP-sec61— and afterwards additionally infected with viruses expressing the
sec61–-binding IB or a control intrabody. Afterwards, cells were treated with fluorophore-
labeled OVA (250 ng/ml for 20min) and chased for additional 20min. Subsequently, the
endosomal compartments were isolated by mechanical homogenization and analyzed by
flow cytometry. Data represent results of 3 independent experiments and are presented as
mean ± SEM. MFI: mean fluorescence intensity.
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Subsequently, we looked at the recruitment of other components of the cross-presentation
machinery to control the specificity of the sec61 ER-retention. Therefore, we stained
the endosomal fraction of IB-expressing DCs against TAP as well as against calnexin,
both shown to be involved in cross-presentation and present on antigen-containing
compartments [62, 63, 80]. Analyses by flow cytometry pointed out that the sec61–-
specific IB does not a ect the recruitment of other components of the cross-presentation
machinery (Fig. 4.25A and B; experiment done by Dagmar Fehrenschild, bachelor student),
emphasizing the high specificity of the sec61–-retaining IB.
Figure 4.25: The recruitment of other ER-associated components of cross-presentation is
not a ected by the sec61–-binding IB A) BMDCs were transduced with lentivirus
encoding the sec61–-binding IB or a control intrabody. After 3 days of incubation, the cells
were fed with fluorophore-labeled OVA (250 ng/ml for 20min) and chased for additional
20min. The endosomal fraction of these BMDC was isolated by homogenization, stained
with a TAP-specific antibody or an isotype antibody and analyzed by flow cytometry.
As indicated OVA-positive compartments are shown on the right side. B) Same as A)
with a Calnexin-specific antibody instead of the TAP-specific antibody. All shown graphs
are representative results of at least 3 independent experiments. Data are presented as
mean ± SEM. MFI: mean fluorescence intensity. Shown experiments were done by Dagmar
Fehrenschild, bachelor student.
72
4 Results
4.4.4 Sec61-retention in the ER exclusively reduces antigen
cross-presentation
To analyze the importance of the sec61 recruitment to endosomal compartments for
cross-presentation, DCs were transduced with the sec61-retaining IB or control IB and
cross-presentation of OVA was measured by T-cell activation and detection of IL-2 se-
cretion. Therefore, the used DCs were virally transfected at least three days before
the antigen was fed for processing and presentation. Analysis showed that the retention
of the sec61 channel protein in the ER specifically reduced MHC-I cross-presenta-
tion (Fig. 4.26A). Under the same conditions MHC-II presentation exhibited no di erence
between sec61–-binding IB and control IB treated DCs, indicating that the MHC-II presen-
tation pathway was not a ected by sec61 retention (Fig. 4.26B). In addition, endogenous
Figure 4.26: Sec61 ER-retention impairs specifically cross-presentation in BMDCs
A) BMDCs were transduced with lentivirus encoding a sec61–-specific IB or a control IB.
After 3 days of expression, BMDCs were co-cultured with di erent OVA-concentrations
for 2 hrs, fixed and T-cells were added overnight. 18 hrs later, the IL-2 content in the
supernatant was determined by ELISA. B) Same as in A) with OT-II cells. C) Same as in
A) with 10nM SIINFEKL peptide instead of OVA. D) BMDCs expressing the sec61-specific
IB or a control IB were electroporated with GFP- or OVA-encoding mRNA and incubated
for 2 hrs. Cells were fixated afterwards and co-cultured with OT-I cells overnight. T-cell
activation was determined by IL-2 ELISA. All graphs depict representative results of at
least 3 independent experiments. Data are represented as mean ± SEM.
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MHC-I presentation of OVA (Fig. 4.26D) as well as extracellular loading of the SIINFEKL
peptide (Fig 4.26C) were not influenced by the expression of the sec61–-specific IB
compared to the expression of a control IB. Besides to the analyses in primary BMDCs,
the e ect of the sec61–-retaining IB was confirmed in the DC2.4 cell line.
In accordance to the results in primary DCs, cross-presentation was diminished by the
sec61 ER-retention (Fig. 4.27A), while endogenous MHC-I presentation (Fig. 4.27D),
T-cell activation after external peptide loading (Fig. 4.27C) and MHC-II presenta-
tion (Fig. 4.27B) remained unchanged.
Figure 4.27: Sec61 ER-retention reduces antigen cross-presentation in DC2.4 cells
A) DC2.4 cells were transduced with lentivirus encoding sec61–-binding IB or a con-
trol IB. After at least 3 days of expression, DC2.4 cells were co-cultured with di erent
OVA-concentrations for 2 hrs, fixed and T-cells were added overnight. 18 hrs later, the IL-2
content in the supernatant was determined by ELISA. B) Same as in A) with OT-II cells.
C) Same as in A) with 10 nM SIINFEKL peptide instead of OVA.D) DC2.4 cells expressing
the dedicated IB were electroporated with GFP or OVA-encoding mRNA and incubated for
2 hrs. Thereafter, the cells were fixed and co-cultured with OT-I T-cells overnight. T-cell
activation was determined by IL-2 ELISA. All shown graphs are representative results of
at least 3 independent experiments. Data are represented as mean ± SEM.
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This points out that the interaction between the IB and the sec61 channel protein neither
influences the MHC-II presentation pathway nor endogenous peptide presentation at the
cell surface in general. In contrast to this, the retention of the channel protein sec61 in
the ER specifically suppresses cross-presentation.
4.4.5 Sec61 localization at endosomal compartments mediates
antigen export
To address, whether the impaired cross-presentation, after exclusion of sec61 from antigen-
containing compartments, is indeed due to a reduced antigen translocation into the cytosol,
we again used three di erent approaches. First, DCs either expressing the sec61–-binding
IB or a control IB were fed with OVA and their cytosolic fraction was isolated. In the
western blot analysis a reduced amount of OVA was detected, when the IB inhibited
the sec61-recruitment, compared to an e cient export in the presence of the control
IB (Fig. 4.28A).
Figure 4.28: Expression of the sec61–-binding IB inhibits antigen export into the cytosol
BMDCs were transduced with lentiviruses expressing sec61-specific IB or control IB. After
3 days of incubation, the antigen export was investigated. A) The cells were incubated
with 0.5mg/ml biotinylated OVA for 45min in the presence of proteasome inhibitor MG132.
Afterwards, the cytosolic fraction was isolated and analyzed by western blot. B) Infected
BMDCs were incubated with 9mg/ml cytochrome c and 200 ng/ml OVA for 8 hrs. The
cells were harvested and stained with AnnexinV. Analysis was done by flow cytometry.
This graphs provide representative results of at least 3 independent experiments. Data are
represented as mean ± SEM. MFI: mean fluorescence intensity.
In agreement with this, the apoptosis ratio detected by AnnexinV staining after feeding
cytochrome c to DCs was reduced in the presence of the sec61–-binding IB, indicating an
impaired export of the engulfed cytochrome c into the cytosol (Fig. 4.28B). Additionally,
we again loaded the FRET substrate CCF4 into the cytosol of DCs expressing the sec61–-
binding IB or a control IB and fed the CCF4-splicing enzyme —-lactamase to these cells.
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Figure 4.29: Sec61 ER-retention results in an impaired antigen translocation into the
cytosol BMDCs transduced with control IB or with sec61–-binding IB were incubated for 3
days. Afterwards, IB-expressing BMDCs were loaded with CCF4 for 1 hr and subsequently
fed with 1mg/ml —-lactamase for 2 hrs. Analysis was done by flow cytometry with the
correlation of spliced and not spliced CCF4-FRET substrate signal. This experiment was
done by Dagmar Fehrenschild, bachelor student, and shows representative data of at least
3 independent experiments. Data are represented as mean ± SEM. MFI: mean fluorescence
intensity.
Analyses by flow cytometry thereby revealed that less CCF4 was processed in presence
of the sec61–-binding IB (Fig. 4.29; the shown —-lactamase assay was done by Dagmar
Fehrenschild, Bachelor student), displaying a reduced translocation of —-lactamase into the
cytosol. This confirms the results of the other two export assays and demonstrates that
the antigen-translocation was a ected, when sec61 was missing in the antigen-containing
endosomes.
These export assays clearly connect the observed reduced cross-presentation with the
impaired antigen translocation into the cytosol. The fact that the translocation of three
di erent substrates (OVA, cytochrome c and —-lactamase) was diminished by the IB-
retention of sec61 emphasizes the importance of the sec61-recruitment to endosomes for
the translocation of di erent extracellular antigens into the cytosol and subsequently for
their cross-presentation on MHC-I molecules.
4.4.6 Impairment of antigen translocation by sec61–-binding IB
strictly depends on ER-retention by the KDEL sequence
To conclusively prove that the ER-retention of sec61 is the reason for the reduced antigen
translocation into the cytosol and subsequently cross-presentation, we used a construct
of the sec61–-binding IB missing the KDEL sequence (IBDKDEL). Expressing this con-
struct in DCs revealed in immunofluorescence microscopy again a colocalization with
calnexin as well as with sec61— (Fig. 4.30A and B). Additionally, because of the lack-
ing KDEL-retention sequence, the IB was, besides its ER localization, also detected
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Figure 4.30: Intracellular localization of sec61–-specific IB missing the KDEL sequence
A) Immunofluorescence microscopy pictures of sec61–-binding IBDKDEL expression in
BMDCs. The cells were stained using antibodies against the IB and calnexin. B) Same
as A) with an antibody against sec61— instead of calnexin. C) Immunofluorescence
microscopy like in A), but with golgi-marking GM130 antibody. Nucleoli were stained with
DAPI (blue). Co-localization analysis was done by Pearson correlation coe cient (PCC)
and Mander’s overlap coe cient (MOC).
77
4 Results
in another compartment of the cell. Further microscopic analysis showed that this com-
partment represents the golgi apparatus, which needs to be passed before protein secretion
occurs (Fig. 4.30C). Importantly, when the KDEL-missing sec61–-binding IB was ex-
pressed in DCs and cross-presentation was analyzed, no di erence to the control IB was
detectable (Fig. 4.31A), although the sec61–-binding IBDKDEL was present in
the ER and able to interact with sec61– (Fig. 4.30B). Additionally, the expression of
IBDKDEL did not alter the transport of OVA, cytochrome c or —-lactamase into the
cytoplasm (Fig. 4.31B-D).
Figure 4.31: KDEL-mediated ER-retention of sec61– is essential for the impairment of
antigen translocation A) BMDCs were transduced with a sec61–-specific IBDKDEL
or a control IB. After 3 days the BMDCs were co-cultured with di erent amounts of
OVA for 2 hrs, fixed and T-cells were added overnight. 18 hrs later, the IL-2 content in
the supernatant was determined by ELISA. B) BMDCs expressing di erent IBs were
loaded with 0.5mg/ml biotinylated OVA for 45min in presence of MG132. Afterwards,
the cytosolic fraction was isolated and analyzed by western blot. C) BMDCs containing
di erent IB constructs were co-incubated with 9mg/ml cytochrome c and 200 ng/ml OVA
for 8 hrs. Afterwards cells were harvested, stained by AnnexinV and analyzed by flow
cytometry. D) BMDCs transduced with a sec61–-specific IBDKDEL or a control IB were
loaded with CCF4 for 1 hr and treated with —-lactamase for additional 2 hrs. Thereafter,
the cells were harvested and analyzed by flow cytometry. Scoring was done by the ratio
of cleaved FRET substrate (535 nm) to the remaining loaded FRET-substrate (450 nm).
The presented —-lactamase data were generated by Dagmar Fehrenschild, bachelor student.
All graphs depict representative results of at least 3 independent experiments and are
represented as mean ± SEM. MFI: mean fluorescence intensity.
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These data, in combination with the previous results, unambiguously demonstrated that
the reduced antigen translocation into the cytosol as well as the reduced cross-presentation
after IB expression was indeed due to the specifically impaired recruitment of sec61 towards
antigen-containing cross-presenting endosomes and not caused by unspecific e ects due to
the presence of the sec61–-binding IB in the ER.
4.5 Sec61-recruitment depends on TRIF signaling, but
not on MYD88 signaling
As indicated by the addition of BrefA before antigen uptake (Fig. 4.16B), the e cient
recruitment of sec61 is not a steady state condition. Therefore, we were also interested,
which signals induce and regulate the translocation of sec61 to endosomal compartments.
Because especially TLR-signaling was shown to be important for the recruitment of
di erent components of the MHC-I loading machinery to endosomal compartments in
the context of cross-presentation [62, 67, 171], we decided to investigate the role of TLRs
during antigen translocation into the cytosol.
First we analyzed, whether an endotoxin stimulus was needed for the sec61 recruitment.
Therefore, we fed endotoxin-containing or endotoxin-free fluorophore-labeled OVA to
DCs expressing the GFP-sec61— protein. The potential endosomal localization of sec61
was measured by flow cytometry of antigen-containing endosomes as described above.
While e cient sec61 recruitment occurred with endotoxin-containing OVA, the recruitment
of sec61 was weak, when endotoxin-free OVA was used (Fig. 4.32A). In addition to
this, we used fluorophore-labeled transferrin, which targets the same compartments as
OVA [62], but does not contain endotoxins. Also the endosomal flow cytometry of
transferrin-containing endosomes revealed only a weak co-localization with the GFP-
sec61— (Fig. 4.32B). To verify these low levels of the sec61 channel protein at endosomal
compartments in absence of endotoxin-containing antigens, we again transduced DC with
GFP-sec61— protein and analyzed the endosomal fraction of these cells without addition
of antigens or additional treatment. Staining of this crude endosome fraction against rab5,
which is present on sec61 positive compartments (Fig. 4.16A), pointed out that in the
absence of OVA only a few rab5 positive endosomal compartments contained additionally
the sec61 protein (Fig. 4.32C).
This confirms the results of DCs loaded with endotoxin-free OVA as well as with transferrin
and proves that a stimulus of the DCs is required for e cient translocation of sec61 from
the ER to the antigen-containing compartments and that only a low number of sec61
positive endosomes is present in resting DCs.
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Figure 4.32: E cient sec61 recruitment depends on an endotoxin stimulus A) Lentiviral
transduced BMDCs expressing the GFP-sec61— fusion protein or plain GFP were incubated
with 250 ng/ml fluorophore-labeled OVA with or without endotoxin for 20min. After 20min
additional chase, the cells were opened up and the compartments were analyzed by flow
cytometry. Histograms on the right side show OVA-positive endosomal compartments as
indicated. B) DC2.4 cells transduced with lentivirus expressing GFP-sec61— or GFP were
loaded with 250 ng/ml fluorophore-labeled OVA or fluorophore-labeled transferrin (Trf).
Subsequently, the endosomes were isolated by mechanistically homogenization and OVA or
respectively Trf positive compartments were analyzed for GFP expression by flow cytometry.
C) GFP-sec61— or GFP expressing BMDCs were homogenized and the crude endosomal
fraction was stained with rab5-detecting antibodies or an isotype control. Afterwards, the
compartments were analyzed by flow cytometry. All graphs show representative results of
at least 3 independent experiments. Data are represented as mean ± SEM.
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4.5.1 No influence of MyD88-signaling on antigen export
To gain deeper insight into the activation signal required for the recruitment of sec61
and subsequent probably for antigen export into the cytosol and cross-presentation,
the adaptor protein MyD88 was a promising first target for analysis. It is used by
many di erent TLRs, including TLR4, which detects LPS that is present in many
reagents and protein preparations (like the antigen-stocks of OVA or —-lactamase used
in this study). It has also been reported that cross-presentation is a ected by
MyD88-deficiency [62].
Therefore, we first analyzed the involvement of MyD88-signaling in cross-presentation
using an IL-2 ELISA of the supernatant of T-cells activated by wild-type or MyD88
knock-out BMDCs. We demonstrated thereby that the cross-presentation as well as the
MHC-II presentation were impaired (Fig. 4.33A and B), while endogenous presentation
Figure 4.33: MHC-I as well as MHC-II presentation of extracellular antigens is controlled
by MyD88-signaling A)Wild-type and MyD88-/- BMDCs were incubated with di erent
OVA-concentrations for 2 hrs. Afterwards, the cells were washed and co-cultured with
MHC-I OVA-specific T-cells overnight. Analysis was done by IL-2 ELISA of the supernatant.
B) same as A) with OT-II cells. C) Wild-type or MyD88-/- BMDCs were electroporated
with OVA- or GFP-encoding mRNA and incubated for 2 hrs. Subsequently, the DCs were
co-cultured with OT-I cells overnight and the IL-2 amount was determined by ELISA.
D) The same as A) with 10 nM SIINFEKL peptide instead of OVA. All graphs depict
representative results of at least 3 independent experiments. Data are represented as
mean ± SEM.
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of OVA on MHC-I molecules (Fig. 4.33C), the external loaded MHC-I peptide
control (Fig. 4.33D) as well as total antigen uptake (Fig. 4.34A) were not influenced by
the lack of MyD88 signaling. This indicates that the di erence in cross-presentation has
to be localized in the cross-presentation specific machinery.
To investigated, whether the transport of sec61 from the ER to the endosomal antigen-
containing compartments and subsequently the antigen translocation into the cytosol
was a ected by MyD88 signaling, we used again flow cytometry of endosomes. Here we
detected no di erence between wild-type DCs and DCs missing the stimulus by MyD88-
signaling (Fig. 4.34B), indicating a minor role of MyD88 during sec61 protein recruitment.
Figure 4.34: MyD88 signaling is not essential for the sec61 recruitment A)Wild-type as well as
MyD88-/- cells were fed with 250 ng/ml OVA for 15min and analyzed by flow cytometry.
B) Endosomal flow cytometry of GFP-sec61— transduced BMDCs from wild-type and
MyD88-/- mice after 20min incubation with fluorophore-labeled OVA and additional
20min chase in fresh medium. Data are represented as mean ± SEM. All graphs depict
representative results of at least 3 independent experiments. MFI: mean fluorescence
intensity.
Thus, it was not surprising that the amount of OVA exported into the cytosol was nearly
una ected by the knock-out of the signaling molecule MyD88 (Fig. 4.35A). Additionally,
also the other export assays, namely detection of apoptosis ratio after cytochrome c
uptake (Fig. 4.35B) as well as FRET-conversion by —-lactamase (Fig. 4.35C) showed
only a marginal or no impairment of the antigen export into the cytosol. These data lead
us to the conclusion that sec61 recruitment and subsequently antigen translocation into
the cytosol are not critically dependent on MyD88 signaling.
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Figure 4.35: Antigen export is not influenced by MyD88 signaling A) Wild-type or
MyD88-/- BMDCs were incubated with 0.5mg/ml biotinylated OVA in presence of protea-
some inhibitor MG132. After 45min incubation, the cytosolic fraction was isolated and
analyzed by western blot. B)MyD88-/- BMDCs as well as control cells were incubated with
9mg/ml cytochrome c and 200 ng/ml OVA for 8 hrs, harvested and stained by AnnexinV
to determine the apoptosis ratio. C) BMDCs from wild-type and MyD88-/- mice were
loaded with CCF4 for 1 hr and co-incubated with —-lactamase for additional 2 hrs. The
cells were harvested and analyzed by flow cytometry. —-lactamase export was determined
by the ratio between the cleaved and the uncleaved FRET substrate. Data are represented
as mean ± SEM. All graphs present the results of at least 3 independent experiments.
MFI: mean fluorescence intensity.
4.5.2 TRIF-signaling induces sec61-recruitment and antigen export
A second activation pathway of TLR4 is the signaling via the adaptor protein TRIF.
Therefore, we decided to analyze also the influence of this TLR pathway on antigen
presentation. Using again the activation of T-cells and secreted IL-2 as indicator for
e cient antigen presentation, we detected a di erence between wild-type and TRIF-/-
DCs in cross-presentation (Fig. 4.36A). In contrast to MyD88-/- DCs the MHC-II
presentation was not a ected in TRIF-/- DCs (Fig. 4.36B). Also endogenous MHC-I
presentation (Fig. 4.36C) and the external loading of MHC-I molecules with the SIINFEKL
peptide were also not altered in TRIF-/- DCs (Fig. 4.36D).
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Figure 4.36: Cross-presentation is specifically impaired in TRIF-/- DCs A) Wild-type and
TRIF-/- BMDCs were incubated with di erent OVA-concentrations for 2 hrs and co-cultured
with OT-I T-cells overnight. 18 hrs later, the IL-2 concentration in the supernatant was
determined by ELISA. B) The same as A) with OT-II cells. C) The same as A) with
10 nM SIINFEKL peptide instead of OVA-protein. D) BMDCs (wild-type or TRIF-/-)
were electroporated with mRNA encoding OVA or GFP and were incubated for 2 hrs.
Afterwards, theses DCs were co-cultured with OT-I cells overnight and T-cell activation
was measured by IL-2 determination. All graphs depict representative results of at least
3 independent experiments. Data are represented as mean ± SEM.
Additionally, we stained OVA-treated wild-type or TRIF-/- cells with the 25-D1-16 antibody
to detect the amount of OVA-peptide loaded MHC-I molecules on the cell surface and
analyzed again the cross-presentation e ciency in TRIF-/- cells. This staining confirmed
the IL2 ELISA results, proving an impaired cross-presentation in TRIF-/- DCs compared
to wild-type DCs. In contrast to this, the staining was equivalent when the processed
SIINFEKL peptide was loaded onto the MHC-I molecules at the cell surface, demonstrating
that the availability of MHC-I molecules suitable for OVA-presentation was equal on wild-
type and TRIF-/- DCs (Fig. 4.37A). Again the reduction of cross-presentation was not
due to di erent amounts of OVA taken up by these DCs (Fig. 4.37B), indicating a specific
impairment in the cross-presentation machinery.
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Figure 4.37: Cross-presentation dependent display of MHC-I OVA complexes is reduced in
TRIF-/- DCs A) Wild-type and TRIF-/- BMDCs were incubated for 6 hrs in presence
of 5mg/ml OVA. Afterwards, OVA-peptide MHC-I complexes were stained with 25.D1-16
antibody and data were analyzed by flow cytometry. B) Wild-type and TRIF-/- BMDCs
were incubated with 250 ng/ml fluorophore-labeled OVA for 15min and analyzed by flow
cytometry. All graphs shown represent the results of at least 3 independent experiments.
Data are represented as mean ± SEM. MFI: mean fluorescence intensity.
Starting on these results we now investigated whether reduced cross-presentation in the
absence of TRIF-signaling might be due to an altered antigen translocation into the
cytosol. To test this hypothesis, we again used three di erent methods to determine
the e ciency of antigen translocation into the cytosol. First we fed the antigen OVA
to wild-type or TRIF-/- DCs and isolated the cytosolic fraction. Here, we observed a
reduction of antigen translocation into the cytosol (Fig. 4.38A, shown experiment was
done by Vera Eulenberg, diploma student), indicating an involvement of TRIF signal-
ing during the antigen translocation. To confirm these results, we fed cytochrome c to
wild-type and TRIF-/- cells. In this assay the AnnexinV staining was reduced, when
the TRIF-signaling was missing, reflecting a reduced cytochrome c export into the cy-
tosol (Fig. 4.38B) and verifying the analysis of the cytosolic fraction of OVA-loaded cells.
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In agreement with these data, also the —-lactamase assay performed by Dagmar Fehren-
schild showed an impaired export e ciency of —-lactamase in TRIF-/- cells (Fig. 4.38C).
By this, we demonstrated that indeed TRIF-/- signaling is required for an e cient antigen
translocation into the cytosol.
Figure 4.38: TRIF signaling is required for e cient antigen export A) BMDCs of wt or
TRIF-/- mice were were loaded with 0.5mg/ml biotinylated OVA for 45min in pres-
ence of the proteasome inhibitor MG132. Afterwards, the cytosolic fraction was isolated
and the exported amount of OVA was determined by western blot. Shown experiment
was done by Vera Eulenberg, diploma student. B) Wild-type or TRIF-/- BMDCs were
treated with 9mg/ml cytochrome c and 200 ng/ml OVA for 8 hrs. Afterwards, the cells
were harvested, stained for AnnexinV and analyzed by flow cytometry. C) TRIF-/-
BMDCs or control cells were loaded with CCF4 for 1 hr and treated with —-lactamase
for another 2 hrs. The cells were harvested and analyzed by flow cytometry. Analy-
sis was done by the ratio of split FRET substrate (emission at 535 nm) to remaining
loaded FRET-substrate (emission at 450 nm). The presented —-lactamase data were
generated by Dagmar Fehrenschild, bachelor student. All shown graphs are representa-
tive results of at least 3 independent experiments. Data are presented as mean ± SEM.
MFI: mean fluorescence intensity.
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To analyze, if this impaired antigen tra cking into the cytosol was caused by a missing
recruitment of sec61, we transduced wild-type or TRIF-/- DCs with the GFP-sec61—
protein and isolated the crude endosomal fraction of these cells after loading them with
fluorophore-labeled OVA. Detecting the antigen-positive endosomes by flow cytometry
pointed out that indeed sec61 was e ciently recruited only in wild-type DCs, while less
co-localization of the antigen-containing compartments and GFP-sec61— was detected
in TRIF-/- DCs. Control endosomal flow cytometry of wild-type or TRIF-/- DCs ex-
pressing only GFP showed no GFP-signal in the cross-presenting OVA-positive compart-
ments (Fig. 4.39). These data verified the importance of TRIF signaling for the sec61
recruitment towards antigen-containing compartments and subsequently antigen transloca-
tion into the cytosol.
Figure 4.39: Sec61 recruitment to antigen-containing compartments is controlled by TRIF-
signaling Wild-type or TRIF-/- BMDCs were transduced by lentiviruses encoding GFP or
GFP-sec61— protein. After additional 3 days of expression the cells were fed with 500 ng/ml
fluorophore-labeled OVA for 20min and chased for another 20min. To analyze the sec61
recruitment, the cells were harvested, homogenized and investigated by flow cytometry of
endosomes. All graphs depict representative results of at least 3 independent experiments.
Data are represented as mean ± SEM. MFI: mean fluorescence intensity.
Altogether, the results of this study provided conclusive functional evidence that sec61
is important for antigen export into the cytosol in context of cross-presentation. The
presence of sec61 at antigen-containing compartments is thereby essential for antigen
translocation and regulated by TRIF-TLR signaling, while it is not significantly influenced
by the MyD88 TLR-adaptor protein.
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Based on experiments with the inhibitor ExoA, which impairs the function of the ERAD
system [156], a role of the ERAD machinery in cross-presentation has been postulated
for a long time [65, 78, 172]. However, the lack of functional data led to an intense and
controversial discussion about the mechanisms mediating antigen translocation into the
cytosol [173]. During my PhD thesis we were able to provide for the first time a functional
evidence that the ERAD machinery participates in the antigen export into the cytosol. In
these experiments, we incontrovertibly showed that sec61 is involved in cross-presentation
and its function is essential for antigen translocation towards proteasomal degradation
and antigen processing. Importantly, the localization of sec61 at the antigen-containing
endosomes was required for e cient antigen export. By blocking the recruitment of sec61
to endosomal compartments without a ecting its function in the ER, the antigen export
was diminished. We were also able to demonstrate that this recruitment is well controlled
by a TRIF-dependent TLR signaling.
5.1 Importance of the ERAD machinery for antigen
cross-presentation
The molecular mechanisms of cross-presentation have been in the center of interest of im-
munological science for a long time and several structures have already been reported to be
involved [98, 174, 175]. For cross-presentation via the endosome to cytosol pathway, which
is propably the most investigated one, several mechanistic aspects have been described.
These include the fact that the antigen processing and peptide loading can take place
spatially separated from the endogenous MHC-I loading machinery. Also the reimport of
peptides into the endosomal cross-presenting compartment via TAP has been convincingly
shown in various publications [68, 69, 176]. However, one still very intensively discussed
question is how the antigens can pass the membrane barrier the other way around, from
the endosomal compartment into the cytosol for proteasomal degradation.
One possibility proposed by some research groups, is that the antigen might leak out of
endosomal compartments or simply di use into the cytosol because the endosomes might
lose their membrane integrity [177, 178, 179]. In line with this it has been shown that
a dectamer of the HIV-1 protein Tat can translocate itself and some cargo proteins of
di erent sizes through a phagosomal membrane into the cytosol [178].
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Additionally, it was reported that phagosomes containing di erent pathogens, like Crypto-
coccus neoformans, lose their membrane integrity. Afterwards, proteins can leak out and get
access to the cytosolic processing machinery [178]. This more or less “passive mechanisms”
might be true for specific pathogens, but it is unlikely that this export-principle can be
used for the majority of antigens. Although it has been described that the cellular proteins
themselves are able to destabilize the membrane of lysosomal compartments [177], many
questions about the di used antigens remain unanswered, for example the mediation of
their further processing in the cytosol and subsequently the MHC-I peptide loading.
However, our results, gained during this thesis, support a second possible antigen-transport
mechanism, which uses a channel protein for antigen translocation. In our experiments
we found that the inhibition of components of the ERAD machinery showed a strong
reduction of antigen cross-presentation e ciency (Figure 4.1 on page 47 and Figure 4.4 on
page 49) due to an impaired antigen export into the cytosol (Figure 4.5 on page 50). One
of the ERAD inhibitors we analyzed was EeyI, which inhibits the function of the ATPase
p97 [164, 165]. Interestingly, this protein has been described before to be involved in the
presentation of extracellular antigens on MHC-I [66, 78]. Both, the localization of p97
at the antigen-containing compartment as well as its ATPase function are important for
e cient cross-presentation. In this context it is supposed that p97 delivers the required
energy for the antigen transfer into the cytosol. This additionally emphasizes that the
antigen translocation is rather an active transport event than a passive rupture of the
endosomal membrane. The other inhibitor we used was ExoA. This inhibitor is described
to interact with the sec61 channel protein and thereby is supposed to block the ERAD
associated protein transport through the membrane itself [78, 156]. Also this inhibitor
impaired cross-presentation and the antigen translocation into the cytosol (Figure 4.5 on
page 50) in our experiments. This is in agreement with results shown by the research
group of Prof. Cresswell before [78].
These inhibitor data clearly indicate an involvement of the ERAD machinery in the
antigen export events and point out that a channel-based transport mechanism takes
place. Because all other antigen presentation pathways remained una ected (Figure 4.1
on page 47 and Figure 4.4 on page 49), the observed e ect on cross-presentation is indeed
specific and not due to cytotoxic e ects of the inhibitors or caused by stress e ects like
an unfolded protein response. These stress-responses, which are for example induced by
the aggregation of misfolded proteins in the ER, can occur, when the ERAD machinery
in the ER is blocked over a longer period of time [180]. Therefore, potential side e ects
a ecting the function of the ERAD machinery in the ER directly or indirectly have to be
considered and controlled during all experiments.
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Besides of theoretical arguments for the involvement of the ERAD machinery during
antigen translocation, like the same transport direction or the use of other ER components
during cross-presentation, these inhibitor e ects led us to a closer investigation of the role
of the ERAD transport machinery in the context of antigen translocation out of endosomal
compartments into the cytosol.
5.2 Involvement of the sec61 channel protein during
cross-presentation
5.2.1 Sec61 as channel protein for ERAD substrates as well as for
antigen translocation
One of the most interesting aspects of the antigen translocation machinery for cross-
presentation is, which channel protein is used for the export step. An often mentioned
and intensively discussed core protein thereby is sec61 [113, 150, 151, 152, 153], which
was, because of the inhibitory e ect of the sec61-associated ERAD inhibitor ExoA in
our analysis, also the most promising candidate to mediate the antigen translocation in
our model system. In line with our data, other research groups have described similar
e ects of ExoA on cross-presentation. Ackerman et al. for example showed in an in-vitro
system that the export of the antigen out of phagosomal compartments can be impaired by
ExoA [78].
One argument often put up against the sec61 channel protein as a candidate for the antigen
export as well as for ERAD substrates is its proposed structure. Analyses postulated
a pore size of about 5-8Å, which was criticized to be too small to e ciently transport
antigens [181]. However, these analyses have been made for the closed state of the channel
protein. An open state was reported to be expanded up to 40-60Å [182], which would be
su cient to transport unfolded proteins in both directions. Even tightly folded subdomains
might fit through this pore size [183].
These presumptions implicate that the antigen needs to be unfolded before the export
can take place. And indeed, the requirement of protein unfolding and therefore the
participation of di erent chaperons during the antigen transport through the membrane
has been indicated in several studies before. Beside of the chaperon function of p97 during
its attendance at the side of antigen export [78, 184], Hsp90 was reported to be involved in
antigen translocation [185, 186]. It was also shown that the thioesterase GILT plays a role
in the context of cross-presentation by splitting disulfide bounds inside of the antigens [79],
emphasizing the importance of peptide unfolding for the export event. These observations
are similar to the mechanisms reported from the ERAD system in the ER itself, where
misfolded proteins have to be at least partly linearized before they can be exported towards
degradation [119, 187].
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However, in the ERAD research field itself, it has been postulated during the last years that
sec61 can only be used for protein synthesis, but not for retrograde transport [135, 188, 189].
Especially the induction of a channel opening of the sec61 core protein from its luminal
side is discussed controversially [190]. Conclusions out of structural analyses predict a
model system in which the sec61 pore is blocked by a short helix, named plug. This plug is
displaced, when a protein is translated into the ER, but is suggested to block the transport
the other way around. Therefore, it is argued that other channel proteins have to take
over the transport events for the ERAD machinery.
Nonetheless, so far a direct sec61-excluding evidence is missing and there are many hints
that sec61 is important for the ERAD system. One of the substrates, reported for the
retrograde transport by sec61 is the cholera toxin, which misuses the ERAD to get into the
cytosol. A very interesting finding, arguing for the bidirectional transport possibility of the
sec61 channel is the fact that the binding of ribosomes to the sec61 complex for protein
translation inhibits the retrograde transport of the cholera toxin [191]. This indicates that
a transport directing mechanism exists within the sec61 channel protein. Furthermore,
a spacial separation of protein translation and retranslocation would be possible. It was
described that sec61 localization is not strictly limited to the ER, but extends into the
ERGIC (ER-golgi intermediate compartment) [192]. There, an accumulation of misfolded
MHC-I proteins was reported [193]. This suggests that the ERGIC might be a preferred
location for the ERAD machinery, while the ER itself is reserved for protein synthesis.
A very recent study in cross-presentation picks up the arguments against sec61 and
postulates that this channel protein is not involved in cross-presentation [194]. They used
a knock down of sec61–, the major subunit of the sec61 channel complex, as method
to analyze its role in cross-presentation. Afterwards, they fed synthetic long peptides
to human DCs and observed a moderate, but not significant reduction of the antigen
presentation on MHC-I molecules. For knock down control they used western blots and
identified a band at 95 kDa as sec61–, which is predicted to be approximately 50 kDa.
Additionally, this band at 95 kDa was also a ected by siRNA directed against p97 and
derlin1, which makes questionable whether the knock down of sec61 was specific and
worked e ciently.
In contrast to this, another group did a siRNA approach in the DC2.4 cell line, showing
an impaired cross-presentation by the sec61 knock down [172]. Although this result brings
sec61 again into the center of interest, important controls like the function of other antigen
presentation pathways during sec61 knock down were missing. As mentioned above, these
controls are essential to exclude stress e ects occurring for example by the unfolded protein
response.
To analyze the role of sec61 in cross-presentation more closely, we also knocked down the
sec61– subunit in our model and looked at the e ects on antigen presentation. After a
specific knock down, we observed an impaired cross-presentation (Figure 4.9 on page 54).
Importantly, this reduction in antigen presentation was only specific for cross-presentation,
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when the cells were analyzed 24 hrs after the knock down and were fixed during the
incubation with T-cells. This emphasizes that missing sec61 over a longer period of time
indeed a ected the general function of the cell (e.g. the MHC-II presentation Figure 4.8
on page 53), perhaps by induced stress e ects.
Analysis of the reason for the impaired cross-presentation after the sec61 knock down
uncovered that the reduced antigen cross-presentation was indeed caused by a diminished
antigen translocation into the cytosol (Figure 4.11 on page 57). In addition we observed
the same e ect after the knock-down of the sec61“ subunit, which is also important for
the function of the sec61 complex (Figure 4.12 on page 58 and Figure 4.13 on page 59),
emphasizing the role of sec61 in antigen translocation and cross-presentation.
Since the often used isolation of the cytosolic fractions to analyze antigen export is
very sensitive to artifacts by rupture of antigen-containing compartments [71, 195, 196],
we did the export analysis with two additional independent assays described by other
research groups before (Figure 4.11 on page 57; [64, 197]). This enabled us to ensure the
accuracy of the export assay and to confirm the observed e ects. Additionally, the usage of
three di erent export assays pointed out that the involvement of sec61 in antigen export
is not restricted to the model antigen OVA, but also the export of the two other model
antigens (cytochrome c and —-lactamase) depended, at least partly, on sec61.
Nonetheless, it is doubtable that sec61 is the only channel protein involved in the ERAD
system as well as in retrograde transport of antigens into the cytosol. So it might depend
on the condition of the cell, the uptake mechanism and the substrate itself, which channel
protein is involved in antigen export.
5.2.2 Derlin1 knock down has no influence on antigen translocation
One other protein described in the ERAD system as potential candidate to build a channel
through the ER membrane is derlin1 [137, 138, 142]. Therefore, derlin1 was also suggested
to be involved during antigen export into the cytosol [98, 197] and we analyzed the influence
of derlin1 on antigen processing in our used system by siRNA knock down (Figure 4.6 on
page 51). However, no e ect was observable, although the derlin1 expression was reduced
to about 20% of the normal protein level (Figure 4.7 on page 51). These data agree well
with the results shown by Menager et al.. They also did not detect any influence of derlin1
knock down on cross-presentation [194]. Additionally, the unchanged MHC-II presen-
tation (Figure 4.7 on page 51) indicates that the lack of derlin1 did not induce potential
stress e ects, which might a ect the antigen presentation. This implies that derlin1 either
plays a minor role in the recycling of misfolded proteins in the ER during these experiments
or that its missing can be compensated by other channel proteins, perhaps derlin2 or der-
lin3. Having a closer look on antigen-containing endosomes showed no derlin1 localization
at these compartments (Figure 4.16 on page 63). These results make it also unlikely that
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derlin1 has a function in antigen cross-presentation, which could be compensated by other
proteins after derlin1 knock down. In the case that derlin1 might nevertheless be involved in
the transport of other antigens than OVA out of endosomal compartments into the cytosol,
a separate and strictly regulated recruitment system for derlin1 to antigen-containing
endosomes would be required.
5.2.3 Ubiqutin-ligases in the context of cross-presentation
A very interesting and still unanswered question is the influence of ERAD associated
E3 ubiquitin ligases in cross-presentation. Besides some functions in substrate recog-
nition for the ERAD system [123], they are required to connect ubiquitin chains to
exported misfolded proteins and mark them as substrates for the proteasomal degradation
machinery [125, 126]. Therefore, they are essential for the function of the ERAD system.
The importance of ubiquitination in context of cross-presentation is largely unknown. In
general it was observed that ubiquitinated, but so far undefined, proteins are present on
the cytosolic side of antigen-containing compartments [176]. The fact that proteasomal
degradation is involved in cross-presentation [44, 80], in combination with the fact that
ubiquitination in general is important for proteasomal degradation [34, 36], makes it likely
that ubiquitination also plays a role in cross-presentation. Additionally, we recently showed
that ubiquitination of the mannose receptor in context of cross-presentation is required for
the recruitment of p97 to antigen-containing compartments, which in turn is important for
the antigen translocation into the cytosol [66]. This points out that ubiquitination indeed
seems to be involved in cross-presentation. Considering the influence of other ERAD
components on cross-presentation, it is supposable that ubiquitination of components
of the export machinery or of the antigen itself is also mediated by ERAD-associated
ubiquitin ligases. Interestingly, ERAD ubiquitin ligases possess, apart from their reactive
center in the cytosol, multiple transmembrane domains indicating more functions than the
protein ubiquitination alone.
One of the most investigated ER-ubiquitin ligases is Hrd1 [120, 121, 122]. For this
ubiquitin ligase also a participation in the ERAD channel system was suggested. So it
has been proposed that Hrd1 takes part in the formation of the derlin-dependent core
complex [188, 198]. This complex generation would make an involvement of Hrd1 in
antigen translocation itself unlikely, because derlin1 was not required for antigen export
into the cytosol (Figure 4.7 on page 51). However, the Hrd1 ubiquitin ligase has also been
described to be important for the ERAD machinery in many other cases, independent of
derlin1. Additionally, it was recently reported that Hrd1 can build a channel for protein
translocation by itself [135]. Hence, it would be interesting to see, whether Hrd1 might be
involved in antigen translocation or even build an alternative export channel for antigen
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cross-presentation. Further experiments and sequential analysis of the export events will be
needed to clarify these questions in more detail. Additionally, the potential participation
of other known ERAD ubiquitin ligases [124], besides of Hrd1, will be an important aspect
for upcoming analyses.
5.3 Recruitment of sec61 towards endosomes is essential
for antigen translocation into the cytosol
In several studies antigen cross-presentation is described to be spatial separated from the
endogenous MHC-I presentation machinery [62, 98, 199]. Although the complete sepa-
ration is still under discussion regarding the peptide loading on MHC-I
molecules [65, 68], the community agrees that the antigen export takes place at en-
dosomal or phagosomal compartments. In contrast to this, sec61 is a very well described
protein with location in the ER and often used as an ER-marker protein. However, for
antigen translocation the channel protein needs to be localized in close contact to the
antigen itself. Therefore, it was important to clarify, whether sec61 is recruited to the
endosomal antigen-containing compartments.
5.3.1 Flow cytometry of endosomes to analyze antigen-containing
compartments and sec61 recruitment
Several research groups have already reported the transport of various proteins, which
are involved in cross-presentation, from the ER to endosomal compartments (like TAP or
MHC-I) [62, 64, 67]. Unfortunately, for the analysis of sec61 recruitment, immunofluo-
rescence microscopy was very di cult to use, because of the very intense signal of sec61
in the ER. Therefore, we decided to use endosomal flow cytometry to get rid of the ER
background signal and to more closely analyze the contents of the antigen-containing
compartments. This method has already been used to detect the recruitment of p97 to
endosomal compartments in the context of cross-presentation [66]. For flow cytometry
of endosomes, as described before [157], we carefully opened up the cells by mechanical
forces, labeled the targeted proteins extra-endosomal and measured the staining by flow
cytometry. This read out is very sensitive and well suitable for the analysis of weak signals
at the endosomal compartments.
The function of this method is additionally demonstrated in this work by characteriza-
tion of the endosomal maturation of antigen-containing compartments in macrophages.
The detection of a decreasing number of rab5 molecules, an early endosomal marker,
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and an increasing signal of lamp1, a late endosomal and lysosomal marker, at the
antigen-containing compartments during the incubation time pointed out that
also dynamic processes can be well characterized by flow cytometry of endosomes (Figure
4.14 on page 61).
To investigate the recruitment of the sec61 channel protein, a GFP-sec61— fusion protein
was used. In the flow cytometry of endosomes this construct co-localized well with the
antigen taken up by the DCs before (Figure 4.15 on page 62). Additionally, to closer
characterize the antigen-containing compartment, we stained the crude endosomal fraction
of GFP-sec61— expressing DCs for the early endosomal marker rab5 (Figure 4.16 on page
63). Here, a co-localization with sec61 was visible, which is in line with previous studies
describing endosomal cross-presentation compartments as structures with stable early
endosomal characteristics [69, 70, 71, 200]. Thus, this endosomal analysis revealed that
sec61 is indeed localized at the side of the antigens in endosomal compartments and is
able to contribute to the cross-presentation machinery. Additionally, we generated in
collaboration with Prof. Abraham Koster and Erik Bos electron microscopy pictures,
which show a specific sec61-staining at antigen-containing endosomal compartments (data
not shown) and confirm our results of endosomal flow cytometry .
In contrast to the sec61 recruitment, derlin1, which was not involved in cross-presentation
during our analyses, was not detected at the endosomal compartments (Figure 4.16 on
page 63) as already mentioned above. This points out that an unspecific recruitment of
sec61 to endosomal compartments does not takes place, like it might occur by fusion events
with the ER [82], but the protein acquisition of antigen cross-presentation compartments
in general is well controlled and restricted to determined ER-components [64, 67, 73]. One
well described example is the ER-localized aminopeptidase ERAP. The ERAP protein
is involved in endogenous MHC-I presentation by trimming peptides in the ER, but is
not present in endosomal compartments during cross-presentation. It is excluded from
antigen-containing compartments [63], whereas TAP is translocalized to cross-presenting
structures [64].
5.3.2 Usage of intrabody constructs to modulate cellular functions
To analyze the importance of the specific sec61 recruitment towards antigen-containing
compartments for cross-presentation, we planned to inhibit this protein translocation. For
this we used an approach with intracellular expressed antibodies (intrabodies) binding
to sec61. This enabled us to specifically block the sec61 protein transport and to avoid
unspecific side e ects, which would occur for example by the use of di erent inhibitors.
An intrabody is a construct consisting out of the variable parts of an antibody connected
by a linker sequence (Figure 4.17 on page 64) and can be expressed within a cell, where it
subsequently binds to its target and modulate it in di erent ways [201, 202]. This system
is a very useful tool and becomes, together with in-vitro generated antibodies, more and
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more interesting for the research community. The evaluated usage of in-vitro selected
antibodies or intrabodies is due to the quick availability of various antibody genes by phage
display for the selection of target-binding constructs [203]. Additionally, the phage display
provides the possibilities to find antibodies or intrabodies against di cult targets and to
select constructs with specific characteristics [204]. Therefore, this approach is beneficial
for many di erent analyses and several functional assays have been reported during the
last years [168, 204, 205]. On the one hand in-vitro selected antibodies can be used to
target cell surface receptors and modulate their activity, like the B-cell stimulation by an
in-vitro selected antibody against CD40 [206]. On the other hand intracellular expressed
antibody constructs, called the intrabodies, can fulfill a broad range of functions. First,
they are very flexible in their location inside of the cell, determined by di erent localization
and retention sequences [201, 207]. Once expressed, the intrabody can for example induce
the degradation of the aimed protein, which results in a down-regulation of the target
protein [168]. Additionally, intrabodies can modify the intracellular localization and
function of proteins [207]. Especially this manipulation of the intracellular tra cking of
proteins by intrabody expression was interesting for our studies. In several publications,
it was reported that proteins, which are normally transported from the ER to other
subcellular compartments can be retained in the ER by intrabodies and thereby are
functionally knocked down without directly inducing protein degradation [205, 208, 209].
One example is TLR9, which is normally, after stimulation of the cells occurred, transported
from the ER to endosomal compartments containing the TLR9 ligands. This recruitment
and subsequently the TLR9-signaling was successfully inhibited by intrabody-mediated
ER-retention of the TLR9 molecules [205].
5.3.3 Sec61 recruitment is needed for antigen export into the cytosol
Based on these reports, we generated, in cooperation with the research group of
Prof. Dübel, an intrabody binding to a peptide of sec61– with the help of a phage
display. The intrabody-binding to the cellular expressed sec61 protein was afterwards
verified by immunoprecipitation (Figure 4.18 on page 65). In addition to this, we modified
this intrabody to be expressed in the ER and be retained there by a KDEL sequence (Fig-
ure 4.19 on page 66) to inhibit the translocation of the sec61 complex towards endosomal
compartments. This approach enabled us to specifically analyze the importance of the
recruitment of sec61, which has so far not been addressed by the inhibitor or knock down
assays done before [78, 172].
Indeed, when we expressed this intrabody in DCs, we detected no sec61 recruitment to endo-
somal compartments any more (Figure 4.24 on page 71), while TAP as
well as calnexin recruitment, which was described by other research groups
before [80, 62, 63], were not inhibited by the presence of the sec61–-binding intrabody (Fig-
ure 4.25 on page 72). The missing of the sec61 recruitment thereby severely impaired specif-
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ically the cross-presentation and inhibited the translocation of various antigens into the
cytosol (Figure 4.26 on page 73 and Figure 4.28 on page 75). Importantly, no knock down
e ects on the expression of the target protein occurred (Figure 4.20 on page 67), which has
been described for some intrabodies before [168]. An aspect potentially arguing against the
direct involvement of sec61 in cross-presentation would be that the binding of the intrabody
to sec61 inhibits the ERAD system and induces stress e ects. Alternatively, it might impair
protein synthesis of components involved in cross-presentation. To exclude potential stress
e ects, we first controlled the other presentation pathways (endogenous MHC-I presentation
or MHC-II presentation; Figure 4.26 on page 73). These were not a ected in the presence of
the sec61–-binding intrabodies. To control the function of sec61 in the ER and to exclude
that the protein translocation pathway was a ected in any kind, we used a tool generated by
Grotzke et al. [162], namely a HEK-cell line expressing a split Venus protein as reporter.
For its function one half of the Venus protein is expressed in the cytosol, while the other
half is synthesized into the ER. The ER-expressed segment is modified in a way that it will
be glycosylated after translation into the ER and has to be deglycosylated before the export
via the ERAD system occurs. Only under these conditions an interaction with the cytosolic
half is possible and subsequently a fluorescence signal can be emitted. This analysis showed
neither an influence of the sec61–-binding intrabody in protein synthesis nor in the ERAD
system itself (Figure 4.21 on page 68). In contrast to this, the inhibition of the ERAD
machinery with the sec61-associated inhibitor ExoA or down-regulation of sec61– by
siRNA for a longer period of time impaired the Venus-fluorescence, verifying the function
of this system. To reinforce this results and to emphasize that the protein translocation by
the ERAD system in the ER is una ected by the sec61–-binding intrabody, we expressed
two proteins, which are well known to be degraded by the ERAD system, inside of our
DCs [169, 170]. These proteins we fused to the part of the OVA-protein sequence contain-
ing the MHC-I epitope SIINFEKL. After protein degradation by the ERAD system, the
MHC-I presentation can be used as measurement for the ERAD function. Also this control
assay showed no influence of the sec61–-binding intrabody on the function of the ERAD
system (Figure 4.22 on page 69).
To additionally exclude that only the synthesis of single proteins, which are not covered
by the used control assays, was a ected and to definitely prove that indeed only the
inhibited recruitment of sec61 was the reason for the reduced antigen translocation into the
cytosol, we controlled the e ects of the expression of the sec61–-binding intrabody without
ER-retention signal. Because this construct is also partly present in the ER (Figure 4.30
on page 77) and is therefore able to interact with sec61, but not to retain it there, it
allowed us to reduce the investigation only to the e ects of the ER-retention of the sec61
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channel protein. Additionally, it excludes side e ects by the sec61–-binding intrabody
expression itself. This KDEL-missing intrabody showed no reduced antigen translocation
or cross-presentation compared to an unspecific control intrabody (Figure 4.31 on page
78) and clearly demonstrates that the intrabody-binding alone has no impairing e ect in
antigen presentation.
These control experiments clearly point out that the observed reduced cross-presentation
was indeed exclusively due to an inhibited sec61 recruitment to endosomal compartments,
and emphasize that the translocation of sec61 is needed for an e cient antigen export
into the cytosol. Additionally, it demonstrates the intrabody approach as an unique
experimental setup to inhibit the recruitment of a protein from the ER to the endosomal
compartments with a high specificity and therefore as a very useful tool for further studies
in the context of cross-presentation.
5.4 Complexity of protein recruitment and regulatory
e ects during cross-presentation
Although the intrabody approach clearly demonstrated that sec61 recruitment is essential
for antigen cross-presentation, the regulatory mechanisms for the antigen translocation
system as well as the recruitment pathway used for important components of this machinery
are still unanswered questions, which need to be clarified.
5.4.1 Regulation of the activity of the protein translocation
machinery
One important question is, at which steps of the antigen export a regulation of the protein
transport is possible. While di erent control or regulation mechanisms are known for the
ERAD machinery at the ER, like the glycosylation structure of target proteins [114] or
extending and trimming of the ubiquitin chain of the ERAD substrate [210], it is largely
unknown how the export-control is done in context of the cross-presentation machinery.
An interesting hint that the antigen export can also be controlled by ubiquitination
was recently discovered in our laboratory [66]. We were able showed that the block of
polyubiquitination by the monoubiquitin-binding factor TSG101 at the side of antigen
export inhibited the recruitment of the ATPase p97, which is needed to deliver the
energy for the translocation event. Another potential target for regulation is the sec61
channel protein itself. A very inspiring and puzzling aspect regarding potential regulating
factors of sec61 was delivered in the screening for members of the ERAD machinery by
Grotzke et al. [162]. In this study the sec61–1 knock down resulted, as expected, in
a reduced retrograde transport, whereas sec61–2 knock down led to an increase of the
degradation of exported proteins. These opposing e ects might connect sec61–2 to a
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regulatory function of the ERAD machinery. Regardless of its low expression level in DCs
under normal conditions (Figure 4.8 on page 53), it remains an open question whether
sec61–2 plays a role in the regulation of antigen processing under certain conditions.
5.4.2 Di erent recruitment pathways available for the loading
machinery of cross-presentation
In contrast to the direct activity control of the antigen translocation machinery, more is
known about the recruitment of the cross-presentation machinery to endosomal compart-
ments. Although still many questions remain unanswered, several potential recruitment
routes of proteins to endosomal cross-presenting compartments have been postulated. In a
recent study a transport pathway for MHC-I molecules was discovered to be essential for
cross-presentation [67]. For this, SNARE proteins localized at antigen-containing compart-
ments were used to analyze potential recruitment directions. It was shown that MHC-I
molecules, most likely originating from the plasma membrane, were transported into a
specialized storage compartment in a rab11a dependent manner. From this compartment
the further transport to the cross-presentation compartment was done by SNAP23, which
is co-localized with the internalized antigen.
Another transport pathway for the recruitment of ER components to antigen-containing
compartments was reported by the research group of Prof. Amigorena [64]. They described
that the transport of ER proteins occurs through the ERGIC to the antigen-containing
compartment. The ERGIC is a stable sub-compartment of the ER, mainly fulfilling the
quality control of newly synthesized proteins [211]. Additionally, it contains parts of the
MHC-I complex, which ensures MHC-I loading with high a nity peptides [212]. This
transport pathway is mediated by the SNARE protein couple sec22b and syntaxin4 [64].
Because of two aspects, this transport pathway is also very interesting for the recruitment
of sec61. First, it was reported by Cebrian et al. that the inhibition of this transport
system by sec22b knock down impaired the antigen export out of the antigen-containing
compartments into the cytosol [64]. One possible reason for this might be a reduced sec61
recruitment to the site of cross-presentation, which is, as shown here in our study, impor-
tant for e cient antigen translocation into the cytosol. Apart from this, the expression of
sec61 within a cell is not completely restricted to the ER, but its presence is extended into
the ERGIC, as already mentioned above. Although the exact reason for this expression
pattern is still unclear, it would provide an adequate supply of sec61 molecules for the
transport event from the ERGIC to the antigen-containing endosomes.
Also several additional proteins regulating the vesicle tra cking have been described to
be involved in cross-presentation and ER protein recruitment, like rab27 for the NOX2
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translocation [73, 84] or potentially rab14 and syntaxin 6 in the context of the IRAP
localization [63, 86]. It remains to be puzzled out, which proteins and recruitment pathways
belong to each other and which regulatory mechanisms are used to get a complete and
e ciently working cross-presenting compartment.
Next, it was shown in recent studies that endosomal compartments tra c and mature in
close relation to the ER. Several contact sites were discovered by high-resolution microscopy
pictures [213]. Thus, also this direct contact between endosomes and ER might contribute
to the transfer of ER proteins to antigen-containing endosomes for the presentation
of extracellular antigens on MHC-I molecules. Considering the fact that only certain
proteins are recruited for cross-presentation, also here a strong regulation of the protein
translocation would be needed. A possibility therefore would be the aggregation of defined
proteins on ER subdomains, which subsequently fuse with the endosomes [214, 215].
During our analyses we showed that the usage of BrefeldinA (BrefA) e ciently inhibited
the recruitment of sec61 to the antigen-containing compartments (Figure 4.15 on page 62).
The inhibitor BrefA blocks the complete vesicular tra cking from the ER towards the golgi
apparatus and the plasma membrane by inducing a retrograde membrane transport to the
ER [167]. This result argues for a transport event actively induced by the antigen uptake
or other stimuli caused by pathogen contact and favors a vesicular transport pathway.
This most likely originates from the ERGIC, which is also destroyed by BrefA. Although
our results of the BrefA inhibition indicate a vesicular recruitment mechanism, it still
has to be clarified by additional analyses, if and how ER fusion events participate in the
cross-presentation machinery.
5.4.3 Importance of TLR signals for the translocation of the
cross-presentation machinery
While still many questions about the exact mechanism of ER-protein transport towards
antigen-containing compartments remain open, additional regulatory aspects make the
analysis of this complex of di erent mechanisms even more di cult. Also in the case of
sec61 translocation it was indicated by the BrefA experiment that the recruitment is not
constitutively active, but an induced and regulated event.
Several previous investigations have already reported that endotoxins are important
to induce the transport of ER-membranes to endosomal compartments. These stim-
ulations came from many di erent sources like protozoa, yeast or simple additions of
LPS [62, 63, 156]. The studies pointed out that the protein transport pathways for cross-
presentation in general are well regulated and not a steady-state system. In our analyses
we showed that e cient sec61 recruitment also needed a stimulus by endotoxins. When
transferrin was fed to the DCs before sec61 recruitment was analyzed by flow cytometry of
endosomes, only a low level of sec61 proteins was visible in transferrin-containing compart-
ments (Figure 4.32 on page 80). Importantly, transferrin is per se endotoxin-free and
100
5 Discussion
is transported into the same compartment as the antigen. Concordant with this, also
endosomal compartments containing endotoxin-free antigen (OVA) did not exhibit a high
level of sec61 protein compared to endosomal compartments originating from cells fed
with endotoxin-containing OVA (Figure 4.32 on page 80).
Closer investigations revealed that a signal mediated via the TRIF pathway induced the
transport of sec61 proteins to endosomal compartments and thereby enabled the e cient
export of the antigen into the cytosol. Therefore, also the cross-presentation e ciency
depended on TRIF signaling and was impaired in TRIF-/- cells (Figure 4.38 on page 86
and Figure 4.36 on page 84). In contrast to this, MyD88 was not required for e cient
antigen translocation into the cytosol, although cross-presentation was a ected in MyD88-/-
DCs (Figure 4.34 on page 82 and Figure 4.33 on page 81). Interestingly, former studies
have shown that the recruitment of other components of the MHC-I loading machinery,
like the TAP transporter [62], needed e cient MyD88 signaling. In addition to this, it
was recently demonstrated that also the MHC-I recruitment is controlled by TLR-MyD88
signaling [67]. This indicates that multiple signaling and protein transport pathways are
needed for the composition of functional endosomal cross-presenting compartments.
How these single pathways are connected with each other is not clarified yet, but a very
interesting aspect arises from the analysis of TLR4 signaling. It has been well described
during the last years that the TLR4 is the only known TLR, which is able to signal
MyD88-dependent as well as TRIF-mediated. The activity is controlled by the localization
of the receptor. While TLR4 on the plasma membrane signals via the MyD88 adaptor
complex, the TRIF-signaling occurs at endosomal compartments [216, 217]. Interestingly,
it has been described that the major source of the TLR4 at endosomal compartments is
the ERC (endosomal recycling compartment), which is the same compartment described
to be the source of MHC-I molecules for cross-presentation. In parallel to the MHC-I
molecules, also the TLR4 supply for this compartment is regulated by the rab11a protein.
When this protein is missing, the amount of both proteins, MHC-I as well as TLR4,
is reduced in the ERC and the recruitment to the antigen-containing compartment is
impaired [67, 102]. Additionally, it has been described that the endocytosed TLR4 receptor,
besides of antigen co-localization, is also partly present in compartments positive for the
transferrin receptor [217], which is a marker of endosomal cross-presenting compartments in
APCs [69]. This may point out a two-step recruitment of the cross-presentation machinery.
First, TLR4 recognizes LPS at the plasma membrane and the antigen is taken up into the
cell. The resulting MyD88 induction leads to the recruitment of components present in the
ERC to the antigen-containing compartments, like MHC-I molecules [67]. Additionally,
some ER components like TAP are recruited, which was described to be translocated in a
MyD88 dependent manner [62]. In parallel to this, TLR4 is recruited from the ERC to
the antigen-containing compartment. Inside of these compartments, a second signaling
via the TLR4-TRIF pathway is activated and subsequently a second recruitment step
from the ER is induced. The missing components like sec61 are thereby translocated, to
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mediate the e cient antigen-processing in the endosomal compartments. Whether the
recruitment really takes place this way and how it is coordinated, will be addressed in
further experiments and will hopefully be clarified during the next years.
In a study of Nair Gupta et al., also first hints were described to understand the mecha-
nistic background of the regulation of protein recruitment during cross-presentation. So it
was shown that the phosphorylation of the SNARE protein SNAP23 in an IKK2 depen-
dent manner, which is controlled on TLR-MyD88 signaling, was needed for the MHC-I
translocation [67]. Considering the fact that many SNARE proteins are controlled by
phosphorylation [218], this might be a good starting point for further analyses of the
regulatory e ects on protein translocation in the context of cross-presentation.
Additionally, it is known from several di erent TLRs (e.g. TLR3, TLR7, TLR9) that
they are mainly localized in the ER and are recruited to endosomal or lysosomal com-
partments as soon as a microbial substance is detected [105, 219, 220]. In combination
with the results that UNC93B, an important regulator for this TLR recruitment, is
involved in cross-presentation e ciency [220], it seems to be possible that parts of the
cross-presentation machinery, like sec61, are transported side by side with TLRs to en-
dosomal compartments. Interestingly, it has been described in human DCs that TLR9
recognizes multimeric CpG in endosomes positive for the transferrin receptor, which is also
present in endosomal cross-presenting compartments [221]. This indicates that the TLR
transport pathway might end up in the same compartments as the MHC-I loading machin-
ery. The fact that many TLRs are only recruited to compartments, which contain their
ligands [222, 223], emphasizes again how strictly the protein transport is regulated in the
context of antigen detection and processing. Whether a side by side pathway of TLR and
cross-presentation components is indeed the case or if these recruitments are independent
from each other, remains to be clarified by further analyses.
In contrast to the reports of TLR-dependent protein acquisition, it was also described
by Nair Gupta et. al. [67] that the sec22b pathway, which has already been mentioned
above, is TLR-independent. This contradicts with other observations, like for example the
TAP recruitment to antigen-containing compartments. This is described to be sec22b-
mediated [64], but in contrary was also shown to depend on a MyD88 stimulus [62].
In the case that some ER proteins, which are involved in cross-presentation, are really
translocated in a TLR independent manner, the question arises, what functions they
have in a resting DC, missing other molecules, which are important for cross-presentation
and recruited in a TLR-dependent manner, like the MHC-I complex at the endosomal
compartments [67]. Interestingly, also we observed in our analysis of the antigen-containing
endosomes by endosomal flow cytometry a low level of sec61 proteins in absence of endotox-
ins (Figure 4.32 on page 80). Additionally, we detected some sec61 positive early endosomal
compartments in resting DCs missing antigen-load, indicating that a low level of sec61
molecules might be translocated independent of antigen presence or other activating stimuli.
This low recruitment might also take place for other components of the cross-presentation
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machinery and is, because of its low amount, hard to detect inside of a cell. The use of
the endosomal flow cytometry might bring some light into these steady state recruitment
mechanisms. Altogether, these aspects of regulating events during cross-presentation need
to be addressed more thoroughly in further experiments.
Interestingly, our results show that MHC-II presentation was impaired only by the knock
out of the adaptor molecule MyD88, but not by the absence of the TRIF signaling. In
agreement to this, TLR-MyD88 signaling was reported to play an important role in
phagosome vesicle fusion events and thereby in maturation towards late phagosomes
and lysosomes. This is important for MHC-II peptide loading [224], but avoided during
cross-presentation. Therefore, next to the regulatory mechanism of cross-presentation,
it also needs to be clarified, how the control of MHC-I cross-presentation and MHC-II
presentation by TLR signaling interacts with each other and how it is synchronized under
di erent conditions and in various cells. This is another big question, which has to be
analyzed in the next years.
5.4.4 Cross-presentation during immunogenic- and non-immunogenic
situations
Progressing from the cellular level of cross-presentation to the influence on the organism
in the context of health or infection is still very di cult. This is mainly the case, because
the importance of cross-presentation in in-vivo systems is hard to determine. Especially to
distinguish the role of endogenous MHC-I presentation and presentation of extracellular
antigens on MHC-I molecules is challenging, since a direct infection and thereby classical
presentation on MHC-I molecules can hardly be completely excluded in the analyses
of cross-presentation. Additionally, the contributions of both pathways to the immune
response largely depend on the type of antigen available for presentation. Nonetheless,
more and more evidences are collected, proving a crucial role of cross-presentation for the
immune response against various pathogens. Thus, it has been shown for Toxoplasma
gondii infections that CD8+ T-cell activation is mainly mediated by cross-presentation
of antigens, which were captured by DCs from infected cells in their surrounding [225].
Similar results about the involvement of cross-presentation have been shown in candida
albicans as well as HSV-1 infections [226, 227]. For HSV-1 it was additionally reported
that most likely lymphoid resident DCs play a major role in cross-presentation. These
receive the antigen from non-infected migratory DCs originating from the skin. Infected
migratory DCs thereby stayed in the peripheral tissue [228]. Interestingly, the peripheral
migratory DCs play an important role in cross-presentation during secondary HSV-1 skin
infections [226], reflecting the complexity of the antigen presentation system.
Additional to the antigen presentation during infections, also cross-presentation in non-
immunogenic situations has been described, often referred to as cross-tolerance. For
the central tolerance, the elimination of self recognizing CD8+ T-cells is described to be
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done by medullary thymic epithelial cells, which express a broad range of tissue specific
antigens [229, 230]. However, they are very poor APCs regarding their expression of
MHC-molecules on their surface. Instead of direct self-antigen presentation by these
epithelial cells, it has been supposed by several research groups that DCs take over the
job of presentation and induction of cross-tolerance [229, 231]. The elucidation of cross-
presentation and cross-tolerance mechanisms thereby play also an important role for the
understanding of central tolerance.
Also in the peripheral tissue cross-tolerance was indicated in several studies [232, 233, 234].
Considering the results concerning TLR-dependence of the recruitment of at least parts
of the cross-presentation machinery, like studies of several research groups (including
ourself) have shown [62, 63, 67], raises up the question, how the molecular mechanisms
of cross-presentation works and which proteins are involved, when no TLR stimulus is
available. As already mentioned above, we were able to show by endosomal flow cytometry
a low level of sec61 at endosomal compartments in resting DCs (Figure 4.32 on page 80),
indicating that sec61 might also take part during cross-presentation in non-immunogenic
situations. Whether sec61 really is important for tolerogenic cross-presentation and which
other proteins are involved this mechanism needs to be addressed in further studies.
How important the understanding of the molecular procedure of cross-presentation is,
became more and more clear during the last years. A first clinical tool, which already
profits of this knowledge, is the cross-presentation-based vaccination. One system of this
vaccination method uses the slow maturation of endosomal structures, which contain the
antigen. This stability of the antigen-containing compartment is important to ensure a
constant supply of antigens for the presentation on MHC-I molecules. During vaccination
the inhibited endosomal maturation can be supported by chloroquine, which blocks the
acidification of endosomal or phagosomal compartments [235, 236, 237]. This protects
the vaccine from degradation, directs it towards MHC-I cross-presentation and thereby
potentiates it e ciency.
A second model system for the induction of cross-presentation by vaccination is the
targeting of a vaccine to specific receptors on the DC surface, which are known to mediate
cross-presentation. For this, mostly receptors which belong to the C-type lectin receptor
family like DEC205 [238] or CLEC9A [239], were used as targets. The advantage of
this second vaccination strategy is that the induction of both, cross-presentation against
infection as well as cross-tolerance to prevent autoimmunity, is possible. Which of these
e ects is achieved depends on many di erent factors, but can be influenced for example
by the used adjuvants and the formulation of the used vaccine [240, 241] as well as by the
binding region of the vector on the targeted receptor [242].
The experimental results of this PhD thesis have clearly demonstrated the involvement
of sec61 in antigen export into the cytosol, which might also be a target for further
investigation towards therapies. On the one hand, the improvement of cross-presentation
dependent vaccinations might be possible by enhancing the recruitment and function of
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the antigen export machinery. With the help of special adjuvants this could be done by
activating the TLR-TRIF signaling pathway, which is here proven to be important for the
e cient sec61 recruitment towards antigen-containing compartments (Figure 4.32 on page
80 and Figure 4.36 on page 84). Additionally, it might also be plausible that pathogens can
misuse or circumvent sec61 and other components of the antigen translocation machinery
to avoid their degradation and presentation. It is well known for several examples that
the ERAD system itself can be manipulated by pathogens, like the herpesviruses, which
exploit the ERAD machinery by inducing the degradation of newly synthesized MHC-I
molecules and thereby block their presentation [243]. Also Sec61 can be misused, for
example by the retrograde transport of the cholera toxin [191]. It remains to decipher
possible influences of pathogens on the antigen translocation during cross-presentation.
The aim to find possible starting points for clinical interventions as well as to identify
the missing links and the regulatory control mechanisms between antigen uptake, antigen
export and antigen degradation is the challenge for the next years.
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Cross-presentation enables the DCs to load peptides with extracellular origin on MHC-I
molecules. One of the major pathways for cross-presentation thereby is the “endosome to
cytosol” pathway. For this, the antigen needs to be taken up by the DC and transported
to specialized endosomal compartments. Afterwards, the antigen is translocated into the
cytosol, processed by proteasomes and in the end loaded on MHC-I molecules either in
the same endosomal compartment or in the ER. While many parts of this mechanism
have been clarified during the last years, it is still poorly described, how the antigen
can pass the membrane barrier of the endosomal compartment to reach the cytosol for
proteasomal degradation, which is required for the generation of presentable peptides.
Although sec61 has been proposed to mediate this antigen export, its role remained elusive
and was discussed controversially.
Here we were able to demonstrate that sec61 is indeed essential for antigen translocation
into the cytosol and hence essential for cross-presentation. Additionally, we proved for the
first time that the recruitment of sec61 to the side of the antigen, which is localized in
endosomal compartments, is required for an e cient antigen translocation into the cytosol
and is well regulated by TLR-signaling.
To encounter this, we showed that the presence of a functional ERAD complex is needed
for e cient antigen export into the cytosol. Additionally, antigen translocation and cross-
presentation were blocked, when sec61 was specifically knocked-down by siRNA, while
endogenous MHC-I as well as MHC-II presentation remained una ected. Importantly, a
short incubation time after knock-down and fixation of the cells after antigen uptake were
required to avoid unspecific e ects due to the down-regulation of sec61.
In addition to this, we were able to prove that sec61 has to be recruited to the side of
antigen processing, the endosomal compartments. To verify this and to investigate the
recruitment of sec61 more closely we generated a sec61-specific intracellularly expressed
antibody (intrabody) to keep sec61 trapped in the ER and to impair its transport to-
wards endosomal compartments. The lack of sec61 in endosomes resulted in a reduced
cross-presentation ability of DCs. The impairment of the presentation of extracellu-
lar antigens on MHC-I molecules was thereby due to a hindered antigen export into
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the cytosol, which was shown by three independent detection assays for di erent
antigens (OVA, cytochrome c and —-lactamase). Decisive for this analysis was the intact
function of sec61 in the presence of sec61–-binding intrabodies in the ER.
Finally, we demonstrated that the presence of sec61 in endosomal compartments is not
a permanent condition, but the e cient recruitment of sec61 and hence the antigen
translocation into the cytosol is a well regulated process and depends on TLR signaling,
namely the signaling via the adaptor protein TRIF.
Taken together, we unambiguously proved that the antigen export into the cytosol is
mediated by the specific recruitment of sec61 to antigen-containing endosomes and is well
controlled by inflammatory signals.
107
Bibliography
[1] Murphy. Janeway’s Immunobiology by Murphy,Kenneth. [2011,8th Edition.] Paperback
(GarIand, 2011).
[2] Blasius, A. L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305–315 (2010).
[3] Medzhitov, R. & Janeway, C. Innate immunity. The New England journal of medicine
343, 338–344 (2000).
[4] Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune
system. Science (New York, NY) 327, 291–295 (2010).
[5] Pepper, M. & Jenkins, M. K. Origins of CD4(+) e ector and central memory T cells.
Nature immunology 12, 467–471 (2011).
[6] Pancer, Z. & Cooper, M. D. The evolution of adaptive immunity. Annual review of
immunology 24, 497–518 (2006).
[7] Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751–758
(1996).
[8] Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C. & Amigorena, S. Antigen presenta-
tion and T cell stimulation by dendritic cells. Annual review of immunology 20, 621–667
(2002).
[9] Squier, M. K. & Cohen, J. J. Cell-mediated cytotoxic mechanisms. Current opinion in
immunology 6, 447–452 (1994).
[10] Aerts, J. G. & Hegmans, J. P. Tumor-specific cytotoxic T cells are crucial for e cacy of
immunomodulatory antibodies in patients with lung cancer. Cancer research 73, 2381–2388
(2013).
[11] Forquet, F. et al. Presentation of antigens internalized through the B cell receptor requires
newly synthesized MHC class II molecules. Journal of immunology (Baltimore, Md : 1950)
162, 3408–3416 (1999).
[12] Lanzavecchia, A. Mechanisms of antigen uptake for presentation. Current opinion in
immunology 8, 348–354 (1996).
[13] Kamphorst, A. O., Guermonprez, P., Dudziak, D. & Nussenzweig, M. C. Route of antigen
uptake di erentially impacts presentation by dendritic cells and activated monocytes.
Journal of immunology (Baltimore, Md : 1950) 185, 3426–3435 (2010).
[14] Taylor, P. R. et al. MACROPHAGE RECEPTORS AND IMMUNE
3&$0(/*5*0/IUUQEYEPJPSHBOOVSFWJNNVOPM
	
.
109
Bibliography
[15] León, B. & Ardavín, C. Monocyte-derived dendritic cells in innate and adaptive immunity.
Immunology and cell biology 86, 320–324 (2008).
[16] Hemmi, H. & Akira, S. TLR signalling and the function of dendritic cells. Chemical
immunology and allergy 86, 120–135 (2005).
[17] Gordon, S. The macrophage: past, present and future. European Journal of Immunology
37,S9–17(2007).
[18] Coquerelle, C. & Moser, M. DC subsets in positive and negative regulation of immunity.
Immunological reviews 234, 317–334 (2010).
[19] Wu, L. & Liu, Y.-J. Development of dendritic-cell lineages. Immunity 26, 741–750 (2007).
[20] Villadangos, J. A. & Heath, W. R. Life cycle, migration and antigen presenting functions
of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm.
Seminars in immunology 17, 262–272 (2005).
[21] Wilson, N. S. et al. Most lymphoid organ dendritic cell types are phenotypically and
functionally immature. Blood 102, 2187–2194 (2003).
[22] Turley, S. J., Fletcher, A. L. & Elpek, K. G. The stromal and haematopoietic antigen-
presenting cells that reside in secondary lymphoid organs. Nature Reviews Immunology 10,
813–825 (2010).
[23] León, B., López-Bravo, M. & Ardavín, C. Monocyte-derived dendritic cells formed at the
infection site control the induction of protective T helper 1 responses against Leishmania.
Immunity 26, 519–531 (2007).
[24] Shortman, K. & Naik, S. H. Steady-state and inflammatory dendritic-cell development.
Nature Reviews Immunology 7, 19–30 (2007).
[25] Van, V. Q. et al. Expression of the self-marker CD47 on dendritic cells governs their
tra cking to secondary lymphoid organs. The EMBO journal 25, 5560–5568 (2006).
[26] Allan, R. S. et al. Migratory dendritic cells transfer antigen to a lymph node-resident
dendritic cell population for e cient CTL priming. Immunity 25, 153–162 (2006).
[27] del Rio, M.-L., Rodriguez-Barbosa, J.-I., Kremmer, E. & Förster, R. CD103- and CD103+
bronchial lymph node dendritic cells are specialized in presenting and cross-presenting
innocuous antigen to CD4+ and CD8+ T cells. Journal of immunology (Baltimore, Md :
1950) 178, 6861–6866 (2007).
[28] Henri, S. et al. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived
antigens irrespective of the presence of Langerhans cells. The Journal of experimental
medicine 207, 189–206 (2010).
[29] Dorner, B. G. et al. Selective expression of the chemokine receptor XCR1 on cross-presenting
dendritic cells determines cooperation with CD8+ T cells. Immunity 31, 823–833 (2009).
110
Bibliography
[30] Kroczek, R. A. & Henn, V. The Role of XCR1 and its Ligand XCL1 in Antigen Cross-
Presentation by Murine and Human Dendritic Cells. Frontiers in immunology 3, 14
(2012).
[31] Cravens, P. D. & Lipsky, P. E. Dendritic cells, chemokine receptors and autoimmune
inflammatory diseases. Immunology and cell biology 80, 497–505 (2002).
[32] Sallusto, F. et al. Rapid and coordinated switch in chemokine receptor expression during
dendritic cell maturation. European Journal of Immunology 28, 2760–2769 (1998).
[33] Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Na-
ture392,245–252(1998).
[34] Goldberg, A. L., Cascio, P., Saric, T. & Rock, K. L. The importance of the proteasome and
subsequent proteolytic steps in the generation of antigenic peptides. Molecular immunology
39, 147–164 (2002).
[35] Rock, K. L., York, I. A., Saric, T. & Goldberg, A. L. Protein degradation and the generation
of MHC class I-presented peptides. Advances in immunology 80, 1–70 (2002).
[36] Rock, K. L. & Goldberg, A. L. Degradation of cell proteins and the generation of MHC
class I-presented peptides. Annual review of immunology 17, 739–779 (1999).
[37] Driscoll, J., Frydman, J. & Goldberg, A. L. An ATP-stabilized inhibitor of the proteasome
is a component of the 1500-kDa ubiquitin conjugate-degrading complex. Proceedings of the
National Academy of Sciences of the United States of America 89, 4986–4990 (1992).
[38] Orlowski, M. & Wilk, S. Catalytic activities of the 20 S proteasome, a multicatalytic
proteinase complex. Archives of biochemistry and biophysics 383, 1–16 (2000).
[39] Salzmann, U. et al. Mutational analysis of subunit i beta2 (MECL-1) demonstrates
conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS
letters 454, 11–15 (1999).
[40] Macagno, A. et al. Dendritic cells up-regulate immunoproteasomes and the proteasome
regulator PA28 during maturation. European Journal of Immunology 29, 4037–4042 (1999).
[41] Tanaka, K. Role of proteasomes modified by interferon-gamma in antigen processing.
Journal of leukocyte biology 56, 571–575 (1994).
[42] Kuckelkorn, U. et al. Incorporation of major histocompatibility complex–encoded subunits
LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products
independent of interferon-gamma. European Journal of Immunology 25, 2605–2611 (1995).
[43] Boes, B. et al. Interferon gamma stimulation modulates the proteolytic activity and
cleavage site preference of 20S mouse proteasomes. The Journal of experimental medicine
179, 901–909 (1994).
[44] Kincaid, E. Z. et al. Mice completely lacking immunoproteasomes show major changes in
antigen presentation. Nature immunology 13, 129–135 (2012).
[45] Neefjes, J. J., Momburg, F. & Hämmerling, G. J. Selective and ATP-dependent transloca-
tion of peptides by the MHC-encoded transporter. Science (New York, NY) 261, 769–771
(1993).
111
Bibliography
[46] Abele, R. & Tampé, R. The ABCs of immunology: structure and function of TAP, the
transporter associated with antigen processing. Physiology (Bethesda, Md) 19, 216–224
(2004).
[47] Sadasivan, B., Lehner, P. J., Ortmann, B., Spies, T. & Cresswell, P. Roles for calreticulin
and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP.
Immunity 5, 103–114 (1996).
[48] Cresswell, P., Bangia, N., Dick, T. & Diedrich, G. The nature of the MHC class I peptide
loading complex. Immunological reviews 172, 21–28 (1999).
[49] Saric, T. et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors
to MHC class I-presented peptides. Nature immunology 3, 1169–1176 (2002).
[50] Levine, B. & Deretic, V. Unveiling the roles of autophagy in innate and adaptive immunity.
Nature Reviews Immunology 7, 767–777 (2007).
[51] Honey, K. & Rudensky, A. Y. Lysosomal cysteine proteases regulate antigen presentation.
Nature Reviews Immunology 3, 472–482 (2003).
[52] Villadangos, J. A. & Ploegh, H. L. Proteolysis in MHC class II antigen presentation: who’s
in charge? Immunity 12, 233–239 (2000).
[53] Biko , E. K. et al. Defective major histocompatibility complex class II assembly, transport,
peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression.
The Journal of experimental medicine 177, 1699–1712 (1993).
[54] Amigorena, S. et al. Invariant chain cleavage and peptide loading in major histocompatibility
complex class II vesicles. The Journal of experimental medicine 181, 1729–1741 (1995).
[55] Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2
congenic cells which do not cross-react in the cytotoxic assay. The Journal of experimental
medicine 143, 1283–1288 (1976).
[56] Rock, K. L., Gamble, S. & Rothstein, L. Presentation of exogenous antigen with class
I major histocompatibility complex molecules. Science (New York, NY) 249, 918–921
(1990).
[57] Heath, W. R. & Carbone, F. R. Cross-presentation in viral immunity and self-tolerance.
Nature Reviews Immunology 1, 126–134 (2001).
[58] den Haan, J. M. & Bevan, M. J. Antigen presentation to CD8+ T cells: cross-priming in
infectious diseases. Current opinion in immunology 13, 437–441 (2001).
[59] Tindle, R. W. & Frazer, I. H. Immune response to human papillomaviruses and the
prospects for human papillomavirus-specific immunisation. Current topics in microbiology
and immunology 186, 217–253 (1994).
[60] Huang, A. Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted
tumor antigens. Science (New York, NY) 264, 961–965 (1994).
[61] Boonman, Z. F. H. M. et al. Intraocular tumor antigen drains specifically to submandibular
lymph nodes, resulting in an abortive cytotoxic T cell reaction. Journal of immunology
(Baltimore, Md : 1950) 172, 1567–1574 (2004).
112
Bibliography
[62] Burgdorf, S., Schölz, C., Kautz, A., Tampé, R. & Kurts, C. Spatial and mechanistic
separation of cross-presentation and endogenous antigen presentation. Nature immunology
9, 558–566 (2008).
[63] Saveanu, L. et al. IRAP identifies an endosomal compartment required for MHC class I
cross-presentation. Science (New York, NY) 325, 213–217 (2009).
[64] Cebrian, I. et al. Sec22b regulates phagosomal maturation and antigen crosspresentation
by dendritic cells. Cell 147, 1355–1368 (2011).
[65] Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous
antigens presented on MHC class I molecules. Science (New York, NY) 267, 243–246
(1995).
[66] Zehner, M. et al. Mannose receptor polyubiquitination regulates endosomal recruitment of
p97 and cytosolic antigen translocation for cross-presentation. Proceedings of the National
Academy of Sciences of the United States of America 108, 9933–9938 (2011).
[67] Nair-Gupta, P. et al. TLR Signals Induce Phagosomal MHC-I Delivery from the Endosomal
Recycling Compartment to Allow Cross-Presentation. Cell 158, 506–521 (2014).
[68] Guermonprez, P. et al. ER-phagosome fusion defines an MHC class I cross-presentation
compartment in dendritic cells. Nature 425, 397–402 (2003).
[69] Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Distinct pathways of
antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (New
York, NY) 316, 612–616 (2007).
[70] Cohn, L. et al. Antigen delivery to early endosomes eliminates the superiority of human
blood BDCA3+ dendritic cells at cross presentation. The Journal of experimental medicine
210, 1049–1063 (2013).
[71] Hotta, C., Fujimaki, H., Yoshinari, M., Nakazawa, M. & Minami, M. The delivery of an
antigen from the endocytic compartment into the cytosol for cross-presentation is restricted
to early immature dendritic cells. Immunology 117, 97–107 (2006).
[72] Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Di erential lysosomal
proteolysis in antigen-presenting cells determines antigen fate. Science (New York, NY)
307, 1630–1634 (2005).
[73] Savina, A. et al. NOX2 controls phagosomal pH to regulate antigen processing during
crosspresentation by dendritic cells. Cell 126, 205–218 (2006).
[74] Mantegazza, A. R. et al. NADPH oxidase controls phagosomal pH and antigen cross-
presentation in human dendritic cells. Blood 112, 4712–4722 (2008).
[75] Bougnères, L. et al. A role for lipid bodies in the cross-presentation of phagocytosed
antigens by MHC class I in dendritic cells. Immunity 31, 232–244 (2009).
[76] Weck, M. M. et al. hDectin-1 is involved in uptake and cross-presentation of cellular
antigens. Blood 111, 4264–4272 (2008).
[77] Herre, J. et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages.
Blood 104, 4038–4045 (2004).
113
Bibliography
[78] Ackerman, A. L., Giodini, A. & Cresswell, P. A role for the endoplasmic reticulum protein
retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25,
607–617 (2006).
[79] Singh, R. & Cresswell, P. Defective cross-presentation of viral antigens in GILT-free mice.
Science (New York, NY) 328, 1394–1398 (2010).
[80] Ackerman, A. L. Early phagosomes in dendritic cells form a cellular compartment su cient
for cross presentation of exogenous antigens. Proceedings of theNationalAcademy of
Sciences of theUnited States ofAmerica 100, 12889–12894 (2003).
[81] Georgiadou, D. et al. Placental leucine aminopeptidase e ciently generates mature antigenic
peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1.
Journal of immunology (Baltimore, Md : 1950) 185, 1584–1592 (2010).
[82] Desjardins, M. ER-mediated phagocytosis: a new membrane for new functions. Nature
Reviews Immunology 3, 280–291 (2003).
[83] Kümmel, D. & Ungermann, C. Principles of membrane tethering and fusion in endosome
and lysosome biogenesis. Current opinion in cell biology 29C, 61–66 (2014).
[84] Jancic, C. et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment
todendriticcellphagosomes. Nature cell biology 9,367–378 (2007).
[85] Matheoud, D. et al. Leishmania evades host immunity by inhibiting antigen cross-
presentation through direct cleavage of the SNARE VAMP8. Cell host & microbe 14,
15–25 (2013).
[86] Weimershaus, M. et al. Conventional dendritic cells require IRAP-Rab14 endosomes for
e cient cross-presentation. Journal of immunology (Baltimore, Md : 1950) 188, 1840–1846
(2012).
[87] Shen, L., Sigal, L. J., Boes, M. & Rock, K. L. Important role of cathepsin S in generating
peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21,
155–165 (2004).
[88] Liu, T. et al. TAP peptide transporter-independent presentation of heat-killed Sendai
virus antigen on MHC class I molecules by splenic antigen-presenting cells. Journal of
immunology (Baltimore, Md : 1950) 159, 5364–5371 (1997).
[89] Pfeifer, J. D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation
to T cells. Nature 361, 359–362 (1993).
[90] Yewdell, J. W., Norbury, C. C. & Bennink, J. R. Mechanisms of exogenous antigen
presentation by MHC class I molecules in vitro and in vivo: implications for generating
CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Advances
in immunology 73, 1–77 (1999).
[91] Lizée, G. et al. Control of dendritic cell cross-presentation by the major histocompatibility
complex class I cytoplasmic domain. Nature immunology 4, 1065–1073 (2003).
114
Bibliography
[92] Pierre, P. Dendritic cells, DRiPs, and DALIS in the control of antigen processing. Im-
munological reviews 207, 184–190 (2005).
[93] Neijssen, J. et al. Cross-presentation by intercellular peptide transfer through gap junctions.
Nature 434, 83–88 (2005).
[94] Saccheri, F. et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation
and antitumor immunity. Science translational medicine 2, 44ra57 (2010).
[95] Mendoza-Naranjo, A. et al. Functional gap junctions facilitate melanoma antigen transfer
and cross-presentation between human dendritic cells. Journal of immunology (Baltimore,
Md : 1950) 178, 6949–6957 (2007).
[96] Dolan, B. P., Gibbs, K. D. & Ostrand-Rosenberg, S. Dendritic cells cross-dressed with
peptide MHC class I complexes prime CD8+ T cells. Journal of immunology (Baltimore,
Md : 1950) 177, 6018–6024 (2006).
[97] Smyth, L. A. et al. The relative e ciency of acquisition of MHC:peptide complexes and
cross-presentation depends on dendritic cell type. Journal of immunology (Baltimore, Md :
1950) 181, 3212–3220 (2008).
[98] Kreer, C., Rauen, J., Zehner, M. & Burgdorf, S. Cross-Presentation: How to Get there -
or How to Get the ER. Frontiers in immunology 2, 1–10 (2011).
[99] Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140,
805–820 (2010).
[100] Hemmi, H. & Akira, S. TLR signalling and the function of dendritic cells. Chemical
immunology and allergy 86, 120–135 (2005).
[101] Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of
interferon-beta. Nature immunology 9, 361–368 (2008).
[102] Husebye, H. et al. The Rab11a GTPase controls Toll-like receptor 4-induced activation of
interferon regulatory factor-3 on phagosomes. Immunity 33, 583–596 (2010).
[103] Mantegazza, A. R. et al. Adaptor protein-3 in dendritic cells facilitates phagosomal toll-like
receptor signaling and antigen presentation to CD4(+) T cells. Immunity 36, 782–794
(2012).
[104] Henault, J. et al. Noncanonical autophagy is required for type I interferon secretion in
response to DNA-immune complexes. Immunity 37, 986–997 (2012).
[105] Kim, Y.-M., Brinkmann, M. M., Paquet, M.-E. & Ploegh, H. L. UNC93B1 delivers
nucleotide-sensing toll-like receptors to endolysosomes. Nature 452, 234–238 (2008).
[106] Goldszmid, R. S. et al. Host ER-parasitophorous vacuole interaction provides a route of
entry for antigen cross-presentation in Toxoplasma gondii-infected dendritic cells. The
Journal of experimental medicine 206, 399–410 (2009).
[107] Ramos, C. Molecular chaperones and protein quality control. Protein and peptide letters
18, 100 (2011).
[108] Jahn, T. R. & Radford, S. E. The Yin and Yang of protein folding. The FEBS journal
272, 5962–5970 (2005).
115
Bibliography
[109] Ellgaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. Nature reviews
Molecular cell biology 4, 181–191 (2003).
[110] Okuda-Shimizu, Y. & Hendershot, L. M. Characterization of an ERAD pathway for
nonglycosylated BiP substrates, which require Herp. Molecular cell 28, 544–554 (2007).
[111] Nishikawa, S. I., Fewell, S. W., Kato, Y., Brodsky, J. L. & Endo, T. Molecular chaperones
in the yeast endoplasmic reticulum maintain the solubility of proteins for retrotranslocation
and degradation. The Journal of cell biology 153, 1061–1070 (2001).
[112] Schmitz, A., Maintz, M., Kehle, T. & Herzog, V. In vivo iodination of a misfolded proinsulin
reveals co-localized signals for Bip binding and for degradation in the ER. The EMBO
journal 14, 1091–1098 (1995).
[113] Plemper, R. K., Böhmler, S., Bordallo, J., Sommer, T. & Wolf, D. H. Mutant analysis
links the translocon and BiP to retrograde protein transport for ER degradation. Nature
388, 891–895 (1997).
[114] Fagioli, C. & Sitia, R. Glycoprotein quality control in the endoplasmic reticulum. Mannose
trimming by endoplasmic reticulum mannosidase I times the proteasomal degradation of
unassembled immunoglobulin subunits. The Journal of biological chemistry 276, 12885–
12892 (2001).
[115] Oda, Y., Hosokawa, N., Wada, I. & Nagata, K. EDEM as an acceptor of terminally
misfolded glycoproteins released from calnexin. Science (New York, NY) 299, 1394–1397
(2003).
[116] Christianson, J. C., Shaler, T. A., Tyler, R. E. & Kopito, R. R. OS-9 and GRP94 deliver
mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nature
cell biology 10, 272–282 (2008).
[117] Cormier, J. H., Tamura, T., Sunryd, J. C. & Hebert, D. N. EDEM1 recognition and
delivery of misfolded proteins to the SEL1L-containing ERAD complex. Molecular cell 34,
627–633 (2009).
[118] Gillece, P., Luz, J. M., Lennarz, W. J., de La Cruz, F. J. & Römisch, K. Export of a
cysteine-free misfolded secretory protein from the endoplasmic reticulum for degradation
requires interaction with protein disulfide isomerase. The Journal of cell biology 147,
1443–1456 (1999).
[119] Molinari, M., Galli, C., Piccaluga, V., Pieren, M. & Paganetti, P. Sequential assistance
of molecular chaperones and transient formation of covalent complexes during protein
degradation from the ER. The Journal of cell biology 158, 247–257 (2002).
[120] Vashist, S. & Ng, D. T. W. Misfolded proteins are sorted by a sequential checkpoint
mechanism of ER quality control. The Journal of cell biology 165, 41–52 (2004).
[121] Carvalho, P., Goder, V. & Rapoport, T. A. Distinct ubiquitin-ligase complexes define
convergent pathways for the degradation of ER proteins. Cell 126, 361–373 (2006).
[122] Huyer, G. et al. Distinct machinery is required in Saccharomyces cerevisiae for the
endoplasmic reticulum-associated degradation of a multispanning membrane protein and a
soluble luminal protein. The Journal of biological chemistry 279, 38369–38378 (2004).
116
Bibliography
[123] Sato, B. K., Schulz, D., Do, P. H. & Hampton, R. Y. Misfolded membrane proteins
are specifically recognized by the transmembrane domain of the Hrd1p ubiquitin ligase.
Molecular cell 34, 212–222 (2009).
[124] Claessen, J. H. L., Kundrat, L. & Ploegh, H. L. Protein quality control in the ER: balancing
the ubiquitin checkbook. Trends in cell biology 22, 22–32 (2012).
[125] Bays, N. W., Gardner, R. G., Seelig, L. P., Joazeiro, C. A. & Hampton, R. Y. Hrd1p/Der3p
is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nature
cell biology 3, 24–29 (2001).
[126] Bordallo, J., Plemper, R. K., Finger, A. & Wolf, D. H. Der3p/Hrd1p is required for
endoplasmic reticulum-associated degradation of misfolded lumenal and integral membrane
proteins. Molecular biology of the cell 9, 209–222 (1998).
[127] Ye, Y., Meyer, H. H. & Rapoport, T. A. Function of the p97-Ufd1-Npl4 complex in
retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated
polypeptide segments and polyubiquitin chains. The Journal of cell biology 162, 71–84
(2003).
[128] Jentsch, S. & Rumpf, S. Cdc48 (p97): a "molecular gearbox" in the ubiquitin pathway?
Trends in biochemical sciences 32, 6–11 (2007).
[129] Rouiller, I., Butel, V. M., Latterich, M., Milligan, R. A. & Wilson-Kubalek, E. M. A
major conformational change in p97 AAA ATPase upon ATP binding. Molecular cell 6,
1485–1490 (2000).
[130] Ye, Y., Meyer, H. H. & Rapoport, T. A. The AAA ATPase Cdc48/p97 and its partners
transport proteins from the ER into the cytosol. Nature 414, 652–656 (2001).
[131] Jarosch, E. et al. Protein dislocation from the ER requires polyubiquitination and the
AAA-ATPase Cdc48. Nature cell biology 4, 134–139 (2002).
[132] Thoms, S. Cdc48 can distinguish between native and non-native proteins in the absence of
cofactors. FEBS letters 520, 107–110 (2002).
[133] Richly, H. et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate
multiubiquitylation and proteasomal targeting. Cell 120, 73–84 (2005).
[134] Carvalho, P., Stanley, A. M. & Rapoport, T. A. Retrotranslocation of a misfolded luminal
ER protein by the ubiquitin-ligase Hrd1p. Cell 143, 579–591 (2010).
[135] Stein, A., Ruggiano, A., Carvalho, P. & Rapoport, T. A. Key steps in ERAD of luminal
ER proteins reconstituted with purified components. Cell 158, 1375–1388 (2014).
[136] Burr, M. L. et al. HRD1 and UBE2J1 target misfolded MHC class I heavy chains for
endoplasmic reticulum-associated degradation. Proceedings of the National Academy of
Sciences of the United States of America 108, 2034–2039 (2011).
[137] Ye, Y., Shibata, Y., Yun, C., Ron, D. & Rapoport, T. A. A membrane protein complex
mediates retro-translocation from the ER lumen into the cytosol. Nature 429, 841–847
(2004).
117
Bibliography
[138] Lilley, B. N. & Ploegh, H. L. A membrane protein required for dislocation of misfolded
proteins from the ER. Nature 429, 834–840 (2004).
[139] Hitt, R. & Wolf, D. H. Der1p, a protein required for degradation of malfolded soluble
proteins of the endoplasmic reticulum: topology and Der1-like proteins. FEMS yeast
research 4, 721–729 (2004).
[140] Sun, F. et al. Derlin-1 promotes the e cient degradation of the cystic fibrosis transmembrane
conductance regulator (CFTR) and CFTR folding mutants. The Journal of biological
chemistry 281, 36856–36863 (2006).
[141] Taxis, C. et al. Use of modular substrates demonstrates mechanistic diversity and reveals
di erences in chaperone requirement of ERAD. The Journal of biological chemistry 278,
35903–35913 (2003).
[142] Wahlman, J. et al. Real-time fluorescence detection of ERAD substrate retrotranslocation
in a mammalian in vitro system. Cell 129, 943–955 (2007).
[143] Oda, Y. et al. Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein
response and are required for ER-associated degradation. The Journal of cell biology 172,
383–393 (2006).
[144] Römisch, K. Surfing the Sec61 channel: bidirectional protein translocation across the ER
membrane. Journal of cell science 112 ( Pt 23), 4185–4191 (1999).
[145] Römisch, K. Endoplasmic reticulum-associated degradation. Annual review of cell and
developmental biology 21, 435–456 (2005).
[146] Görlich, D., Prehn, S., Hartmann, E., Kalies, K. U. & Rapoport, T. A. A mammalian
homolog of SEC61p and SECYp is associated with ribosomes and nascent polypeptides
during translocation. Cell 71, 489–503 (1992).
[147] Görlich, D. & Rapoport, T. A. Protein translocation into proteoliposomes reconstituted
from purified components of the endoplasmic reticulum membrane. Cell 75, 615–630
(1993).
[148] Rapoport, T. A. Protein translocation across the eukaryotic endoplasmic reticulum and
bacterial plasma membranes. Nature 450, 663–669 (2007).
[149] Hartmann, E. et al. Evolutionary conservation of components of the protein translocation
complex. Nature 367, 654–657 (1994).
[150] Pilon, M., Schekman, R. & Römisch, K. Sec61p mediates export of a misfolded secretory
protein from the endoplasmic reticulum to the cytosol for degradation. The EMBO journal
16, 4540–4548 (1997).
[151] Zhou, M. & Schekman, R. The engagement of Sec61p in the ER dislocation process.
Molecular cell 4, 925–934 (1999).
[152] Wiertz, E. J. et al. Sec61-mediated transfer of a membrane protein from the endoplasmic
reticulum to the proteasome for destruction. Nature 384, 432–438 (1996).
[153] Schäfer, A. & Wolf, D. H. Sec61p is part of the endoplasmic reticulum-associated degrada-
tion machinery. The EMBO journal 28, 2874–2884 (2009).
118
Bibliography
[154] Kalies, K.-U., Allan, S., Sergeyenko, T., Kröger, H. & Römisch, K. The protein translocation
channel binds proteasomes to the endoplasmic reticulum membrane. The EMBO journal
24, 2284–2293 (2005).
[155] Willer, M., Forte, G. M. A. & Stirling, C. J. Sec61p is required for ERAD-L: genetic
dissection of the translocation and ERAD-L functions of Sec61P using novel derivatives of
CPY. The Journal of biological chemistry 283, 33883–33888 (2008).
[156] Koopmann, J. O. et al. Export of antigenic peptides from the endoplasmic reticulum
intersects with retrograde protein translocation through the Sec61p channel. Immunity 13,
117–127 (2000).
[157] Zehner, M. et al. Intraendosomal flow cytometry: A novel approach to analyze the protein
composition of antigen-loaded endosomes. European Journal of Immunology (2012).
[158] Burgdorf, S. & Kurts, C. Endocytosis mechanisms and the cell biology of antigen presenta-
tion. Current opinion in immunology 20, 89–95 (2008).
[159] Shen, Z., Rezniko , G., Drano , G. & Rock, K. L. Cloned dendritic cells can present
exogenous antigens on both MHC class I and class II molecules. Journal of immunology
(Baltimore, Md : 1950) 158, 2723–2730 (1997).
[160] Hanahan, D. Studies on transformation of Escherichia coli with plasmids. Journal of
molecular biology 166, 557–580 (1983).
[161] Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227, 680–685 (1970).
[162] Grotzke, J. E., Lu, Q. & Cresswell, P. Deglycosylation-dependent fluorescent proteins
provide unique tools for the study of ER-associated degradation. Proceedings of the National
Academy of Sciences of the United States of America 110, 3393–3398 (2013).
[163] Lin, M.-L. et al. Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome
c injection shows functional heterogeneity within this subset. Proceedings of the National
Academy of Sciences of the United States of America 105, 3029–3034 (2008).
[164] Fiebiger, E. et al. Dissection of the dislocation pathway for type I membrane proteins with
a new small molecule inhibitor, eeyarestatin. Molecular biology of the cell 15, 1635–1646
(2004).
[165] Wang, Q., Li, L. & Ye, Y. Inhibition of p97-dependent protein degradation by Eeyarestatin
I. The Journal of biological chemistry 283, 7445–7454 (2008).
[166] Wainszelbaum, M. J., Proctor, B. M., Pontow, S. E., Stahl, P. D. & Barbieri, M. A.
IL4/PGE2 induction of an enlarged early endosomal compartment in mouse macrophages
is Rab5-dependent. Experimental cell research 312, 2238–2251 (2006).
[167] Donaldson, J. G., Finazzi, D. & Klausner, R. D. Brefeldin A inhibits Golgi membrane-
catalysed exchange of guanine nucleotide onto ARF protein. Nature 360, 350–352 (1992).
[168] Böldicke, T. Blocking translocation of cell surface molecules from the ER to the cell surface
by intracellular antibodies targeted to the ER. Journal of cellular and molecular medicine
11, 54–70 (2007).
119
Bibliography
[169] Yu, H., Kaung, G., Kobayashi, S. & Kopito, R. R. Cytosolic degradation of T-cell receptor
alpha chains by the proteasome. The Journal of biological chemistry 272, 20800–20804
(1997).
[170] Yang, M., Omura, S., Bonifacino, J. S. & Weissman, A. M. Novel aspects of degradation
of T cell receptor subunits from the endoplasmic reticulum (ER) in T cells: importance of
oligosaccharide processing, ubiquitination, and proteasome-dependent removal from ER
membranes. The Journal of experimental medicine 187, 835–846 (1998).
[171] Blander, J. M. & Medzhitov, R. On regulation of phagosome maturation and antigen
presentation. Nature immunology7,1029–1035(2006).
[172] Imai, J., Hasegawa, H., Maruya, M., Koyasu, S. & Yahara, I. Exogenous antigens are
processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-
presentation by dendritic cells. International immunology 17, 45–53 (2005).
[173] Nair-Gupta, P. & Blander, J. M. An updated view of the intracellular mechanisms
regulating cross-presentation. Frontiers in immunology 4, 401 (2013).
[174] Amigorena, S. & Savina, A. Intracellular mechanisms of antigen cross presentation in
dendritic cells. Current opinion in immunology 22, 109–117 (2010).
[175] Wagner, C. S., Grotzke, J. E. & Cresswell, P. Intracellular events regulating cross-
presentation. Frontiers in immunology 3, 138 (2012).
[176] Houde, M. et al. Phagosomes are competent organelles for antigen cross-presentation.
Nature 425, 402–406 (2003).
[177] Werneburg, N. W., Guicciardi, M. E., Bronk, S. F. & Gores, G. J. Tumor necrosis factor-
alpha-associated lysosomal permeabilization is cathepsin B dependent. American journal
of physiology. Gastrointestinal and liver physiology 283, G947–56 (2002).
[178] Tucker, S. C. & Casadevall, A. Replication of Cryptococcus neoformans in macrophages
is accompanied by phagosomal permeabilization and accumulation of vesicles containing
polysaccharide in the cytoplasm. Proceedings of the National Academy of Sciences of the
United States of America 99, 3165–3170 (2002).
[179] Leyva-Cobián, F., Outschoorn, I. M., Carrasco-Marín, E. & Alvarez-Domínguez, C. The
consequences of the intracellular retention of pathogen-derived T-cell-independent antigens
on protein presentation to T cells. Clinical immunology and immunopathology 85, 1–15
(1997).
[180] Chan, S.-W. & Egan, P. A. Hepatitis C virus envelope proteins regulate CHOP via
induction of the unfolded protein response. FASEB journal : o cial publication of the
Federation of American Societies for Experimental Biology 19, 1510–1512 (2005).
[181] Van den Berg, B. et al. X-ray structure of a protein-conducting channel. Nature 427,
36–44 (2004).
[182] Hamman, B. D., Chen, J. C., Johnson, E. E. & Johnson, A. E. The aqueous pore through
the translocon has a diameter of 40-60 A during cotranslational protein translocation at
the ER membrane. Cell 89, 535–544 (1997).
120
Bibliography
[183] Tirosh, B., Furman, M. H., Tortorella, D. & Ploegh, H. L. Protein unfolding is not a
prerequisite for endoplasmic reticulum-to-cytosol dislocation. The Journal of biological
chemistry 278, 6664–6672 (2003).
[184] Rabinovich, E., Kerem, A., Fröhlich, K.-U., Diamant, N. & Bar-Nun, S. AAA-ATPase
p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein
degradation. Molecular and cellular biology 22, 626–634 (2002).
[185] Oura, J. et al. Extracellular heat shock protein 90 plays a role in translocating chaperoned
antigen from endosome to proteasome for generating antigenic peptide to be cross-presented
by dendritic cells. International immunology 23, 223–237 (2011).
[186] Imai, T. et al. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of
extracellular antigen for cross-presentation by dendritic cells. Proceedings of the National
Academy of Sciences of the United States of America 108, 16363–16368 (2011).
[187] Tsai, B., Rodighiero, C., Lencer, W. I. & Rapoport, T. A. Protein disulfide isomerase acts
as a redox-dependent chaperone to unfold cholera toxin. Cell 104, 937–948 (2001).
[188] Hampton, R. Y. & Sommer, T. Finding the will and the way of ERAD substrate retro-
translocation. Current opinion in cell biology (2012).
[189] Ruggiano, A., Foresti, O. & Carvalho, P. Quality control: ER-associated degradation:
protein quality control and beyond. The Journal of cell biology 204, 869–879 (2014).
[190] Li, W. et al. The plug domain of the SecY protein stabilizes the closed state of the
translocation channel and maintains a membrane seal. Molecular cell 26, 511–521 (2007).
[191] Schmitz, A., Herrgen, H., Winkeler, A. & Herzog, V. Cholera toxin is exported from
microsomes by the Sec61p complex. The Journal of cell biology 148, 1203–1212 (2000).
[192] Greenfield, J. J. & High, S. The Sec61 complex is located in both the ER and the ER-Golgi
intermediate compartment. Journal of cell science 112 ( Pt 10), 1477–1486 (1999).
[193] Raposo, G., van Santen, H. M., Leijendekker, R., Geuze, H. J. & Ploegh, H. L. Misfolded
major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi
intermediate compartment. The Journal of cell biology 131, 1403–1419 (1995).
[194] Ménager, J. et al. Cross-presentation of synthetic long peptides by human dendritic cells:
a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PloS
one 9, e89897 (2014).
[195] Wagner, C. S., Grotzke, J. & Cresswell, P. Intracellular regulation of cross-presentation
during dendritic cell maturation. PloS one 8, e76801 (2013).
[196] Delamarre, L., Holcombe, H. & Mellman, I. Presentation of exogenous antigens on major
histocompatibility complex (MHC) class I and MHC class II molecules is di erentially
regulated during dendritic cell maturation. The Journal of experimental medicine 198,
111–122 (2003).
[197] Lin, M.-L., Zhan, Y., Villadangos, J. A. & Lew, A. M. The cell biology of cross-presentation
and the role of dendritic cell subsets. Immunology and cell biology 86, 353–362 (2008).
121
Bibliography
[198] Bagola, K., Mehnert, M., Jarosch, E. & Sommer, T. Protein dislocation from the ER.
Biochimica et biophysica acta 1808, 925–936 (2011).
[199] Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R. & Wearsch, P. A. Mechanisms
of MHC class I-restricted antigen processing and cross-presentation. Immunological reviews
207, 145–157 (2005).
[200] Kutomi, G. et al. Targeting to static endosome is required for e cient cross-presentation of
endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes. Journal
of immunology (Baltimore, Md : 1950) 183, 5861–5869 (2009).
[201] Stocks, M. R. Intrabodies: production and promise. Drug discovery today 9, 960–966
(2004).
[202] Biocca, S., Neuberger, M. S. & Cattaneo, A. Expression and targeting of intracellular
antibodies in mammalian cells. The EMBO journal 9, 101–108 (1990).
[203] Colwill, K., Renewable Protein Binder Working Group & Gräslund, S. A roadmap to
generate renewable protein binders to the human proteome. Nature methods 8, 551–558
(2011).
[204] Bradbury, A. R. M., Sidhu, S., Dübel, S. & McCa erty, J. Beyond natural antibodies: the
power of in vitro display technologies. Nature biotechnology 29, 245–254 (2011).
[205] Reimer, E. et al. Molecular cloning and characterization of a novel anti-TLR9 intrabody.
Cellular & molecular biology letters 18, 433–446 (2013).
[206] Ellmark, P., Andersson, H., Abayneh, S., Fenyö, E. M. & Borrebaeck, C. A. K. Identification
of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection.
AIDS research and human retroviruses 24, 367–373 (2008).
[207] Kontermann, R. E. Intrabodies as therapeutic agents. Methods (San Diego, Calif.) 34,
163–170 (2004).
[208] Beerli, R. R., Wels, W. & Hynes, N. E. Intracellular expression of single chain antibodies
reverts ErbB-2 transformation. The Journal of biological chemistry 269, 23931–23936
(1994).
[209] Marschall, A. L. J. et al. Delivery of antibodies to the cytosol: debunking the myths. mAbs
6, 943–956 (2014).
[210] Crosas, B. et al. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin
ligase and deubiquitinating activities. Cell 127, 1401–1413 (2006).
[211] Appenzeller-Herzog, C. & Hauri, H.-P. The ER-Golgi intermediate compartment (ERGIC):
in search of its identity and function. Journal of cell science 119, 2173–2183 (2006).
[212] Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annual review
of immunology 31, 443–473 (2013).
[213] Friedman, J. R., Dibenedetto, J. R., West, M., Rowland, A. A. & Voeltz, G. K. Endoplasmic
reticulum-endosome contact increases as endosomes tra c and mature. Molecular biology
of the cell 24, 1030–1040 (2013).
122
Bibliography
[214] Vedrenne, C. & Hauri, H.-P. Morphogenesis of the endoplasmic reticulum: beyond active
membrane expansion. Tra c (Copenhagen, Denmark) 7, 639–646 (2006).
[215] Borgese, N., Francolini, M. & Snapp, E. Endoplasmic reticulum architecture: structures in
flux. Current opinion in cell biology 18, 358–364 (2006).
[216] P≥óciennikowska, A., Hromada-Judycka, A., BorzÍcka, K. & Kwiatkowska, K. Co-operation
of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cellular and
molecular life sciences : CMLS (2014).
[217] Tanimura, N., Saitoh, S., Matsumoto, F., Akashi-Takamura, S. & Miyake, K. Roles
for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling.
Biochemical and biophysical research communications 368, 94–99 (2008).
[218] Snyder, D. A., Kelly, M. L. & Woodbury, D. J. SNARE complex regulation by phosphory-
lation. Cell biochemistry and biophysics 45, 111–123 (2006).
[219] Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
Nature immunology 5, 190–198 (2004).
[220] Tabeta, K. et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and
signaling via Toll-like receptors 3, 7 and 9. Nature immunology 7, 156–164 (2006).
[221] Guiducci, C. et al. Properties regulating the nature of the plasmacytoid dendritic cell
response to Toll-like receptor 9 activation. The Journal of experimental medicine 203,
1999–2008 (2006).
[222] Underhill, D. M. et al. The Toll-like receptor 2 is recruited to macrophage phagosomes
and discriminates between pathogens. Nature 401, 811–815 (1999).
[223] Barton, G. M. & Kagan, J. C. A cell biological view of Toll-like receptor function: regulation
through compartmentalization. Nature Reviews Immunology 9, 535–542 (2009).
[224] Blander, J. M. & Medzhitov, R. Regulation of phagosome maturation by signals from
toll-like receptors. Science (New York, NY) 304, 1014–1018 (2004).
[225] John, B. et al. Dynamic Imaging of CD8(+) T cells and dendritic cells during infection
with Toxoplasma gondii. PLoS pathogens 5, e1000505 (2009).
[226] Bedoui, S. et al. Cross-presentation of viral and self antigens by skin-derived CD103+
dendritic cells. Nature immunology 10, 488–495 (2009).
[227] Igyártó, B. Z. et al. Skin-resident murine dendritic cell subsets promote distinct and
opposing antigen-specific T helper cell responses. Immunity 35, 260–272 (2011).
[228] Eidsmo, L. et al. Di erential migration of epidermal and dermal dendritic cells during skin
infection. Journal of immunology (Baltimore, Md : 1950) 182, 3165–3172 (2009).
[229] Gallegos, A. M. & Bevan, M. J. Central tolerance to tissue-specific antigens mediated
by direct and indirect antigen presentation. The Journal of experimental medicine 200,
1039–1049 (2004).
[230] Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by
the aire protein. Science (New York, NY) 298, 1395–1401 (2002).
123
Bibliography
[231] Gray, D., Abramson, J., Benoist, C. & Mathis, D. Proliferative arrest and rapid turnover
of thymic epithelial cells expressing Aire. The Journal of experimental medicine 204,
2521–2528 (2007).
[232] Luckashenak, N. et al. Constitutive crosspresentation of tissue antigens by dendritic cells
controls CD8+ T cell tolerance in vivo. Immunity 28, 521–532 (2008).
[233] Belz, G. T. et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral
self-tolerance to tissue-associated antigens. The Journal of experimental medicine 196,
1099–1104 (2002).
[234] Bonifaz, L. et al. E cient targeting of protein antigen to the dendritic cell receptor DEC-205
in the steady state leads to antigen presentation on major histocompatibility complex class
I products and peripheral CD8+ T cell tolerance. The Journal of experimental medicine
196, 1627–1638 (2002).
[235] Garulli, B., Stillitano, M. G., Barnaba, V. & Castrucci, M. R. Primary CD8+ T-cell
response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clinical and
vaccine immunology : CVI 15, 1497–1504 (2008).
[236] Garulli, B. et al. Enhancement of T cell-mediated immune responses to whole inactivated
influenza virus by chloroquine treatment in vivo. Vaccine 31, 1717–1724 (2013).
[237] Accapezzato, D. et al. Chloroquine enhances human CD8+ T cell responses against soluble
antigens in vivo. The Journal of experimental medicine 202, 817–828 (2005).
[238] Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the
DEC-205 receptor improves T cell vaccination. The Journal of experimental medicine 199,
815–824 (2004).
[239] Caminschi, I. et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target
for vaccine enhancement. Blood 112, 3264–3273 (2008).
[240] Tacken, P. J., de Vries, I. J. M., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy:
from ex vivo loading to in vivo targeting. Nature Reviews Immunology 7, 790–802 (2007).
[241] Tacken, P. J. et al. Targeted delivery of TLR ligands to human and mouse dendritic cells
strongly enhances adjuvanticity. Blood 118, 6836–6844 (2011).
[242] Tacken, P. J. et al. Targeting DC-SIGN via its neck region leads to prolonged antigen
residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood
118, 4111–4119 (2011).
[243] Wiertz, E. J. et al. The human cytomegalovirus US11 gene product dislocates MHC class
I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769–779 (1996).
124
A Shortcuts
°C Celsius degrees
—-ME —-mercaptoethanol
Ab antibody
ABTS 2,2’-Azino-di-(3-ethylbenzthiazolin)-6-sulfonacid
APC antigen-presenting cell
ATPase adenosintriphosphatase
BMDC bone marrow-derived dendritic cells
BSA bovine serum albumin
CaCl2 calcium chloride
cDNA ‚complementary’ DNA produced out of mRNA
CLIP class-II-associated chain peptide
DAPI 4’, 6-Diamidino-2-phenylindol
DC dendritic cell
DMEM Dulbecco’s Modified Eagle’s Medium
DNA deoxyribonucleic acid
dNTP deoxyribonucleotide
FCS fetal calf serum
EDTA ethylenediaminetetraacetic acid
fig. figure
EEA-1 early endosomal antigen 1
e.g. exempli gratia (for example)
ELISA Enzyme-Linked Immunosorbent Assay
ER endoplasmatic reticulum
ERAD ER-associated degradation machinery
ERGIC ER-golgi intermediate compartment
forw. forward
FRED Förster resonance energy transfer
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A Shortcuts
GFP green fluorescence protein
GM-CSF granulocytes/monocytes-colony stimulating factor
IB intrabody
hr hour
H2O water
HRP horseradish peroxidase
IL-2 interleukin 2
IMDM Iscove’s modified Dulbecco’s Medium
IP immunoprecipitation
IRES internal ribosomal entry site
kB kilobase-pair
kDa kilodalton
l liter
lamp-1 lysosome associated membrane protein 1
LPS lipopolysaccharide
LTR long terminal repeats
M molar
M„ macrophage
MES 2-(N-Morpholino)ethansulfon acid
MFI mean fluorescence intensity
MHC-I/II major histocompatibility complex
min minute
ml milliliter
mRNA messenger ribonucleic acid
MyD88 myeloid di erentiation primary response gene
NADPH nicotinamide adenine dinucleotide phosphate
NEM N-Ethylmaleinimid
NOX2 NADPH oxidase 2
OT-I cells CD8+-T-cells recognizing OVA-peptide SIINFEKL loaded on MHC-I
OT-II cells CD4+-T-cells recognizing OVA-peptide ISQAVHAAHAEINEAGR loaded on
MHC-II
OVA ovalbumin
PAMP pathogen associated molecular patterns
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A Shortcuts
PBS phosphate-bu ered solution
PCR polymerase-chain reaction
PDI protein disulfide isomerase
PLP phosphate lyse-bu er
PRR pattern recognition receptor
rag1 recombinase activating gene 1
rab5 Ras-related protein
rcf relative centrifugal force
rev. reverse
RNA ribonucleic acid
RPMI Roswell Park Memorial Institute Medium
RRE rev responsive element
RT room temperature
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
sec seconds
SIINFEKL OVA peptide 257-264
siRNA short interfering RNA
SNARE soluble N-ethylmaleimide-sensitive-factor attachment receptor
TAE tris-acetat-EDTA
TAP transporter associated with antigen processing
TCR T-cell receptor
TEMED tetramethylethylendiamin
TfR transferrin receptor
TGN trans-golgi network
TLR Toll-like-receptor
TM-domain transmembrane domain
TRIF Toll/IL-1 receptor‚ domain-containing adaptor inducing IFN-ß
VSV-G vesicular stomatitis virus glycoprotein
w/o without
WB western blot
wt wild-type
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